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Abstract	
Medulloblastoma	 survivors	 frequently	 suffer	 from	 low	 quality	 of	 life	 as	 a	 result	 of	
aggressive	 treatment.	 New	 treatments	 are	 urgently	 needed	 to	 reduce	 down-stream	
sequelae.	GD3,	an	oncofoetal	ganglioside,	has	roles	in	embryonic	brain	development	and	
is	commonly	modified	to	9-O-acetyl	GD3	(GD3A).	GD3A	plays	a	role	in	protecting	cells	from	
pro-apoptotic	 GD3	 during	 brain	 development,	 after	 which	 GD3	 accumulates	 above	 a	
threshold	to	collapse	the	mitochondrial	membrane	potentials	of	supernumary	progenitor	
cells.	GD3	and	GD3A	then	become	minor	ganglioside	species	of	the	postpartum	brain.	In	
medulloblastoma	 however,	 GD3	 and	 GD3A	 are	 re-expressed	 as	 shown	 here	 by	 the	
medulloblastoma	cell	lines	RES256,	UW402	and	CHLA-01-Med	where	expression	of	GD3	is	
seen	in	56.7%,	61.3%	and	45.1%	of	the	cell	populations	respectively.		GD3A	is	expressed	by	
84.5%,	74.4%	and	79.4%	of	the	populations	respectively.	By	bioinformatic	analysis	we	also	
show	that	the	human	endogenous	deacetylation	enzyme	of	GD3A,	Sialate-O-acetylesterase	
(SIAE),	 is	 significantly	down-regulated	 in	medulloblastoma	patient	 tissue	 (p<0.001).	 This	
enzyme	is	thought	to	restore	GD3	levels	by	cleaving	the	acetyl	groups	from	GD3A.	In	order	
to	evaluate	this	pathway	as	a	potential	therapeutic	target	we	used	an	inducible	SIAE	over-
expression	 approach	 in	 RES256	 cells,	 the	 highest	 intracellular	 GD3A	 expresser.	 This	
transfection	resulted	in	two	SIAE	wild-type	expressing	clones.	Upon	over-expression	of	SIAE	
(in	clone	2)	we	show	a	significant	increase	in	GD3	expression	(p<0.05),	and	in	preliminary	
experiments	 a	 significant	 increase	 in	 depolarisation	 of	 the	 mitochondrial	 membrane	
potential	was	seen	in	SIAE	expressing	clone	1	(p<0.05).	These	changes	were	not	seen	on	
induction	 of	 expression	 of	 a	 catalytic	 mutant	 SIAE-S127A	 or	 vector	 controls.	 We	 also	
demonstrate	that	wild-type	SIAE	expressing	clones	do	not	secrete	the	enzyme,	however	
the	catalytic	mutant	SIAE-S127A	protein	is	secreted.	We	hypothesise	that	possible	cleavage	
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of	caspase	1	could	be	responsible	for	this	secretion.	The	expression	of	SIAE	and	SIAE-S127A	
in	 cell	 lysates	 were	 confirmed	 by	Western	 blot	 and	 demonstrated	 a	 possible	 cleavage	
product.	We	hypothesise	 that	 this	 possible	 cleavage	may	 result	 in	different	 abilities	 for	
these	clones	to	secrete	the	enzyme.	Furthermore,	we	show	that	 induction	of	SIAE	over-
expression	in	combination	with	etoposide	treatment	resulted	in	a	significant	reduction	in	
IC50	in	SIAE	overexpressing	clones	after	72	hours	of	treatment	(p<0.001;	clone	2).	Changes	
in	IC50	for	empty	vector	controls	and	SIAE-S127A	were	not	significant.		
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1.1 Paediatric	Brain	tumours	
1.1.1 Incidence		
	
Brain	tumours	are	the	most	common	solid	form	of	cancer	in	children	and	the	second	most	
common	paediatric	cancer,	affecting	3.3	per	100,000	children	(Gilbertson	2004).	In	England	
brain	tumours	have	accounted	for	approximately	18%	of	all	newly	diagnosed	cancers	of	
childhood	when	averaged	between	2008	and	2013.	In	England	in	2010	there	were	217	new	
cases	of	paediatric	brain	 cancer	and	76	 resulting	deaths,	meaning	over	a	 third	of	 these	
patients	 succumbed	 to	 their	 disease	 (35%)	 (Office	 for	 National	 Statistics	 2013).	 These	
statistics	 have	 been	 generated	 from	 data	 obtained	 from	 patients	 under	 the	 age	 of	 15,	
making	 this	 a	 likely	 under-estimation	 of	 true	 incidence.	 Today,	 brain	 tumours	 are	 the	
leading	cause	of	childhood	cancer	related	deaths	(Brain	Tumour	Research	2015).		
There	are	several	embryonic	brain	tumours	that	can	occur	in	the	central	nervous	system	
(CNS).	These	have	recently	undergone	re-classification	by	the	World	Health	Organisation	
(WHO)	 (Louis	 et	 al.	 2016).	 The	 currently	 recognised	 embryonal	 tumours	 are	
medulloblastoma	 (genetically	 or	 histologically	 defined;	 or	 not	 otherwise	 specified);	
embryonal	 tumour	with	multilayer	 rosettes	 (C19MC-altered	or	not	otherwise	specified);	
CNS	 neuroblastoma;	 CNS	 ganglioneuroblastoma;	 medulloepithelioma;	 atypical	
teratoid/rhabdoid	tumour;	CNS	embryonal	tumour	with	rhabdoid	features;	and	finally,	CNS	
embyronal	 tumour	 not	 otherwise	 specified	 (Louis	 et	 al.	 2016;	 National	 cancer	 institute	
2015).		
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1.1.2 Epidemiology	
	
There	are	very	few	known	risk	factors	associated	with	brain	tumour	development.	The	only	
well-established	environmental	risk	factor	is	radiation	exposure	(American	Cancer	Society	
2014).	Most	 radiation-induced	 brain	 tumours	 however	 are	 caused	 by	 the	 treatment	 of	
other	cancers,	such	as	leukaemia.		These	secondary	tumours	usually	develop	10	to	15	years	
after	radiotherapy	to	the	head,	so	tend	not	to	affect	children	(Cancer	Research	UK	2015).	
Other	causes	of	childhood	brain	tumours	include,	in	rare	instances	(<	5%	of	cases),	inherited	
genetic	mutations,	which	can	increase	the	risk	of	some	brain	tumours.	In	other	cases,	the	
mutations	are	somatic.	Known	conditions	which	can	increase	the	risk	of	childhood	brain	
tumours,	 include	neurofibromatosis	type	1,	the	most	common	syndrome	linked	to	brain	
and	spinal	cord	tumours;	neurofibromatosis	type	2,	tuberous	sclerosis,	Von	Hippel-Lindau	
disease,	 Li-Fraumeni	 syndrome,	Gorlin	 syndrome,	 Turcot	 syndrome,	 Cowden	 syndrome,	
hereditary	 retinoblastoma	 and	 Rubinstein-Taybi	 syndrome	 (American	 Cancer	 Society	
2014).	Some	of	these	syndromes	have	helped	to	understand	some	of	the	underlying	biology	
of	their	associated	tumours,	such	as	Gorlin	syndrome,	in	which	patients	have	mutations	in	
the	 patched	 1	 gene	 PTCH1,	 which	 predisposes	 them	 to	 certain	 cancers	 including	
medulloblastoma	(Fujii	&	Miyashita	2014).		
1.1.3 Location	and	Symptoms	of	childhood	brain	tumours	
	
The	symptoms	of	brain	tumours	are	general.	Tumours	 in	any	part	of	the	brain	can	raise	
intracranial	pressure	due	to	the	location	and/or	size	of	the	tumour	in	the	confined	space	of	
the	 skull	 (American	 Cancer	 Society	 2014).	 General	 symptoms	 that	 may	 indicate	 raised	
intracranial	pressure	include	headaches,	nausea,	vomiting,	crossing	of	the	eyes	or	blurred	
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vision,	balance	problems,	behavioural	changes,	seizures,	drowsiness	or	coma	(HeadSmart	
2011).	Headaches	that	worsen	over	time	are	a	symptom	of	brain	tumours,	but	importantly	
not	 all	 brain	 tumours	 cause	 headaches	 (American	 Cancer	 Society	 2014).	 Patients	 may	
present	with	symptoms	that	gradually	worsen	over	time,	or	their	symptoms	may	present	
suddenly	(Macmillan	2014).	
In	the	first	few	years	of	life,	symptoms	of	brain	tumours	can	also	include	irritability,	loss	of	
appetite,	developmental	delay,	and	a	drop	in	intellectual	and	physical	ability	(Macmillan	
2014).	In	very	young	children	a	parent	may	also	notice	an	increased	head	circumference	
that	 can	 be	 accompanied	 by	 bulging	 of	 the	 fontanelles	 as	 the	 tumour	 pushes	 outward	
against	 the	 unfused	 bone	 plates	 (American	 Cancer	 Society	 2014).	 This	 diverse	 range	 of	
symptoms	 make	 brain	 tumours	 particularly	 devastating	 as	 they	 are	 often	 difficult	 to	
diagnose	(Brain	Tumour	Research	2015).		
Symptoms	of	brain	tumours	are	often	a	result	of	their	location,	with	the	space-occupying	
lesions	impacting	on	the	function	of	surrounding	tissue.	Childhood	brain	tumours	are	most	
commonly	infratentorial,	meaning	they	occur	at	the	lower	portion	of	the	back	of	the	head	
(below	the	tentorium)	(Patel	et	al.	2011).	The	structures	that	reside	in	this	area	include	the	
cerebellum,	 brainstem	 and	 spinal	 cord.	Most	 of	 the	 childhood	 tumours	 occur	 in	 these	
regions	due	 to	 rapid	proliferation	of	 cells	 in	 this	 area	during	development	of	 the	brain,	
including	 the	 granule	 neuron	 precursors	 of	 the	 cerebellum	 which	 can	 give	 rise	 to	
medulloblastoma	when	faults	occur	(Gibson	et	al.	2010).	Medulloblastoma	is	an	embyronal	
cancer	which	most	commonly	arises	from	the	neuronal	precursor	cells.	This	cellular	origin	
differs	 from	adult	brain	 tumours	which	are	most	commonly	glial	 in	origin	and	are	most	
often	located	supratentorially	(Swartling	et	al.	2013).	
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1.1.4 Prognosis	
	
Brain	tumours	are	generally	associated	with	a	worse	prognosis	than	many	other	paediatric	
cancers,	 such	 as	 leukaemia,	 and	 as	 a	 group	 they	 account	 for	 more	 than	 a	 quarter	 of	
childhood	 deaths	 from	 cancer	 (Gilbertson	 2004).	 Survivors	 of	 childhood	 brain	 tumours	
commonly	have	 life-long	treatment-induced	side	effects	that	are	exemplified	 in	patients	
with	medulloblastoma,	the	leading	cause	of	childhood	related	mortality	and	the	focus	of	
this	study	(Hooper	et	al.	2014).		
1.2 Medulloblastoma	
Medulloblastoma	is	a	malignancy	of	the	cerebellum	and	is	the	most	common	malignant	
paediatric	brain	tumour,	accounting	for	around	20%	of	cases	(Millard	&	De	Braganca	2015).	
Most	 cases	 of	 this	 disease	 are	 diagnosed	 in	 children	 under	 ten,	 with	 a	 peak	 incidence	
between	 the	 ages	 of	 three	 and	 eight	 (Millard	&	 De	 Braganca	 2015).	 The	WHO	 defines	
medulloblastoma	as	a	grade	IV	disease.	Grade	IV	is	the	highest	grade	of	malignancy	that	
the	WHO	 assigns.	 This	 classification	means	 that	 this	 tumour	 is	 cytologically	 malignant,	
mitotically	active,	prone	to	necrosis	and	is	associated	with	rapid	pre-	and	post-operative	
disease	evolution.	Medulloblastoma	also	meets	grade	 IV	criteria	as	 the	disease	 features	
widespread	 infiltration	 of	 surrounding	 brain	 tissue	 and	 tendency	 for	 cranial-spinal	
dissemination	(World	Health	Organisation	2007).		
Symptoms	 of	 medulloblastoma	 encompass	 the	 general	 symptoms	 of	 brain	 tumours	
described	 in	 section	 1.1.3,	 but	 due	 to	 their	 location	 patients	 also	 show	 symptoms	
associated	with	 cerebellar	 dysfunction	 and	 blockage	 of	 cerebral	 spinal	 fluid	 (CSF)	 flow.	
Symptoms	of	medulloblastoma	include	vomiting,	particularly	in	the	morning.	The	time	of	
day	 a	patient	 vomits	 is	 important	because	 the	 increased	 intracranial	 pressure	 from	 the	
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tumour	blocking	the	flow	of	CSF	through	the	fourth	ventricle	is	affected	by	movement	from	
the	prone	position	to	standing.	Patients	may	also	show	‘sunset	sign’,	a	phenomenon	where	
the	eyes	appear	 like	a	setting	sun	(the	sclera	of	the	eye	is	visible	above	the	iris	which	is	
partly	covered	by	the	lower	eyelid,	as	if	the	eyes	are	being	forced	downwards);	this	is	a	sign	
of	raised	intracranial	pressure.	Other	symptoms	of	medulloblastoma	also	include	a	loss	of	
fine	motor	movement,	and	rarely	vision	problems.		
1.2.1 Origins	of	medulloblastoma	
	
Medulloblastoma	 is	 a	 developmental	 tumour	 of	 the	 cerebellum	 so	 named	 by	 Harvey	
Cushing	 and	 Percival	 Bailey	 in	 1925.	 The	 name	 medulloblastoma	 was	 given	 as	 they	
hypothesised	the	cell	of	origin	as	the	‘medulloblast’	(Millard	&	De	Braganca	2015).	We	now	
know	that	the	medulloblast,	or	cell	of	origin	is	actually	several	cells	of	origin,	described	later	
(Marshall	et	al.	2014)	but	its	name	has	been	retained.	It	is	also	known	that	some	signalling	
pathways	which	 have	 roles	 in	 the	 patterning	 and	 development	 of	 the	 cerebellum	have	
cross-overs	with	medulloblastoma	tumorigenesis	(Wechsler-Reya	&	Scott	2001b).	Patients	
who	have	Turcot	and	Gorlin	syndrome	have	helped	in	the	understanding	of	some	of	the	
underlying	tumour	biology	as	these	patients	are	predisposed	to	medulloblastoma	(Millard	
&	 De	 Braganca	 2015).	 It	 is	 important	 to	 understand	 how	 these	 oncogenic	 signalling	
pathways	contribute	to	medulloblastoma	as	this	will	help	to	improve	clinical	management	
of	the	disease.	With	these	discoveries	there	will	be	more	accurate	predictors	of	disease	risk	
and	 refinement	 of	 appropriate	 therapeutic	 strategies.	 Pharmacological	 intervention	 of	
these	pathways	will	become	more	targeted	and	could	lead	to	the	development	of	new	and	
effective	 treatments	 for	 this	 disease.	 In	 order	 to	 understand	 the	 tumorigenesis	 of	 this	
tumour,	we	must	consider	the	development	of	the	cerebellum.		
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1.3 Development	of	the	cerebellum		
The	 cerebellum	 (or	 ‘little	 brain’)	 is	 located	 at	 the	back	of	 the	 skull	 and	 is	 an	 important	
structure	of	the	brain	that	controls,	among	others,	learning	and	motor	co-ordination.	The	
cerebellar	cortex	contains	intricate	connections	and	five	varieties	of	neuron	(the	granule	
neuron,	Golgi	cells,	Purkinje	cells,	basket	cells	and	stellate	cells)	(Bihannic	&	Ayrault	2016).	
The	 granule	 neuron	 in	 particular	 is	 implicated	 in	 the	 pathogenesis	 of	medulloblastoma	
(Butts	et	al.	2014).		
The	granule	neuron	is	by	far	the	most	numerous	cell	type	of	the	cerebellum	and	actually	
outnumbers	the	rest	of	the	neurons	in	the	brain	(Butts	et	al.	2014).	The	role	of	the	granule	
neuron	is	to	regulate	the	output	and	activity	of	the	Purkinje	cells,	which	means	that	they	
ultimately	control	the	output	of	the	cerebellum	to	the	rest	of	the	brain.	Patients	who	have	
congenital	granule	cell	degeneration	have	severe	deficits	in	motor	co-ordination,	language	
and	cognitive	function	which	indicates	their	importance	in	these	processes	(Wechsler-Reya	
&	Scott	2001a).		
Neurogenesis	 of	 the	 granule	 cell	 has	 unique	 features;	 most	 neurons	 arise	 around	 the	
ventricles	and	migrate	outwards	towards	the	cortex.	Granule	cells	however	are	generated	
outside	of	the	cerebellum	and	migrate	inwards,	using	the	Bergmann	glial	tracts	(reviewed	
by	Butts	et	al.	2014).	This	process	involves	the	dorsal	hindbrain	structure	the	rhombic	lip,	
where	granule	neurons	arise	and	migrate	across	the	surface	of	the	early	cerebellum	to	form	
the	external	granule	layer	(EGL)	(Alcántara	et	al.	2000;	Wingate	2001;	Alder	et	al.	1996).	In	
rodents,	a	single	layer	of	undifferentiated	cells	proliferates	rapidly	and	generates	a	large	
pool	of	granule	cell	precursors	(GCPs)	at	birth	(Wechsler-Reya	&	Scott	2001a).	As	the	GCPs	
are	 generated,	 the	older	 cells	 begin	 to	differentiate	 and	migrate	 inwards,	 by	 extending	
	 32	
across	 the	 axons	 of	 Bergmann	 glia	 which	 are	 in	 contact	 with	 Purkinje	 cell	 dendrites	
(Wechsler-Reya	2003).	The	GPC	cell	bodies	then	migrate	past	the	Purkinje	cell	bodies.	The	
granule	cells	are	then	at	their	final	destination,	the	internal	granule	layer	(IGL)	(Butts	et	al.	
2014).	The	proliferation	and	differentiation	of	GCPs	continues	until	about	3	weeks	of	age	
when	 the	 EGL	 depletes	 and	 the	 GCPs	 all	 mature	 into	 granule	 neurons	 (Wechsler-Reya	
2003).	 It	 is	 thought	 that	 if	 faults	 arise	 during	 this	 process,	 medulloblastoma	 occurs	
(Wechsler-Reya	&	Scott	2001b).	Medulloblastoma	cells	are	not	completely	 like	any	non-
neoplastic	 cerebellar	 cell,	 but	 they	 are	most	 similar	 to	 the	 granule	 neuron	 precursors,	
leading	 investigators	to	believe	that	the	GCPs	are	the	cell	of	origin	for	medulloblastoma	
(Wechsler-Reya	&	Scott	2001a).		
1.4 Brain	development	and	molecular	subgroups	of	medulloblastoma	
Patients	 with	 Turcot	 syndrome	 and	 Gorlin	 syndrome	 have	 a	 higher	 incidence	 of	
medulloblastoma	and	have	shed	some	light	on	the	origins	of	this	disease	(Cancer	Research	
UK	2015).	These	patients	have	germline	mutations	in	proteins	involved	in	wingless	(WNT)	
signalling	and	sonic	hedgehog	(SHH)	signalling	respectively,	leading	investigators	to	explore	
and	confirm	the	roles	of	these	developmental	pathways	in	medulloblastoma	pathogenesis	
(de	Bont	et	al.	2008;	Fujii	&	Miyashita	2014).	The	discovery	of	these	pathways	has	allowed	
the	stratification	of	patients	into	molecular	subgroups	of	disease.			
In	2012,	the	consensus	on	the	molecular	classification	of	medulloblastoma	was	published	
by	 Taylor	 et	 al.	 (2012).	 These	 molecular	 subgroups	 are	 defined	 by	 genetic	 and	
transcriptional	 signatures,	 which	 include	mutations	 in	 the	WNT	 and	 the	 SHH	 signalling	
pathways.	Generic	names	are	given	to	subgroups	3	and	4	as	there	is	much	less	known	about	
the	underlying	biology	of	 these	subgroups,	 importantly	 the	subgroups	are	also	clinically	
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distinct.	 These	 molecular	 subgroups	 will	 ultimately	 lead	 to	 the	 identification	 of	 new	
treatments	and	improvements	in	the	way	existing	therapies	are	utilised.	
1.4.1 The	WNT	Subgroup	
	
The	WNT	signalling	pathway	controls	a	diverse	range	of	developmental	processes	including	
the	proliferation	and	fate	of	neural	progenitor	cells	and	also	functions	in	cerebellar	growth,	
patterning,	 and	 differentiation	 (Kalderon	 2002).	WNT	 proteins	 are	 a	 family	 of	 secreted	
molecules.	Wnt-1,	the	first	WNT	protein	to	be	identified,	is	known	to	be	required	in	early	
embryogenesis	 for	 midbrain/hindbrain	 boundary	 (isthmus)	 formation	 from	 which	 the	
cerebellum	arises	(Buckles	et	al.	2004).	When	Wnt-1	mutations	have	been	studied	in	mice	
they	have	serious	defects	of	their	midbrain	and	little	to	no	cerebellum	formation,	indicating	
the	importance	of	this	pathway	(Buckles	et	al.	2004).	Another	WNT	protein,	Wnt-7a,	has	
been	implicated	in	axon	branching	and	synapse	formation	in	granule	cells	and	mossy	fibres	
of	the	cerebellum	(Ciani	&	Salinas	2005).		
The	WNT	pathway	regulates	expression	of	proteins	such	as	V-Myc	Avian	Myelocytomatosis	
Viral	Oncogene	Homolog	(C-Myc)	and	cyclin	D1,	proteins	which	have	roles	in	development,	
but	 are	 also	 known	 oncogenes	 (Gilbertson	 2004).	 This	 pathway	 works	 through	 the	
controlled	degradation	of	β-catenin	and	is	summarised	in	figure	1.1.	
1.4.2 Inactive	WNT	signalling	
	
In	the	absence	of	WNT	protein	β-catenin	concentrations	are	kept	low	through	degradation	
(Ciani	&	Salinas	2005).	This	degradation	is	achieved	through	a	protein	complex	that	includes	
glycogen	synthase	kinase	3	(GSK3),	the	scaffolding	protein	axin,	casein	kinase	1α	(CK1a)	
and	 adenomatous	 polyposis	 coli	 (APC).	 	 In	 the	 absence	 of	 ligand,	 casein	 kinase	 1α	
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phosphorylates	β-catenin	for	further	phosphorylation	by	GSK3	on	residues	33,	37	and	41	
(Gilbertson	2004).	These	phosphorylated	residues	provide	binding	sites	for	a	protein,	which	
promotes	the	polyubiquitination	and	complete	proteolysis	of	β-catenin.	Another	complex	
that	is	known	to	degrade	β-catenin	has	been	described	that	includes	presenilin	1	and	shown	
in	figure	1.1	(Kang	et	al.	2002).	
1.4.3 Active	WNT	signalling	
	
WNT	 proteins	 bind	 to	 their	 receptors,	 frizzleds	 (FZDs).	 With	 WNT	 protein	 bound,	 the	
protein	 dishevelled	 (DSH)	 is	 phosphorylated.	 This	 phosphorylation	 leads	 to	 GSK3	
inactivation	and	results	in	the	reduced	phosphorylation	and	degradation	of	β-catenin	(Ciani	
&	Salinas	2005).	The	β-catenin	can	then	be	released	from	the	protein	complex	containing	
APC,	Axin,	GSK3	and	CK1a	or	the	complex	containing	protein	kinase	A	(PKA),	Presenilin-1	
and	GSK3	(Kang	et	al.	2002).	β-catenin	then	accumulates	and	translocates	to	the	nucleus	
where	it	interacts	with	transcription	factors	such	as	T-cell	factor/lymphoid	enhancer	factor	
(LEF/TCF).	LEF/TCF	transcription	factors	can	initiate	transcription	of	C-Myc	and	cyclin	D1,	
known	oncogenes	(Ciani	&	Salinas	2005).		
1.4.4 WNT	Signalling	in	Medulloblastoma	
	
Mutations	 in	 APC	 were	 first	 implicated	 in	 medulloblastoma	 pathogenesis	 in	 Turcot	
syndrome	patients	(Hatten	&	Roussel	2011).	Mutations	in	APC	have	only	been	found	in	4%	
of	 sporadic	 medulloblastomas	 (Huang	 et	 al.	 2000).	 Activating	 somatic	 mutations	 in	
CTNNB1,	the	gene	encoding	β-catenin	have	been	found	in	between	8	and	15%	of	sporadic	
cases	(Eberhart	et	al.	2000;	Dahmen	et	al.	2001;	Zurawel	et	al.	1998;	Huang	et	al.	2000).	
Most	of	the	reported	activating	β-catenin	mutations	in	sporadic	medulloblastomas	target	
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residues	 S33	 and	 S37	 (Gilbertson	 2004).	 These	mutations	 prevent	 the	 phosphorylation-
dependent	 degradation	 of	 β-catenin	 by	 GSK3.	 These	 mutations	 cause	 β-catenin	 to	
accumulate,	 driving	 oncogenic	 gene	 transcription	 (Gilbertson	 2004).	 This	 occurs	 in	 the	
hypothesised	cell	of	origin	for	this	subgroup,	the	neural	stem	cell	(Gajjar	&	Robinson	2014),	
the	location	and	characteristics	of	which	are	described	in	table	1.1.	
1.4.5 Subgroup	features	
	
Patients	with	WNT	subgroup	tumours	have	a	very	good	long-term	prognosis	and	five-year	
survival	 rates	 are	 around	 95%	 (Gajjar	&	 Robinson	 2014).	 This	 subgroup	 is	 the	 rarest	 in	
incidence,	accounting	for	10%	of	cases	(Goschzik	et	al.	2015).	Of	these	only	5%	of	cases	
present	with	metastatic	disease	(Gajjar	&	Robinson	2014).	Generally,	patients	who	die	from	
this	 subgroup	 of	 medulloblastoma	 die	 from	 complications	 of	 treatment	 or	 secondary	
neoplasm	rather	than	the	primary	disease	Taylor	et	al.	2012.	Treatment	of	this	subgroup	is	
justifiably	 considered	 too	 aggressive	 given	 the	 high	 survival	 rates.	 Some	 patients	 are	
therefore	 given	 reduced-dose	 craniospinal	 radiotherapy	 and	 reduced	 intensity	
chemotherapy	because	of	 this,	but	 they	must	not	have	metastatic	disease	and	must	be	
enrolled	in	clinical	trial	(Gilbertson	2004).	The	reason	for	better	outcome	for	WNT	patients	
remains	unknown	 (Phoenix	 et	 al.	 2016).	However	 it	 has	been	 suggested	 that	 it	may	be	
because	these	cells	exhibit	increased	radio-sensitivity	or	that	they	have	reduced	invasive	
capacity	(Salaroli	et	al.	2015).	Others	have	suggested	a	disrupted	blood	brain	barrier	only	
seen	in	WNT	disease	which	allows	for	a	higher	concentration	of	drug	to	reach	the	tumour	
(Phoenix	et	al.	2016).		
The	 location	 of	 this	 subgroup	 of	 tumour	 is	 distinct,	 it	 occurs	 in	 the	 cerebellar	midline,	
occupying	 the	 fourth	 ventricle	 where	 it	 can	 infiltrate	 the	 brain	 stem	 (Gilbertson	 2004;	
	 36	
Raybaud	et	al.	2015).	In	the	WNT	mouse	model	of	medulloblastoma	the	cell	of	origin	is	in	
the	lower	rhombic	lip.	When	the	cells	gain	oncogenic	mutations	of	the	WNT	pathway,	the	
cells	fail	to	migrate	and	tumour	forms	(Eberhart	2012).		
Overall	 this	 subgroup	 has	 an	 incidence	 of	 1:1	male:	 female,	 differing	 from	 the	 general	
medulloblastoma	ratio	of	incidence	being	2:1	male:	female.	This	subgroup	of	disease	can	
occur	at	all	ages	but	is	less	common	in	infants	(0-3	years	of	age)	(Gajjar	&	Robinson	2014).	
Histologically	WNT	subgroup	tumours	demonstrate	positive	nuclear	staining	for	β-catenin	
which	guides	diagnosis	(Gajjar	&	Robinson	2014).	Monosomy	6	also	occurs	in	this	subgroup	
but	does	not	occur	 in	every	patient.	Other	 than	monosomy	6	 there	are	 very	 few	other	
genetic	 amplifications	 or	 deletions	 in	 the	 genome	 of	 this	 subgroup	 (Gajjar	 &	 Robinson	
2014).		
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Figure	 1.1	 The	 WNT	 signalling	 pathway	 functions	 in	 cerebellar	 development	 and	
medulloblastoma.	When	the	WNT	pathway	is	inactive	no	ligand	is	bound	to	the	frizzled	
receptor	 (FZD)	and	β-catenin	 is	bound	to	the	destruction	complexes	containing	Casein	
kinase	1a	(CK1a),	adenomatous	polyposis	coli	(APC),	Axin	and	glycogen	synthase	kinase	
3	(GSK3)	or	protein	kinase	A	(PKA),	presenilin-1	and	GSK3).	The	bound	β-catenin	is	then	
phosphorylated	(blue	circles)	and	allows	the	protein	to	be	ubiquitinated	and	degraded	in	
the	cytoplasm.	When	the	WNT	pathway	is	active,	WNT	ligand	is	bound	to	FZD	and	the	
protein	dishevelled	(DSH)	is	phosphorylated,	this	inactivates	GSK3	meaning	β-catenin	is	
not	phosphorylated	and	the	destruction	complex	dissociates.	β-catenin	then	accumulates	
and	 translocates	 to	 the	 nucleus	 where	 it	 binds	 to	 the	 transcription	 factor	 T-cell	
factor/lymphoid	 enhancer	 factor	 (LEF/TCF)	 and	 initiates	 the	 transcription	 of	 known	
oncogenes	 such	 as	 c-myc	 and	 cyclin	 D1.	 In	Medulloblastoma,	WNT	 signalling	 can	 be	
activated	 without	 WNT	 ligand	 binding	 due	 to	 mutations	 in	 the	 β-catenin	 protein	
sequence	 that	 prevent	 its	 phosphorylation.	 These	 mutations	 mean	 β-catenin	 is	 not	
degraded	as	it	cannot	be	ubiquitinated.	Adapted	from	Gilbertson	2004.		
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Table	 1.1	Disease	 features	 of	WNT	medulloblastoma.	 The	proposed	 cell	 of	 origin	 and	
developmental	 stage	 are	 thought	 to	 be	 when	 aberrant	 WNT	 signalling	 drives	
tumorigenesis	adapted	from	Gajjar	&	Robinson	(2014).		
Disease	Feature	 WNT	Subgroup	
Proposed	cell	of	origin	 Neural	Stem	cell	<6	weeks	post-embryonic	
Origin	 Possibly	the	sub-ventricular	zone	or	fourth	
ventricle	
Location	of	disease	 Dorsal	stem	
Neoplastic	event	 WNT	deregulation	(among	others?)	
Candidate	genes	 WNT	 pathway,	 Dickkopf-related	 protein	 1	
(DKK1),	 Mitogen-Activated	 Protein	 Kinase	
Kinase	3	(SKK2),	Dickkopf-related	protein	4	
(DKK4)	
Underlying	mechanism		 Over-activation	of	stem	cell	maintenance	
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1.4.6 The	SHH	subgroup	
	
PTCH1	 is	 an	 example	 of	 a	 gene	 that	 controls	 cell	 fate	 and	 growth	 in	 the	 developing	
cerebellum	(Tichy	et	al.	2015).	If	PTC1	function	is	reduced,	for	example	by	mutation,	then	
this	growth	can	become	unregulated	and	contribute	to	pathogenesis	of	medulloblastoma	
(Northcott	et	al.	2015).	The	discovery	of	PTC1	 in	medulloblastoma	pathology	 led	 to	 the	
identification	of	the	PTC1	ligand	SHH	as	a	mitogen	for	cerebellar	granule	neuron	precursors	
(Wallace	1999;	Wechsler-Reya	&	Scott	1999;	Tanaka	et	al.	2009;	Dahmane	&	Ruiz	i	Altaba	
1999).		
In	embryonic	brain	development	SHH,	a	glycoprotein,	is	secreted	by	the	Purkinje	cells	and	
maintains	granule-neuron	precursor	cells	in	the	undifferentiated,	proliferating	state	(Tichy	
et	al.	2015).	Components	of	the	signalling	pathway,	PTC1,	PTC2,	SMO,	GLI1	and	GLI2	are	
produced	by	the	GCPs	in	the	EGL	(Wechsler-Reya	&	Scott	2001a).	When	Purkinje	cells	are	
absent	GCP	proliferation	fails	suggesting	that	SHH	from	the	Purkinje	cells	plays	a	major	role,	
or	may	be	required	for,	the	proliferation	of	GCPs	(Smeyne	et	al.	1995).		
1.4.7 Inactive	SHH	signalling		
	
The	SHH	receptor	patched	1	(PTC1)	supresses	the	activity	of	smoothened	protein	which	is	
closely	 related	 to	 the	 frizzled	 family	 of	WNT	 receptors	 (Taipale	 et	 al.	 2002).	 PTC1	may	
supress	 smoothened	 (SMO)	 indirectly,	 by	 acting	 as	 a	 transmembrane	 transporter	 for	 a	
small	intermediary	molecule		(Gilbertson	2004).	In	the	absence	of	SMO	activity,	the	glioma-
associated	oncogene	homologue	(GLI)	transcription	factors,	which	are	the	effectors	of	the	
SHH	pathway,	are	tethered	to	microtubules	in	the	cytoplasm	by	a	multi-protein	complex	
that	 includes	 fused	and	 suppressor-of-fused	 (SUFU)	 (Rubin	&	de	Sauvage	2006).	GLI1	 is	
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sequestered	into	this	complex,	preventing	the	activation	of	gene	transcription.	GLI2	and	
GLI3	 are	 cleaved	 to	 produce	 transcriptional	 repressors	 (Ruiz	 i	 Altaba	 1997;	 Gilbertson	
2004).	
1.4.8 Active	SHH	signalling	
	
The	binding	of	the	SHH	ligand	to	PTC1	removes	the	suppression	of	smoothened	(Gupta	et	
al.	2010).	Active	smoothened	can	disrupt	the	multi-protein	complexes	which	contain	fused	
and	 SUFU	 (Gilbertson	 2004).	 The	 binding	 of	 SHH	 to	 PTC1	 removes	 the	 suppression	 of	
smoothened	(Taipale	et	al.	2002).	When	smoothened	is	active	the	multi-protein	complex,	
which	 contains	 fused	 and	 suppressor-of-fused,	 is	 disrupted	 (Gilbertson	 2004).	
Subsequently,	GLI1	is	released	and	activates	gene	expression	(Rubin	&	de	Sauvage	2006).	
Cleavage	of	GLI1	 and	GLI3	 is	 blocked.	Although	 full	 length	GLI2	 and	GLI3	 can	enter	 the	
nucleus,	how	they	can	affect	gene	transcription	is	currently	unknown	(Ruiz	i	Altaba	1997).	
A	summary	of	this	pathway	is	shown	in	figure	1.2.	
1.4.9 SHH	signalling	in	medulloblastoma	
	
In	the	hereditary	disease,	Gorlin’s	syndrome,	patients	were	found	to	have	a	predisposition	
for	neoplasms,	including	medulloblastoma	(Smith	et	al.	2014).	The	patients	were	found	to	
have	germline	mutations	in	PTCH1	(Smith	et	al.	2014).		
Other	mutations	have	also	been	identified	in	this	subgroup,	suggesting	that	heritable	forms	
of	the	disease	can	result	from	several	mutations	in	the	SHH	pathway	Taylor	et	al.	2012.		
Murine	models	of	medulloblastoma	exist	and	of	these	14%	of	mice	with	a	heterozygous	
loss	of	PTCH	develop	medulloblastoma.	This	low	incidence	may	indicate	that	second-hits	of	
the	genome	are	required	for	tumourigenesis.	Note	that	these	mice	do	not	exhibit	loss	of	
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p53,	however	tumours	are	more	rapidly	and	frequently	seen	in	heterozygous	PTCH	mice	
that	have	a	deletion	in	TP53.	Gilbertson	(2004)	has	suggested	that	tumours	occur	in	PTCH	
heterozygous	TP53	wild-type	mice	not	due	to	disruption	of	the	P53	pathway,	but	rather	
this	deletion	destabilises	the	genome	(Gilbertson	2004).	Finally,	there	is	also	evidence	to	
suggest	 that	 overexpression	 of	 SHH	 in	 granule-neuron	 precursor	 cells	 can	 induce	
medulloblastoma	in	mouse	models	even	in	the	absence	of	GLI1	(H.	L.	Weiner	et	al.	2002).		
1.4.10 Subgroup	Features		
This	subgroup	of	medulloblastoma	accounts	for	30%	of	cases,	with	15	–	20%	of	patients	
presenting	with	metastatic	disease	(Gajjar	&	Robinson	2014).	Five-year	survival	for	patients	
with	this	subgroup	is	in	excess	of	80%	(Northcott	et	al.	2015),	however	a	subset	of	patients	
with	mutations	in	TP53	have	extremely	poor	prognosis,	similar	to	that	of	group	3	patients	
(Zhukova	et	al.	2013).	This	subgroup	has	a	distinct	 location	compared	to	WNT	tumours,	
suggesting	 a	 different	 origin	 (Gibson	 et	 al.	 2010).	 SHH	 tumours	 tend	 to	 occur	 in	 the	
cerebellar	hemispheres,	and	rarely	in	the	midline	(Raybaud	et	al.	2015;	Gajjar	&	Robinson	
2014).	
The	SHH	subgroup	of	medulloblastoma	occurs	largely	in	infants	(0-3	years)	and	adults	
(<16	years)	but	is	much	less	frequent	in	the	ages	between	(Taylor	et	al.	2012).	There	is	an	
incidence	of	1	:	1	male	:	female	for	this	subgroup	(Gajjar	&	Robinson	2014).	SHH	subgroup	
medulloblastomas	are	mostly	identified	by	transcriptional	profiling	(Taylor	et	al.	2012;	
Northcott	et	al.	2015).	Other	approaches	to	identifying	this	subgroup	have	been	via	
immunohistochemical	staining	for	Secreted	Frizzled-Related	Protein	1	(SFRP1)	and	GRB2-
associated-binding	protein	1(GAB1)	(Taylor	et	al.	2012).	Other	characteristics	for	this	
subgroup	include	loss	of	chromosome	9q	(where	the	PTCH	gene	is	located)	(Ellison	et	al.	
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2011).	Because	PTC1	is	a	negative	regulator	of	the	SHH	pathway,	deletion	of	PTCH1	in	
granule-neuron	precursor	cells	may	result	in	malignant	transformation	(Gilbertson	2004).	
In	fact,	most	SHH	medulloblastomas	are	thought	to	arise	from	the	transformed	granule-
neuron	precursor	cells,	the	location	and	characteristics	of	this	subgroup	are	summarised	
in	table	1.2.	Mutations	of	PTCH	have	also	been	identified	in	10-20	%	of	sporadic	cases	
(Wechsler-Reya	&	Scott	2001a;	Northcott	et	al.	2015).		
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Figure	1.2	The	SHH	pathway	in	cerebellar	development.	In	SHH	is	a	secreted	ligand	which	
binds	 to	 the	 receptor	 Patched	 1	 (PTC1),	 this	 removes	 the	 inhibition	 on	 the	 receptor	
smoothened	(SMO)	and	inhibits	a	multi-protein	complex	containing	fused	or	suppressor	
of	fused	allowing	glioma-associated	homologue	1	(GLI1)	and	GLI2/3	to	drive	transcription.	
When	the	pathway	is	inactive	gene	transcription	is	silent	due	to	inhibition	of	SMO.	In	SHH	
medulloblastomas	there	are	mutations	in	this	pathway,	such	as	mutations	of	SMO	and	
PTCH1,	which	drive	expression	of	the	oncogenes.	Adapted	from	(Gilbertson	2004)		
	 44	
Table	 1.2	 Disease	 features	 of	 SHH	medulloblastoma.	 The	 proposed	 cell	 of	 origin	 and	
developmental	 stage	 are	 thought	 to	 be	 when	 aberrant	 SHH	 signalling	 drives	
tumorigenesis.	Adapted	from	Gajjar	&	Robinson	2014.		
Disease	Feature	 SHH	Subgroup	
Proposed	cell	of	origin	 Neural	 Stem	 cell	 or	 granule	 precursor	 cell	
<10	weeks	embryonic	
Origin	 External	granule	layer	of	the	cerebellum	
Location	of	disease	 External	granule	layer	
Neoplastic	event	 SHH	 deregulation	 in	 the	 granule	 precursor	
cell	
Candidate	genes	 SHH	pathway	PTCH1,	GLI1,	V-Myc	Avian	
Myelocytomatosis	Viral	Oncogene	
Neuroblastoma	Derived	Homolog	
	(MYCN)	
Underlying	mechanism		 Over-activation	of	stem	cell	maintenance	
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1.4.11 Group	3	and	Group	4	medulloblastomas	
	
There	is	much	less	known	about	the	signalling	pathways	involved	in	the	pathogenesis	of	
group	3	and	group	4	medulloblastoma,	and	 they	are	 so	named	as	 currently	 there	 is	no	
known	consistent	signalling	pathway	involvement	for	either	(Taylor	et	al.	2012).		
1.4.12 Group	3	
	
25%	of	medulloblastoma	patients	have	group	3	disease	(Gajjar	&	Robinson	2014).	Group	3	
carries	the	worst	prognosis	of	the	medulloblastoma	subgroups	(Taylor	et	al.	2012).		5	year-
survival	is	currently	around	50%	(Gajjar	&	Robinson	2014).	Patients	who	have	this	subgroup	
of	 tumour	 very	 frequently	 present	 with	 metastatic	 disease	 (40-45	 %	 cases)	 (Gajjar	 &	
Robinson	2014).	This	subgroup	is	more	common	in	infants	and	children	but	is	almost	never	
seen	 in	 adults,	 it	 is	 also	more	 common	 in	males	 than	 females	 (Taylor	 et	 al.	 2012).	 No	
germline	mutations	have	been	found	(Schroeder	&	Gururangan	2014).	The	location	of	the	
group	3	tumours	is	generally	in	the	fourth	ventricular	midline	(Gajjar	&	Robinson	2014).		
Group	3	tumours	overexpress	a	number	of	genes	that	were	 initially	discovered	for	their	
roles	in	retinal	development	(de	Haas	et	al.	2006).	It	is	currently	not	known	what	role	these	
genes	play	in	the	pathogenesis	of	this	subgroup	(Northcott	et	al.	2015).	This	subgroup	also	
expresses	high	levels	of	MYC	(but	not	MYCN)	which	lead	some	investigators	to	suggest	this	
group	should	be	remained	the	MYC	subgroup	(Taylor	et	al.	2012).	Over-expression	of	MYC	
however	is	not	strictly	limited	to	this	subgroup	(Roussel	&	Robinson	2013).	For	example,	
some	patients	with	favourable	prognosis	WNT	tumours	may	exhibit	overexpression	of	MYC,	
although	this	almost	never	occurs	(Roussel	&	Robinson	2013).	Despite	this,	the	favourable	
outcome	of	 the	WNT	subgroup	 is	 retained	 in	 these	patients	 (Staal	et	al.	2015).	Another	
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suggested	marker	of	this	subgroup	is	 immunohistochemical	positivity	for	atrionatriuretic	
peptide	 receptor	 C	 (NPR3)	 (Taylor	 et	 al.	 2012).	 Despite	 these	 suggestions	 group	 3	 is	
currently	 stratified	 by	 a	 similar	 molecular	 signature	 to	 other	 group	 3	 tumours,	 and	 a	
different	signature	from	the	other	subgroups	(Northcott	et	al.	2011)	.		
Group	3	share	some	of	the	characteristics	of	group	4	tumours,	such	as	amplification	of	the	
patterning	gene	Orthodenticle	Homeobox	2	 (OTX2),	which	 represses	differentiation	and	
can	up-regulate	MYC	(Marshall	et	al.	2014).		
Genetic	 characteristics	 of	 this	 subgroup	 are	 also	 shared	with	 group	 4,	 however	 gain	 of	
chromosome	1q	and/or	loss	of	chromosomes	5q	and	10q	are	much	more	likely	to	be	seen	
in	 group	 3	 tumours	 than	 group	 4	 (Taylor	 et	 al.	 2012;	 Gilbertson	 2004).	 Genetic	
abnormalities	seen	in	this	subgroup	are	gains	in	1q	and	7	and	losses	in	10q	and	16q	(Taylor	
et	al.	2012;	Packer	et	al.	1994).	This	subgroup	can	also	exhibit	isochromosome	17q,	seen	in	
26	%	of	patients,	this	is	also	seen	in	group	4	patients,	but	not	in	WNT	or	SHH	tumours	(Gajjar	
&	Robinson	2014).	The	characteristics	of	this	subgroup	are	summarised	in	table	1.3.	
One	mouse	model	of	group	3	 is	currently	available,	 the	GTML	(Glt1-tTA/TRE-MYCN-Luc)	
mouse	driven	by	the	MYCN	oncogene	(Ahmad	et	al.	2015;	Gendoo	et	al.	2015).	Despite	
MYC	 amplification	 being	 more	 common	 in	 this	 subgroup,	 these	 mice	 exhibit	 similar	
histology	to	group	3	tumours	in	humans	(Pöschl	et	al.	2014).	
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Table	1.3	Disease	features	of	group	3	medulloblastoma.	Adapted	from	Gajjar	&	Robinson	
2014.		
Disease	Feature	 Group	3	
Proposed	cell	of	origin	 Granule	neuron	precursor	cell	10-20	weeks	early	foetal	
Origin	 Immature	pineal	or	retinal	region	
Location	of	disease	 External	granule	layer	
Neoplastic	event	 Granule	neuron	precursor	lineage	switch	to	rod	precursor	
Candidate	genes	 MYC,	neural	retina	leucine	zipper	(NRL),	rod	proliferation	
Underlying	mechanism		 Decoupling	of	differentiation/proliferation	
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1.4.13 Group	4	
	
Group	4	is	the	most	common	subgroup	of	medulloblastoma,	encompassing	approximately	
one	 third	 of	 patients	 (Gajjar	 &	 Robinson	 2014).	 Currently,	 group	 4	 medulloblastoma	
patients	are	identified	through	a	transcriptional	profile	that	clusters	them	with	other	group	
4	patients	(Northcott	et	al.	2011).	This	subgroup	as	a	higher	incidence	in	males	with	a	3:1	
male	:	female	incidence	(Taylor	et	al.	2012;	Gajjar	&	Robinson	2014).	This	subgroup	carries	
an	intermediate	prognosis	similar	to	that	of	the	SHH	subgroup.	35-40	%	of	patients	present	
with	metastatic	disease	(Gajjar	&	Robinson	2014).		
Group	4	tumours	have	been	shown	to	overexpress	neuronal	differentiation	markers	which	
may	 help	 to	 define	 this	 subgroup	 (Taylor	 et	 al.	 2012).	 It	 has	 also	 been	 suggested	 that	
positive	immunohistochemical	staining	of	the	protein	Potassium	Channel,	Voltage	Gated	
Shaker	Related	Subfamily	A,	Member	1	 (KCNA1),	a	potassium	channel,	could	define	this	
subgroup	 (Taylor	 et	 al.	 2012).	 Both	 of	 these	 markers	 requires	 further	 validation	 as	
expression	may	not	 be	 exclusive	 to	 group	4	 tumour	 and	 the	 clinical	 relevance	of	 these	
markers	are	not	yet	apparent	(Taylor	et	al.	2012).	The	most	frequent	mutation	seen	in	this	
subgroup	 is	 in	 Lysine	 (K)-Specific	 Demethylase	 6A (KDM6A),	 a	 demethylase	 gene	 that	
regulates	trimethylation	status	of	lysine	27	of	histone	3	(H3K27)	in	stem	cells	(Robinson	et	
al.	2012;	Northcott,	Jones,	et	al.	2012;	Jones	et	al.	2012;	Pugh	et	al.	2012).	The	KDM6A	gene	
is	located	on	the	X	chromosome	and	there	is	a	homologue	located	on	the	Y	chromosome,	
however	 this	mutation	 is	more	 commonly	 seen	 in	males	 than	 females	 (Robinson	 et	 al.	
2012).	 In	addition	10%	of	patients	also	have	a	single	copy	gain	of	5q23.2,	where	the	a-
synclein-interacting	 protein	 (SNCAIP)	 gene	 is	 located	 (Gajjar	 &	 Robinson	 2014).	 In	
Parkinson’s	disease	patients	the	encoded	synphillin-1	binds	to	a-synuclein	to	promote	the	
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formation	of	Lewy	bodies.	The	role	of	synphillin-1	in	medulloblastoma	is	however	currently	
unknown	(Northcott,	Jones,	et	al.	2012;	Northcott,	Shih,	et	al.	2012).	This	subgroup	does	
not	overexpress	MYC	like	the	group	3	tumours,	the	expression	of	MYCN	is	also	generally	
low	apart	from	a	few	cases	which	have	MYCN	amplification	(Roussel	&	Robinson	2013).	
Although	isochromosome	17q	is	seen	in	group	3	tumours,	it	is	much	more	common	in	group	
4	tumours,	seen	 in	66	%	of	patients,	and	 is	 the	most	common	genetic	change	(Gajjar	&	
Robinson	2014).	The	only	other	genetic	change	in	group	4	tumours	that	is	commonly	seen	
is	the	loss	of	the	X	chromosome	in	female	patients	that	occurs	in	80	%	of	cases	(Gajjar	&	
Robinson	2014).	No	mouse	model	of	this	subgroup	currently	exists	(Eberhart	2012;	Gajjar	
&	Robinson	2014).	The	characteristics	of	this	subgroup	are	summarised	in	table	1.4.	
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Table	1.4.	Disease	features	of	group	4	medulloblastoma.	Adapted	from	Gajjar	&	Robinson	
2014.	
Disease	Feature	 Group	4	
Proposed	cell	of	origin	 Granule	neuron	precursor	cell	>20	weeks	late	foetal	
Origin	 Premature	glutamatergic	neuronal	networks	
Location	of	disease	 External	granule	layer/	internal	granule	layer	
Neoplastic	event	 Deregulation	during	synaptic	pruning	
Candidate	genes	 α-Synuclein-Interacting	 Protein	 (SNCAIP),	 α-
synuclein/semaphorin	apoptosis	
Underlying	mechanism		 Imbalance	of	apoptosis,	survival	and	proliferation	
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In	summary	the	four	molecular	subgroups	of	medulloblastoma	that	have	currently	been	
identified	share	some	disease	features	and	have	distinct	defining	features.	These	are	
summarised	in	table	1.5.	
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Table	 1.5	 Summary	 of	 disease	 features	 in	 each	 of	 the	 molecular	 subgroups	 of	
medulloblastoma	 demonstrating	 similarities	 and	 differences	 within	 each	 of	 the	
subgroups.	Adapted	from	Gajjar	&	Robinson,	2014.	
Disease	
Feature	
WNT	 SHH	 Group	3	 Group	4	
Proposed	
cell	of	
origin	
Neural	Stem	
cell	<6	weeks	
post-embryonic	
Neural	Stem	cell	
or	granule	
precursor	cell	<10	
weeks	embryonic	
Granule	neuron	
precursor	cell	
10-20	weeks	
early	foetal	
Granule	neuron	
precursor	cell	>20	
weeks	late	foetal	
Origin	 Possibly	the	
sub-ventricular	
zone	or	fourth	
ventricle	
External	granule	
layer	of	the	
cerebellum	
Immature	
pineal	or	retinal	
region	
Premature	
glutamatergic	
neuronal	
networks	
Location	of	
disease	
Dorsal	stem	 External	granule	
layer	
External	
granule	layer	
External	granule	
layer/	internal	
granule	layer	
Neoplastic	
event	
WNT	
deregulation	
(among	
others?)	
SHH	deregulation	
in	the	granule	
precursor	cell	
Granule	neuron	
precursor	
lineage	switch	
to	rod	
precursor	
Deregulation	
during	synaptic	
pruning	
Candidate	
genes	
WNT	pathway,	
Dickkopf-
related	protein	
1	(DKK1),	
Mitogen-
Activated	
Protein	Kinase	
Kinase	3		
(SKK2),	
Dickkopf-
related	protein	
4	(DKK4)	
SHH	pathway	
PTCH1,	GLI1,	V-
Myc	Avian	
Myelocytomatosis	
Viral	Oncogene	
Neuroblastoma	
Derived	Homolog	
(MYCN)	
MYC,	neural	
retina	leucine	
zipper	(NRL),	
rod	
proliferation	
α-Synuclein-
Interacting	
Protein	(SNCAIP),	
α-synuclein/	
semaphorin	
apoptosis	
Underlying	
mechanism		
Over-activation	
of	stem	cell	
maintenance	
Over-activation	of	
stem	cell	
maintenance	
Decoupling	of	
differentiation/
proliferation	
Imbalance	of	
apoptosis,	
survival	and	
proliferation	
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1.5 Other	signalling	pathways	implicated	in	medulloblastoma	pathogenesis	
The	WNT	and	SHH	pathways	are	unlikely	 to	be	 the	only	 cell-signalling	 systems	 that	are	
deregulated	 during	medulloblastoma	 formation.	 For	 example,	 the	 amplification	 of	MYC	
occurs	quite	commonly	in	large-cell	anaplastic	medulloblastomas,	described	later,	and	is	
thought	to	be	associated	with	poor	clinical	outcome	(Roussel	&	Robinson	2013).	In	contrast,	
tumour	cell	expression	of	the	neurotrophic	receptor	Tropomyosin	receptor	kinase	C	(TRKC)	
has	been	associated	with	 favourable	outcome	 in	medulloblastoma	patients	 (Segal	et	al.	
1994).	 Studies	have	also	 identified	platelet-derived	growth	 factor	 receptor	 (PDGFR)	and	
RAS	 MAPK	 pathway	 activation	 as	 potential	 mediators	 for	 dissemination	 of	
medulloblastoma	(Gilbertson	&	Clifford	2003;	MacDonald	et	al.	2001).		
There	is	also	evidence	that	the	aberrant	expression	of	Erb-B2	Receptor	Tyrosine	Kinase	2	
(ERBB2)	 in	 granule-neuron	 precursor	 cells	 of	 the	 cerebellum	 may	 have	 a	 role	 in	
medulloblastoma	 formation	 (Gilbertson	 et	 al.	 1997;	Gilbertson	 et	 al.	 2001;	Gajjar	 et	 al.	
2004).	 In	 studies	 of	more	 than	150	paediatric	medulloblastoma	patients	 ERBB2	protein	
expression	was	shown	in	80	%	of	the	tumour	samples	(Gilbertson	et	al.	1997;	Gilbertson	et	
al.	2001;	Gajjar	et	al.	2004).	The	finding	contrasts	from	non-neoplastic	cerebellum	where	
ERBB2	is	not	expressed	at	any	stage	during	normal	development	(Gilbertson	et	al.	1998).	
ERBB2	has	been	associated	with	poor	clinical	outcome	in	these	patients	(Gilbertson	et	al.	
1997;	Gilbertson	et	al.	2001;	Gajjar	et	al.	2004).		
ERBB1,	ERBB2,	ERBB3	and	ERBB4	are	members	of	the	receptor	tyrosine	kinase	I	family.	A	
summary	of	this	pathway	is	shown	in	figure	1.3.	These	receptors	interact	through	a	complex	
network	 of	 hetero-	 and	 homodimerisations	 (Muthuswamy	 et	 al.	 1999).	 ERBB	 dimers	
activate	the	cell	signalling	pathways	of	mitogen-activated	protein	kinase	(MAPK),	AKT	and	
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signal	 transducer	 and	 activator	 of	 transcription	 (STAT),	 which	 allows	 them	 to	 regulate	
several	key	cell	processes	such	as	proliferation,	apoptosis,	migration	and	differentiation	
(Zomerman	et	al.	2015).			
When	 aberrant	 up-regulation	 of	 ERBB2	 occurs	 cell	 transform	 can	 also	 occur	 (Yarden	&	
Sliwkowski	2001;	 Segatto	et	al.	 1988).	 In	 rodents,	 a	point	mutation	 (V664E)	 results	 in	a	
significant	increase	in	homodimerisation	of	the	transmembrane	domain	of	Neu	(the	rodent	
orthologue	of	ERBB2)	(Weiner	et	al.	1989;	Padhy	et	al.	1982)	inducing	tumour	formation	in	
the	CNS.	Although	an	equivalent	mutation	in	human	ERBB2	transforms	cells,	this	mutation	
has	not	been	identified	in	sporadic	human	tumours	(Segatto	et	al.	1988;	Gilbertson	2004)	.		
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Figure	1.3	ERBB	signalling	 in	medulloblastoma.	ERBB1,	3	or	4	can	heterodimerise	with	
ERBB2,	 and	 when	 overexpressed	 ERBB2	 can	 homodimerise.	 Upon	 dimerization	
autophosphorylation	occurs	 (P)	and	activates	downstream	signalling	via	RAS	and	PI3K	
leading	to	increased	proliferation,	metastasis	and	inhibition	of	apoptosis.	Adapted	from	
(Gilbertson	2004)	
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1.6 Emerging	molecular-subgroup	targeted	therapies	
Survival	of	patients	with	medulloblastoma	varies	according	to	molecular	subgroup	(Taylor	
et	al.	2012).	In	order	to	address	this	problem	more	targeted	therapeutics	are	beginning	to	
emerge.	 These	 therapeutics	 target	 cell-signalling	 pathways	 that	 function	 abnormally	 in	
medulloblastoma.	
Cyclopamine	 is	 a	 plant-derived	 teratogen	 that	 inhibits	 the	 SHH	pathway	 (Samkari	 et	 al.	
2015).	The	mechanism	of	action	of	this	drug	is	to	bind	to	and	thus	inactivate	smoothened	
(Samkari	 et	 al.	 2015).	 This	 drug	 is	 only	 suitable	 for	 patients	with	 recurrent	 disease	 and	
either	 PTC1	 mutations	 or	 some	 SMO	 mutations,	 leaving	 around	 50%	 of	 SHH	 patients	
predicted	to	respond	(Gilbertson	2004).		Cyclopamine	specifically	targets	the	SHH	pathway	
in	medulloblastoma	cells,	causing	the	inhibition	of	GLI-mediated	gene	expression,	cell	cycle	
arrest	 and	 therefore	 has	 antineoplastic	 activity	 (Gilbertson	 2004;	 Samkari	 et	 al.	 2015).	
Other	smoothened	antagonists	are	in	preclinical	development	and	are	expected	to	enter	
early	clinical	trials	for	medulloblastoma	within	the	next	few	years.	Recently,	resistance	to	
SHH	 pathway	 inhibitors	 have	 been	 reported	 (Gilbertson	 2004).	 The	 mechanism	 of	
resistance	is	reported	to	be	mutations	in	SMO	which	occur	with	prolonged	exposure,	these	
mutations	prevent	drug	binding	and	therefore	a	reduction	in	efficacy	(Samkari	et	al.	2015;	
Gilbertson	2004).		
Small-molecular	 inhibitors	 of	 receptor	 tyrosine	 kinases	 are	 a	 second	 class	 of	 potential	
molecular-targeted	therapies	for	medulloblastoma	(Hernan	et	al.	2003).	A	diverse	range	of	
agents	 that	 inhibit	ERRB2	expression	and	function	are	currently	being	developed.	These	
inhibitors	 include	the	non-selective	ERBB1	and	ERBB2	antagonist	erlotinib	(Hernan	et	al.	
2003).	Erlotinib	treatment	selectively	blocks	the	expression	of	several	ERBB2-dependent	
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pro-metastatic	 genes	 and	 reduces	 the	 invasive	 capacity	 of	 medulloblastoma	 cells	
(Gilbertson	2004).	This	drug	is	currently	under	phase	I	and	II	trials	for	medulloblastoma	in	
the	Children’s	Oncology	Group	and	through	the	US	Paediatric	Brain	Tumour	Consortium	
and	has	shown	good	tolerance	and	efficacy	in	phase	I	trials	(Jakacki	et	al.	2008;	Gilbertson	
2004).		
Other	treatments	that	may	prove	useful	for	subgroup	directed	therapy	for	group	3	tumours	
are	 gemcitabine	 and	pemetrexed,	 these	drugs	have	been	 shown	 to	have	 some	efficacy	
against	 MYC	 amplification	 (Morfouace	 et	 al.	 2014).	 Bromodomain	 and	 extraterminal	
domain	 (BET)	 antagonists,	 which	 interfere	with	MYC-associated	 transcription	 have	 also	
shown	 some	 efficacy	 against	 these	 tumours	 in	 mice	 and	 some	 xenografted	 cell	 lines	
(Bandopadhayay	et	al.	2014;	Henssen	et	al.	2013).		
1.7 Histopathological	variants	
Molecular	 subtyping	 has	 not	 yet	 found	 a	 place	 within	 most	 UK	 clinical	 settings	 and	
therefore	patients	are	stratified	based	on	their	histological	subgrouping	(Packer	et	al.	2003;	
Ramaswamy	et	al.	2015).	Overlap	of	histological	and	molecular	subgroups	is	shown	in	table	
1.6.	
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Table	1.6	Overlap	of	molecular	subgroup	and	histology.	Adapted	from	Taylor	et	al.	2012.	
Molecular	Subgroup	 Histology	
WNT	 Classic,	rarely	large	cell/anaplastic	
SHH	 Classic,	 desmoplastic/nodular	 (predominantly),	 large	
cell/anaplastic,	MBEN	(nearly	all	MBENs	are	SHH)	
Group	3	 Classic,	 large	cell/anaplastic	 (40%	of	all	 large	cell/anaplastic	
tumours	are	group	3)	
Group	4	 Classic,	rarely	large	cell/anaplastic	
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Histological	variants	of	medulloblastoma	have	been	recognised	by	the	WHO	and	so	named	
classic,	desmoplastic/nodular,	 large	cell/anaplastic,	and	medulloblastoma	with	extensive	
nodularity	 (MBEN)	 subgroups	may	 also	 exhibit	myogenic	 or	melanotic	 features,	 (World	
Health	Organisation	2007;	Gajjar	&	Robinson	2014).		
1.7.1 Classic	Variant	of	medulloblastoma	
	
The	classic	variant	of	medulloblastoma	is	defined	as	having	sheets	of	cells	with	small	round	
nuclei,	 a	 high	 ratio	 of	 nuclei	 to	 cytoplasm	 and	mild	 nuclear	 polymorphism.	 These	 cells	
occasionally	show	features	of	neuroblastic	differentiation,	demonstrated	by	the	presence	
of	neuroblastic	rosettes	figure	1.4A	(World	Health	Organisation	2007;	Gajjar	&	Robinson	
2014).		
1.7.2 Desmoplastic	/nodular	variant	of	medulloblastoma	
	
This	 histological	 subgroup	 is	 defined	 by	 nodules	 of	 differentiated	 neurocytic	 cells	 that	
express	neuronal	proteins.	There	are	also	internodular	regions	which	are	characterised	by	
undifferentiated	embryonal	cells	and	reticulin-rich	strands	of	collagen	figure	1.4B	(World	
Health	Organisation	2007;	Gajjar	&	Robinson	2014).		
1.7.3 Large	Cell/	Anaplastic	variant	of	medulloblastoma	(LCA)	
	
Large	cell	and	anaplastic	variants	of	medulloblastoma	have	considerable	cytological	overlap	
and	are	therefore	grouped	together	as	the	large	cell/anaplastic	variant.	
Histologically	classified	as	having	marked	nuclear	pleomorphism,	nuclear	moulding,	cell-
cell	wrapping	and	high	mitotic	activity,	often	with	atypical	forms	and	abundant	apoptotic	
bodies.	 To	 be	 defined	 as	 an	 anaplastic	 tumour	 there	must	 be	 extensive	 regions	 of	 this	
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phenotype.		The	large	cell	variant	has	spherical	cells	with	round	nuclei,	open	chromatin	and	
prominent	central	nucleoli	(figure	1.4C).	All	medulloblastomas	show	some	degree	of	atypia,	
these	 changes	 however	 are	 particularly	 pronounced	 in	 the	 anaplastic	 variant.	 In	 some	
patients,	 when	 biopsies	 are	 taken,	 a	 transition	 between	 classic	 and	 large/anaplastic	
histology	can	be	seen	(World	Health	Organisation	2007;	Gajjar	et	al.	1999)	.		
1.7.4 Medulloblastoma	with	extensive	nodularity	(MBEN)	
	
This	variant	is	closely	related	to	desmoplastic/nodular	disease	but	differs	as	it	exhibits	an	
expanded	 lobular	 architecture.	 Expansion	of	 these	areas	are	due	 to	 reticulin-free	 zones	
which	become	usually	large	and	rich	in	neuropil-like	tissue.	Reticulin-free	zones	contain	a	
population	of	cells	which	resemble	those	of	a	neurocytoma	and	exhibit	a	streaming	pattern.	
Between	 nodules	 the	 areas	 are	 rich	 in	 reticulin	 (figure	 1.4D),	 it	 is	 this	 histology	 that	 is	
prevalent	in	the	desmoplastic/nodular	variant	which	is	much	reduced	in	this	subgroup.	This	
subgroup	carries	a	more	favourable	prognosis	than	the	classic	subgroup	medulloblastomas	
(World	Health	Organisation	2007;	Gajjar	&	Robinson	2014).		
1.7.5 Myogenic	differentiation	
	
Medulloblastoma	with	myogenic	differentiation	was	referred	to	as	medullomyoblastoma	
but	is	no	longer	considered	a	distinct	subgroup,	but	rather	a	feature	of	any	subgroup.	To	
define	myogenic	differentiation,	the	tumour	must	contain	rhabdomyoblastic	elements	and	
stain	positive	for	desmin,	myoglobin,	fast	myocin,	but	not	smooth	muscle	a-actin	alone.	An	
example	of	this	feature	is	shown	in	figure	1.4E.	
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1.7.6 Melanotic	differentiation	
	
This	 was	 previously	 termed	 melanocytic	 medulloblastoma,	 but	 much	 like	
medullomyoblastoma,	this	is	no	longer	a	distinct	subtype	but	rather	a	feature	of	any	other	
subgroup.	An	example	of	this	histology	is	shown	in	figure	1.4F	Cells	with	melanotic	features	
may	appear	to	be	undifferentiated,	or	epithelial,	with	tubule	or	papillae	formation,	they	
also	usually	express	S-100	protein	(World	Health	Organisation	2007;	Gajjar	et	al.	1999).		
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Figure	1.4	Histological	subgroups	of	medulloblastoma.	(A)	Classic	medulloblastoma	showing	
a	 typical	 arrangement	 of	 sheets	 of	 undifferentiated	 cells.	 (B)	 Desmoplastic/nodular	
medulloblastoma	showing	pale	nodular	areas	surrounded	by	densely	packed	hyperchromatic	
cells.	(C)	Large	cell/anaplastic	medulloblastoma	showing	enlarged	vesicular	nuclei,	prominent	
nucleoli	 and	 moderate	 cytoplasm.	 (D)	 Medulloblastoma	 with	 extensive	 nodularity	 has	 a	
lobular	 architecture	 with	 large	 elongated	 reticulin-free	 zones.	 These	 zones	 contain	 small	
round	 neurocytic	 cells	 in	 the	 fibrillary	 background.	 (E)	 Medulloblastoma	 with	 myogenic	
differentiation	showing	striated	muscle	fibres	with	brisk	mitotic	activity.	(F)	Medulloblastoma	
with	melanotic	differentiation	showing	typical	tubular-like	features.	Images	from	the	World	
Health	Organisation	classification	of	central	nervous	system	tumours	(2007)	
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1.8 Treatment	of	medulloblastoma	
Current	 treatment	 for	 medulloblastoma	 includes	 maximal	 safe	 surgical	 resection,	
radiotherapy	if	the	patient	is	over	3	years	of	age,	and	high-dose	chemotherapy	(Schuler	et	
al.	 2014).	 Survivors	 of	 this	 disease	 often	 suffer	 significant	 treatment-related	 sequelae	
including	 endocrine	 disorders	 and	 neurocognitive	 deficits	 (Michiels	 et	 al.	 1996).	 These	
problems	occur	as	the	nature	of	treatment	is	aggressive	and	damaging	to	the	developing	
brain	tissue	(Gajjar	et	al.	1999).		
Multimodality	 treatments	 have	 substantially	 improved	 survival	 for	 patients	 with	
medulloblastoma,	however	approximately	one	third	of	cases	remain	incurable	(Gilbertson	
2004).	Medulloblastoma	in	children	younger	than	three	years	is	twice	as	likely	to	progress	
within	five	years	of	diagnosis	than	medulloblastoma	occurring	in	older	children	(Gilbertson	
2004).	One	explanation	 for	 age-dependent	disease	behaviour	 is	 the	 restriction	 that	 age	
imposes	on	treatment.	Children	under	three	do	not	have	radiotherapy	as	it	would	inflict	
severe	 damage	 to	 their	 developing	 brains	 that	 is	 deemed	unacceptable	 (Polkinghorn	&	
Tarbell	2007).	Others	have	speculated	that	young	children	have	more	aggressive	tumours	
(Packer	et	al.	2003).	Initial	treatment	for	patients	less	than	three	years	of	age	is	generally	
restricted	to	surgical	resection	and	chemotherapy	(Michiels	et	al.	1996).	This	approach	is	
associated	with	a	median	time	to	progression	of	less	than	nine	months	(Gilbertson	2004).		
Poor	clinical	outcome	is	seen	when	surgical	resection	leaves	more	than	1.5	cm2	on	post-
operative	MRI	and	 if	 there	 is	presence	of	secondary	 tumours	 (Ramaswamy	et	al.	2015).	
Medulloblastoma	has	the	ability	to	migrate	and	form	secondary	tumour	masses	through	
leptomeningeal	 dissemination	 or	 possibly	 via	 vascular	 metastasis	 (Garzia	 et	 al.	 2015).	
Around	a	 third	of	 	patients	present	with	CNS	dissemination	at	 time	of	diagnosis	 (World	
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Health	Organisation	2007).	A	 small	 but	 important	 group	of	patients	 also	develop	extra-
neural	 metastasis	 to	 the	 bone,	 bone	marrow,	 lymph	 nodes,	 liver	 or	 lung.	 This	 type	 of	
medulloblastoma	is	staged	according	to	Chang’s	criteria	(metastatic	or	M	stage;	table	1.7)	
and	 these	secondary	 tumours	 remain	one	of	 the	most	 important	prognostic	markers	of	
medulloblastoma	(Dufour	et	al.	2012;	Gilbertson	2004).		
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Table	1.7	M	stages	of	Chang’s	staging	classification	of	medulloblastoma	adapted	from	
(Dufour	et	al.	2012)	
M	stage	 	
M0	 No	gross	subarachnoid	or	haematogenous	metastasis.	
M1	 Tumour	cells	found	in	cerebral	spinal	fluid	on	microscopic	analysis.	
M2	 Gross	nodular	seeding	in	the	cerebellum,	cerebral	subarachnoid	space,	
or	in	third	or	fourth	ventricles.		
M3	 Gross	nodular	seeding	in	spinal	arachnoid	space.	
M4	 Extra-neural	metastasis.	
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Accurate	predictions	of	disease-risk	are	necessary	with	medulloblastoma	patients	in	order	
to	reduce	the	risk	of	tumour	recurrence,	which	is	frequently	fatal	(Ramaswamy	et	al.	2013),	
and	to	avoid	overtreatment	of	patients	who	would	be	 likely	to	survive	with	 less	 intense	
therapeutic	intervention	(Schuler	et	al.	2014).		
Currently	children	with	medulloblastoma	are	characterised	into	two	risk	groups.	Patients	
with	average-risk	disease	are	those	diagnosed	over	the	age	of	three,	with	no	secondary	
tumour	masses	and	<1.5	cm2	residual	disease	on	post-operative	MRI	and	no	presence	of	
anaplasia	 on	histological	 examination	 (Borowska	&	 Jóźwiak	 2016).	 Patients	who	do	not	
meet	these	criteria	are	classified	as	high-risk	(Tarbell	et	al.	2013).	In	Europe,	the	patient’s	
age	and	m	stage	(≤M1	vs	≥	M2)	alone	are	used	to	assign	disease	risk	(Gilbertson	2004).	This	
method	 of	 assessment	 is	 not	 precise;	 it	 does	 not	 identify	 the	 20-30%	 of	 patients	 with	
average-risk	disease.	Nor	does	this	method	identify	the	unknown	number	of	average-risk	
patients	who	are	over-treated	with	current	protocols	which	leads	to	increased	toxicity	and	
downstream	sequelae	for	these	children	(de	Bont	et	al.	2008).			
1.8.1 Treatment	protocols	based	on	disease	risk	
	
Average-risk	medulloblastoma	is	treated	with	maximal	safe	surgical	resection,	followed	by	
chemotherapy	and	whole	neuraxis	radiotherapy	(Kortmann	et	al.	2000;	Taylor	et	al.	2003;	
Packer	 et	 al.	 1999;	 Strother	 et	 al.	 2001).	 As	 radiotherapy	 is	 so	 damaging	 to	 the	 non-
neoplastic	 brain,	 in	 the	 US,	 standard	 radiation	 to	 the	 neuraxis	 for	 average-risk	
medulloblastoma	has	been	reduced	from	35	Gy	to	23.4	Gy	(Packer	et	al.	1999;	Strother	et	
al.	2001;	Thomas	et	al.	2000).	The	concurrent	introduction	of	adjuvant	therapy	has	enabled	
this	reduction	in	radiation	dose	without	affecting	the	survival	rate.	A	radiation	dose	of	23.4	
Gy	is	however	still	associated	with	neurological	deficits,	especially	in	patients	who	are	less	
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than	8	years	of	age	(Ris	et	al.	2001).	 	Because	of	this	a	phase	 III	study	by	the	Children’s	
Oncology	Group	(ACNS0331)	was	carried	out	that	tests	the	safety	of	further	reductions	in	
radiation	dose	down	to	18.0	Gy	for	average-risk	patients	aged	between	three	and	eight	
years.	The	aim	of	this	study	is	to	ensure	that	if	reductions	of	radiation	dose	reduced	disease	
morbidity,	they	did	not	do	so	at	the	expense	of	under	treating	the	pathology.	This	study	is	
still	 in	 its	 recruitment	 stage	 (Children's	 Oncology	 Group	 2013).	 Post-operative	
chemotherapy	 and	 radiation	 are	 also	 used	 to	 treat	 average-risk	 patients	 in	 Europe,	
although	the	neuraxis	dose	has	not	yet	been	reduced	from	35.0	Gy	(Gilbertson	2004).	
There	have	been	several	chemotherapeutic	regimens	that	have	been	investigated	for	the	
treatment	 of	 average-risk	 medulloblastoma.	 These	 include	 pre-radiation	 (sandwich)	
regimens	and	post-radiation	chemotherapy	(Taylor	et	al.	2003;	Packer	et	al.	1999;	Strother	
et	al.	2001).		These	studies	have	shown	that	a	combination	of	post-operative	chemotherapy	
and	radiotherapy	is	more	effective	at	treating	average-risk	medulloblastoma	than	surgery	
and	radiotherapy	alone.	However,	which	of	the	adjuvant	chemotherapy	regimens	carries	
the	greatest	survival	advantage	is	currently	unclear	as	the	5-year	survival	rates	for	many	
tested	protocols	are	reported	to	be	around	75%	(Kortmann	et	al.	2000;	Taylor	et	al.	2003;	
Packer	et	al.	1999;	Thomas	et	al.	2000).		
Progression-free	survival	in	children	with	high-risk	medulloblastoma	has	been	typically	less	
than	 50%	 (Ellison	 et	 al.	 2003).	 Some	 combination	 chemotherapy	 and	 radiotherapy	
treatments	have	yielded	more	promising	results.	A	study	by	St.	Jude’s	Children’s	hospital	
(SJMB’96)	 has	 used	 radiotherapy	 followed	 by	 high-dose	 chemotherapy	 and	 autologous	
stem-cell	rescue	and	has	proven	to	be	tolerated	well	and	overall-survival	was	reported	to	
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be	85%	for	average-risk;	and	70%	for	high-risk	patients	(Gajjar	et	al.	2006).	This	treatment	
however	is	still	associated	with	endocrine	disorder	risk	(Laughton	et	al.	2008).	
Patients	whose	disease	recurs	after	the	combined-modality	therapy	have	very	poor	survival	
(Ramaswamy	et	al.	2013).	Although	several	studies	have	shown	the	efficacy	of	high-dose	
chemotherapy	for	these	patients,	only	children	with	isolated	local	relapse,	chemo-sensitive	
disease	and	minimal	residual	disease	at	the	time	of	high-dose	chemotherapy	benefit	from	
such	an	approach	(Ellison	et	al.	2003).		
1.9 Opportunity	for	new	therapy	
Clearly	refined	risk	analysis	and	new	treatments	will	come	hand-in-hand.	New	treatments	
are	urgently	needed	to	reduce	the	risk	of	adverse	side-effects	and	improve	quality	of	life	
for	survivors	while	also	improving	survival	rates	for	those	with	high-risk	disease.		
One	 such	 approach	 involves	 a	 ganglioside	 acetylation	 pathway	 known	 to	 function	
abnormally	 in	 high-grade	 gliomas	 (Birks	 et	 al.	 2011).	 This	 pathway	 has	 been	 shown	 to	
influence	cell	survival	and	have	roles	in	embryonic	brain	development	(Svennerholm	et	al.	
1989).	As	medulloblastoma	is	a	brain	tumour	of	development,	we	hypothesised	that	this	
pathway	may	have	a	role	in	the	pathology	of	this	tumour.		
1.10 Gangliosides	
Gangliosides	were	first	discovered	by	Ernst	Klenk	in	1942	while	he	was	analysing	the	lipids	
found	in	the	post-mortem	brains	of	patients	with	a	fatal	infantile	condition	known	as	Tay-
Sachs	disease	(Svennerholm	1963).	Gangliosides	are	glycosphingolipids	(GSLs)	ubiquitously	
expressed	 throughout	 the	body	but	 are	most	 abundant	 in	 the	grey	matter	of	 the	brain	
(Schengrund	 2015).	 There	 are	 currently	 188	 known	 gangliosides	 which	 differ	 in	 their	
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structure	(Yu	et	al.	2004).	Gangliosides	have	diverse	structures	(Krengel	&	Bousquet	2014)	
which	allows	their	diverse	roles	in	processes	such	as	cell-signalling,	adhesion	and	survival	
among	others	(Regina	Todeschini	&	Hakomori	2008).	Gangliosides	are	co-localised	in	the	
microdomain	 structures	 of	 the	 lipid	 rafts,	 often	with	 signalling	 and	 adhesion	molecules	
(Sorice	et	al.	2012).	In	addition	to	being	localised	on	the	cell	surface,	gangliosides	are	also	
found	within	 cells	 and	 associate	with	 organelles	 such	 as	 nuclear	membranes,	 the	Golgi	
apparatus	and	the	endoplasmic	reticulum	(ER)	(Schwarz	&	Futerman	1997).		
Gangliosides	are	also	components	of	the	neuronal	plasma	membrane	and	they	can	affect	
neuronal	 function	(Schengrund	2015).	Their	expression	patterns	are	tightly	regulated	by	
their	biosynthetic	and	catabolic	steps	as	well	as	their	intracellular	trafficking	(Yu	et	al.	2004;	
Sandhoff	&	Harzer	2013).	Ganglioside	metabolism	is	highly	regulated	by	their	constitutive	
degradation	 in	 endosomes	 and	 lysosomes	 (Sandhoff	 &	 Harzer	 2013).	 Defects	 in	 the	
degradation	process	can	result	 in	massive	accumulation	of	gangliosides	 in	the	lysosomal	
compartment	and	other	organelles	(Ryan	et	al.	2013).		
The	nomenclature	of	the	gangliosides	is	according	to	Lars	Svennerholm,	who	initially	based	
their	names	on	the	migration	order	of	the	gangliosides	when	separated	by	chromatography	
(Svennerholm	1963).		
1.10.1 Ganglioside	Biosynthesis	
	
Gangliosides	are	synthesised	from	ceramide	which	is	translocated	to	the	Golgi.	Here,	the	
addition	of	carbohydrate	residues	which	make	up	the	ganglioside	backbone	are	added	by	
a	series	of	glycosyltransferases	(Yu	et	al.	2004).	Only	GM4	differs	in	synthesis,	every	other	
ganglioside	is	derived	from	glucosylceramide	(GluCer)	or	lactosylceramide	(LacCer)	(Yu	et	
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al.	2004).	The	addition	of	the	sialic	acid	residues	which	define	the	ganglioside	are	added	by	
a	series	of	sialyltransferases	onto	their	LacCer	or	GluCer	backbones	shown	in	figure	1.5.	
GM3,	 the	 simplest	 ganglioside,	 is	 generated	 by	 the	 addition	 of	 sialic	 acid	 to	 its	 LacCer	
backbone	by	GM3	synthase	(Proia	2004).		Further	sialic	acid	residues	are	then	added	to	this	
GM3	 structure	 by	 other	 specific	 sialyltransferases,	 for	 example	GD3	 synthase	 (ST8Sia1)	
forming	GD3	(Yu	et	al.	2004).	When	GM3,	GD3	and	GT3	lack	N-acetylgalactosamine,	they	
serve	 as	 precursors	 for	 the	 more	 complex	 gangliosides	 which	 are	 generated	 through	
addition	 of	 sialic	 acids	 through	 more	 promiscuous	 sialyltransferases	 along	 specific	
pathways	(Yu	et	al.	2004).	The	start	of	the	ganglioside	biosynthesis	pathway	is	shown	in	
figure	 1.5.	 The	 expression	 levels	 and	 patterning	 of	 the	 gangliosides	 undergo	 dramatic	
changes	 throughout	 brain	 development	 and	 disease	 states	 such	 as	 cancer	 (Schengrund	
2015).	 For	 example,	 in	 the	 human	 embryonic	 brain,	 the	major	 gangliosides	 are	 simple,	
GM3,	 GD3	 and	 9-O-acetyl	 GD3	 (GD3A)	 (Ryan	 et	 al.	 2013).	 As	 the	 brain	 develops,	 the	
expression	of	 these	simple	gangliosides	 is	 replaced	with	 the	more	complex	gangliosides	
such	 as	 GM1,	 GD1a	 and	 GT1b	 (Yu	 et	 al.	 2012).	 This	 change	 is	 tightly	 regulated	 at	 the	
transcriptional	 and	 post-translational	 levels	 by	 multiple	 systems	 and	 epigenetic	
modifications	(Yu	et	al.	2004).		
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Figure	1.5	The	ganglioside	biosynthesis	pathway.	Ceramide	has	glucose	and	galactose	
residues	added	to	it	by	glucosyl-	and	galactosyl-transferases	respectively.	The	resulting	
lactosylceramide	 then	 has	 sialic	 acids	 added	 to	 it	 by	 a	 series	 of	 sialyltransferases	
generating	the	gangliosides.	Biosynthesis	of	the	individual	gangliosides	runs	in	parallel	
pathways	forming	the	a-	b-	and	c-	series	gangliosides.	The	synthesis	of	the	gangliosides	
is	 regulated	 by	 control	 of	 the	 activity	 and	 expression	 of	 the	 sialyltransferases	 and	
modifications	of	the	sugar-ceramide	backbone.	Adapted	from	Yu	et	al.	2004.		
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1.11 GD3	and	GD3A	in	the	developing	non-neoplastic	brain	
Gangliosides	have	 important	roles	 in	embryonic	and	foetal	brain	development	(Yu	et	al.	
2004;	Ngamukote	et	al.	2007;	Schengrund	2015;	Ryan	et	al.	2013;	Svennerholm	et	al.	1989;	
Basu	et	al.	2012).	During	brain	development	there	is	a	high	abundance	of	gangliosides	such	
as	GD3	and	GD3A	(Miyakoshi	et	al.	2001;	Kotani	et	al.	1995).	The	expression	of	gangliosides	
in	the	brain	changes	significantly	throughout	neural	development	according	to	the	specific	
function	of	each	of	the	cell	 types	(Yu	et	al.	2004).	For	example,	during	proliferation	and	
migration,	which	occurs	between	8	and	25	weeks	of	gestation,	neuronal	and	glial	precursor	
cells	predominantly	express	GD3	and	GM3	(Ryan	et	al.	2013).	However,	 later	 in	 life,	 for	
example	after	birth,	the	expression	of	these	gangliosides	is	significantly	reduced	(Molander	
et	al.	2000;	Yu	et	al.	2004)	.		
GD3	is	an	example	of	a	ganglioside	that	has	very	restricted	expression	in	non-neoplastic	
tissue	but	enhanced	expression	in	some	malignancies	(Birklé	et	al.	2003).	GD3	is	a	minor	
ganglioside	in	most	non-neoplastic	tissues	after	birth,	except	the	thymus	(Dyatlovitskaya	&	
Bergelson	1987),	placenta	(Dyatlovitskaya	&	Bergelson	1987)	and	a	small	number	of	T-cells	
in	the	blood	(Welte	et	al.	1987).	GD3	expression	may	also	be	increased	in	non-neoplastic	
cells	such	as	activated	microglia	(Wolswijk	1995)	and	reactive	astrocytes	(K.	Kawai	et	al.	
1994)	which	has	been	shown	in	rat	brain.			
In	the	1980s	several	groups	discovered	that	GD3	expression	in	the	external	granule	layer	
(EGL)	of	the	developing	cerebellum	was	high	(Goldman	&	Reynolds	1996).	These	cell	types	
were	both	of	neuronal	and	glial	lineage	and	were	described	as	neuroectodermal	cells.	Later	
the	amoeboid	microglia	of	the	subventricular	zone	were	also	identified	as	GD3	expressing	
cells	in	the	developing	CNS	(Goldman	&	Reynolds	1996).	The	dendrites	of	the	Purkinje	cells	
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also	express	GD3	in	their	cell	membranes,	this	is	first	seen	at	post-natal	day	7,	and	increases	
in	 intensity	when	the	dendritic	tree	 increases	 in	complexity	(Goldman	&	Reynolds	1996;	
Reynolds	&	Wilkin	1988).	
In	the	developing	cerebellum	the	immature	GD3	positive	granule	neurons	of	the	EGL	retain	
the	 ganglioside	 until	 they	 begin	 to	 migrate	 through	 the	 molecular	 layer	 (Goldman	 &	
Reynolds	 1996).	 The	 role	 of	 GD3	 in	 development	 has	 linked	 the	 ganglioside	 to	 cell	
proliferation	and	activation	which	is	thought	to	be	due	to	its	interaction	with	extracellular	
matrix	(ECM)	and	integrin	receptors	(Cheresh	et	al.	1986;	Ohkawa	et	al.	2010;	Ohkawa	et	
al.	2008)	particularly	the	integrin	b1	receptor.		
GD3	has	 been	 shown	 to	 have	 roles	 in	 differentiation	 and	 neurite	 sprouting	 (Sato	 et	 al.	
2002),	in	a	cell	type	dependent	manner	(Malisan	&	Testi	2002a).	For	example,	in	ST8Sia1	
(GD3	 synthase)	 overexpression	 experiments	 using	 mouse	 neuroblastoma	 cells	
demonstrated	that	cell	differentiation	and	neurite	sprouting	was	induced	(Sato	et	al.	2002).	
However,	GD3	was	not	essential	as	shown	by	Kawai	in	1998	where	mouse	embryonic	stem	
cells	which	overexpressed	ST8Sia1	had	a	normal	neuronal	differentiation	pattern	(Kawai	et	
al.	 1998).	 In	 a	 rat	 model	 of	 pheochromocytoma,	 proliferation	 was	 also	 enhanced	
(Fukumoto	et	al.	2000).	In	this	model,	surface	GD3	was	shown	to	be	associated	with	src-
family	kinases	and	the	neuronal	adhesion	molecule	Transient	Axonal	Glycoprotein	1	(TAG1)	
in	cerebellar	granule	cells	(Kasahara	et	al.	1997;	Kasahara	et	al.	2000;	Prinetti	et	al.	2001).	
In	HeLa	and	CHO	cells	(Shi	et	al.	1996)	(Malisan	&	Testi	2002a),	GD3	expression	was	not	
reported	to	influence	cell	growth	and	differentiation	(Malisan	&	Testi	2002a).		
GD3	 levels	 decline	 after	 birth,	 in	 order	 to	 do	 this	 GD3	 is	 rapidly	 up-regulated	 and	
translocated	to	the	mitochondria	resulting	 in	mitochondrially-mediated	apoptosis	of	the	
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supernumary	cells	(Birks	et	al.	2011).		
The	mechanism	 by	which	GD3	 causes	 apoptosis	 has	 been	 subject	 to	 some	 debate.	 For	
example,	GD3	is	known	to	rapidly	accumulate	upon	signalling	from	cluster	of	differentiation	
95	(CD95)	which	releases	ceramide	(Giussani	et	al.	2014).	Ceramide	promotes	apoptosis	
through	its	rapid	conversion	to	GD3	(Malisan	&	Testi	2002a).	GD3	accumulation	requires	
ceramides	liberated	from	plasma	membranes	by	acidic	sphingomyelinase	(De	Maria	et	al.	
1998).	Further	evidence	for	GD3-mediated	apoptosis	comes	from	experiments	of	ST8Sia1	
over-expression,	 demonstrating	 that	 GD3	 expression	 is	 sufficient	 to	 cause	 apoptosis	
(Malisan	&	Testi	2002a).		
In	other	studies,	the	collapse	of	the	mitochondrial	membrane	potential	is	the	mechanism	
by	 which	 GD3	 leads	 to	 cell	 death	 (Birks	 et	 al.	 2011).	 This	 is	 the	 most	 well-accepted	
mechanism	of	action	for	GD3-mediated	apoptosis	(Malisan	&	Testi	2002a).	The	collapse	of	
the	 mitochondrial	 membrane	 potential	 is	 a	 method	 of	 determining	 the	 health	 of	 the	
mitochondria	(Perry	et	al.	2011).	The	collapse	is	thought	to	occur	via	the	opening	of	the	
mitochondrial	permeability	transition	pore	complex	(PTPC)	the	components	of	which	are	
subject	to	much	debate.	The	PTPC	is	located	at	contact	sites	between	the	inner	and	outer	
mitochondrial	membranes	(Zamzami	&	Kroemer	2001)	and	is	under	the	control	of	B-cell	
lymphoma	2	 (bcl-2)	 (Rippo	et	al.	2000).	When	 the	PTPC	 is	opened,	 there	 is	an	outward	
movement	 of	 molecules	 under	 1.5	 kDa,	 a	 loss	 in	 the	 proton	 gradient	 between	 the	
membranes	and	inactivation	of	the	oxidative	phosphorylation	system	(Zamzami	&	Kroemer	
2001).	Once	the	mitochondria	have	swelled	as	a	result	of	these	events,	there	is	the	release	
of	apoptogenic	factors	such	as	cytochrome	c.	From	this	the	cell	is	committed	to	apoptosis	
and	 the	 activation	of	 the	 caspase	 cascade	 is	 initiated	 via	 caspase	9.	Apoptosis	 inducing	
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factor	(AIF)	is	also	released	by	the	mitochondria	(Susin	et	al.	1999),	this	can	drive	nuclear	
apoptosis	(Ferri	&	Kroemer	2000).		
In	 a	 study	 by	 Colell	 GD3	 was	 shown	 to	 suppress	 the	 activation	 of	 the	 pro-survival	
transcription	 factor	nuclear	 factor	of	kappa	 light	polypeptide	gene	enhancer	 (NF-kB)	by	
preventing	its	nuclear	translocation	(Colell	et	al.	2001).		
Another	 mechanism	 of	 GD3-induced	 cell	 death	 that	 has	 been	 described	 is	 autophagy	
(Garcia-Ruiz	et	al.	2015).	Recent	findings	have	revealed	a	previously	undetermined	role	for	
GD3	 in	 autophagy.	 GD3	 has	 been	 shown	 in	 a	 study	 by	 Matarresse	 to	 regulate	 the	
autophagosome	 formation	 (Matarrese	et	al.	 2014).	Cells	were	amino	acid	deprived	and	
ganglioside	GD3	was	shown	to	contribute	to	the	biogenesis	and	maturation	of	autophagic	
vacuoles.	 Knock	down	 studies	 of	 ST8Sia1	 showed	 impaired	 autophagy	while	 exogenous	
GD3	administration	was	 shown	 to	 resume	autophagy,	providing	 supporting	evidence	of	
GD3’s	 involvement	 in	 this	 process	 (Matarrese	 et	 al.	 2014).	 In	 addition	 to	 these	 effects,	
gangliosides	 have	 been	 shown	 to	 induce	 autophagic	 cell	 death	 in	 astrocytes	 by	 a	
mechanism	 dependent	 on	 the	 generation	 of	 reactive	 oxygen	 species.	 GD3-induced	 cell	
death	was	abolished	by	knock	down	of	beclin-1/Atg-6	or	Atg-7	gene	expression	of	by	3-
methyladenine,	a	known	autophagy	inhibitor	(Hwang	et	al.	2010)	.	These	results	suggest	
that	GD3	is	capable	of	inducing	autophagy,	and	that	it	can	do	so	in	several	ways.		
The	apoptotic	role	of	GD3	can	be	modified	through	acetylation	to	9-O-acetyl	GD3	(GD3A)	
(Malisan	et	al.	2002;	Kniep	et	al.	2006).	The	acetyl	group	responsible	for	this	modification	
of	properties	is	located	at	carbon	9	of	sialic	acid	found	in	GD3	(Kniep	et	al.	2006).		
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1.12 Sialic	acids		
Sialic	acids	are	a	family	of	acidic	nine-carbon	amino	acid	sugars	found	in	gangliosides	and	
are	commonly	modified	by	the	addition	of	functional	groups	(Schauer	2004;	Li	&	X.	Chen	
2012).	 The	most	 common	 sialic	 acid	 in	 vertebrates,	 and	 the	 sialic	 acid	 found	 in	 human	
gangliosides	is	N-acetylneuraminic	acid	(Neu5Ac)	(Li	&	X.	Chen	2012).	The	most	commonly	
studied	modification	of	Neu5Ac	found	in	GD3	is	O-acetylation	(Baumann	et	al.	2015)	which,	
as	described	above,	affects	its	properties.	
1.13 GD3	acetylation	to	GD3A	
The	O-acetylation	 of	GD3	 requires	 both	 an	 active	 acetyl	 CoA	 transporter	 (acetyl	 CoA	 is	
thought	to	be	the	donor	of	the	acetyl	group),	and	an	active	O-acetyltransferase	(Baumann	
et	al.	2015).	The	acetylation	of	GD3	to	GD3A	is	thought	to	be	via	the	carbon	at	position	7	
(Baumann	et	al.	2015).	GD3A’s	acetyl	group	is	actually	found	on	carbon	9	of	the	terminal	
Neu5Ac	however,	this	is	thought	to	be	from	the	spontaneous	migration	of	the	group	from	
carbon	7	to	carbon	9,	although	some	have	suggested	that	this	requires	an	enzymatic	step	
(Vandamme-Feldhaus	 &	 Schauer	 1998).	 The	 structures	 of	 GD3	 and	 GD3A	 are	 shown	 in	
figure	1.6	as	well	as	the	possible	mechanism	of	acetylation	by	cas1	and	deacetylation	by	
SIAE.		
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Figure	1.6	The	proposed	mechanism	of	acetylation	of	GD3	to	9-O-acetyl	GD3	by	Cas1.	The	
chemical	structures	of	the	gangliosides	show	the	site	of	acetylation	on	the	terminal	sialic	
acid.	The	acetyl	group	is	thought	to	be	donated	by	acetyl	CoA	and	transferred	to	the	7-O-
position	of	GD3	(red	box).	Then	the	acetyl	group	is	either	catalytically	transferred	to	the	9-
O-position	or	it	spontaneously	migrates	there.	SIAE	is	shown	as	the	deacetylation	enzyme,	
cleaving	the	acetyl	group	from	9-O-acetyl	GD3	only	(green	box).	Images	drawn	on	Marvin	
Sketch	(ChemAxon).		
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The	balance	between	acetylated	and	non-acetylated	sialic	acids	(and	therefore	between	
GD3	and	GD3A)	is	dependent	on	the	activities	of	sialic	O-acetyl	transferases	and	sialic	acid	
O-acetyl	esterases	which	add	and	cleave	acetyl	groups	from	sialic	acids	(Mandal	et	al.	2012).	
In	some	neoplastic	diseases,	such	as	acute	lymphoblastic	leukaemia,	this	balance	has	been	
shown	to	be	in	favour	of	acetyltransferases,	and	in	this	case,	GD3A	(Mandal	et	al.	2012).		
The	enzyme	responsible	for	the	transfer	of	acetyl	groups	from	acetyl-CoA	has	remained	
elusive	 in	cell-systems	(Baumann	et	al.	2015).	Candidate	proteins	for	acetyl	transferases	
include	Cas1	(Arming	et	al.	2011).	The	enzyme	responsible	for	the	cleavage	of	acetyl	groups	
from	the	9	carbons	position	of	Neu5Ac	is	the	human	endogenous	acetyl	esterase	enzyme	
sialic	acid	O-acetyl	esterase	(SIAE)	(Mandal	et	al.	2012).		
In	mice	GD3A	is	expressed	in	a	stacked	pattern	in	the	EGL	at	post-natal	week	1.	The	intensity	
of	staining	was	shown	by	Santiago	et	al.	2001	to	be	different	between	various	folia	and	
suggested	 that	 the	 expression	 differences	 may	 reflect	 different	 stages	 of	 maturation.	
(Santiago	 et	 al.	 2001).	 In	 co-labelling	 experiments	with	GD3A	 antibodies	 and	 antibodies	
directed	against	glial	acidic	fibrillary	protein	(GFAP),	staining	was	seen	in	cells	of	both	glial	
and	neuronal	lineages	(Santiago	et	al.	2001).		
GD3A	has	distinct	roles	in	neuronal	development	and	has	been	shown,	in	mice,	to	be	co-
localised	in	the	contact	sites	between	migrating	granule	cells	and	radial	glial	in	the	EGL	and	
molecular	layer	of	the	developing	cerebellum	(Santiago	et	al.	2004).	In	a	melanoma	cell	line	
abc-1	knock-down	experiments	using	a	viral	O-acetyl	esterase	that	cleaves	acetyl	groups	
from	GD3A,	differentiation	and	proliferation	were	promoted,	indicating	that	GD3A	may	be	
have	roles	in	maintaining	an	undifferentiated	state	(Santiago	et	al.	2001).		
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In	work	 done	 by	 the	 same	 group,	 (Santiago	 et	 al.	 2004),	 early	 post-natal	 rats	 received	
intraventricular	injections	of	an	antibody	specific	to	GD3A.	In	these	animals	the	migration	
of	the	granule	neuron	precursors	was	arrested	in	the	EGL	(Santiago	et	al.	2004).	In	control	
animals,	the	proliferating	neuroblasts	in	the	EGL	of	the	cerebellum	were	also	labelled	via	
intraperitoneal	 injections	 of	 5-bromo-2’-deoxyuridine	 (BrdU),	 allowing	 the	 directional	
movement	of	the	granule	cell	precursors	to	be	evaluated.	 Immunolabelled	cells	showed	
that	GD3A	expression	was	restricted	in	the	brain	in	regions	such	as	the	subventricular	zone	
and	the	cerebellum	(Santiago	et	al.	2004).	The	staining	pattern	GD3A	in	the	cerebellum	of	
a	post-natal	day	9	rat	showed	that	the	EGL	and	the	molecular	layer	have	the	highest	degree	
of	staining.	Cells	that	are	migrating	from	the	EGL	that	express	GD3A	do	so	in	the	cell	bodies	
and	 also	 their	 processes.	 In	 addition,	 very	 few	 cells	 stain	 positively	 for	GD3A	 in	 the	 IGL	
(Santiago	et	al.	2001).	These	results	were	similar	to	those	found	by	(Santiago	et	al.	2001)	
and	(Mendez-Otero	et	al.	1988)	and	further	implicates	GD3A	in	the	migration	of	the	granule	
neuron	precursors	to	the	IGL.		
Unlike	GD3,	GD3A	is	unable	to	induce	apoptosis	and	has	been	shown	to	counteract	the	pro-
apoptotic	effects	of	GD3	(Kniep	et	al.	2006).	 In	this	study	Jurkat	cells	were	treated	with	
micromolar	concentrations	of	GD3A	and	then	apoptosis	inducing	agents	such	as	N-acetyl	
sphingosine	 as	 well	 as	 daunorubicin.	 The	 cells	 became	 resistant	 to	 apoptosis	 inducing	
agents	and	had	an	 increased	viability.	When	cells	were	pre-treated	with	GD3,	 cells	also	
became	resistant	and	was	shown	to	be	correlated	with	increased	GD3A	production	(Kniep	
et	al.	2006).	In	this	study	the	group	suggest	that	GD3A	formation	may	be	a	mechanism	for	
how	 tumour	 cells	 evade	 apoptosis	 (Kniep	 et	 al.	 2006).	 One	 of	 the	 reasons	 why	 pre-
treatment	of	cells	may	become	resistant	to	apoptosis	 is	suggested	by	(Chen	et	al.	2006)	
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who	 suggested	 that	 GD3	 can	 include	 its	 own	 acetylation	 machinery.	 This	 group	 used	
exogenously	added	GD3	to	determine	if	the	expression	of	GD3A	increased	with	treatment.	
Their	 results	 show	 that	 when	 exogenous	 GD3	 was	 added	 to	 CHO	 cells,	 the	 cells	
incorporated	the	molecule	and	within	6	hours	GD3A	expression	was	induced	(Chen	et	al.	
2006).		
1.14 The	roles	of	GD3	and	GD3A	in	primary	brain	tumours		
Changes	 in	ganglioside	expression	 in	brain	 tumours	was	 first	 reported	 in	1966	 (Brezicka	
2015).	Since	then	it	has	been	established	that	changes	in	ganglioside	expression	levels	are	
associated	with	many	tumour	types,	but	of	particular	note	are	those	of	neuroectodermal	
origin,	including	medulloblastoma.	Gangliosides	are	present	throughout	the	tissues	of	the	
body	are	particularly	abundant	in	the	nervous	system	(Maidment	et	al.	1996).	On	the	cell	
surface,	gangliosides	occur	in	clusters	of	aggregates	or	micelles	are	found	close	to	proteins	
embedded	 in	 the	 lipid	 bilayer	 (Merzak	 et	 al.	 1994).	 Gangliosides	 are	 thought	 to	 have	
functional	control	over	proteins	on	the	cell	surface	(Merzak	et	al.	1994).	Gangliosides	also	
localised	intracellularly,	in	association	with	the	Golgi	apparatus	and	the	rough	endoplasmic	
reticulum	where	they	are	synthesised	and	metabolised,	and	also	in	the	lysosomes	where	
they	are	degraded	(Pilkington	1992).		
Ganglioside	expression	may	be	altered	in	neoplastic	disease	and	this	alteration	may	refer	
to	over-expression	of	gangliosides	which	are	present	also	in	the	non-neoplastic	tissue,	and	
over-expression	of	gangliosides	usually	seen	in	different	stages	of	development.	The	idea	
that	 tumour	progression	occurs	 in	 a	 ganglioside	dependent	manner	has	been	 shown	 in	
conjunction	 with	 clinicopathological	 studies	 which	 demonstrate	 that	 there	 are	 some	
ganglioside	 species	 with	 relatively	 simple	 structures,	 GD3	 is	 an	 example	 of	 such	 a	
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ganglioside	 (Pukel	 et	 al.	 1982),	 that	 shows	 very	 restricted	 expression	 in	 non-neoplastic	
tissues	 and	markedly	 increased	 expression	 in	 some	malignancies	 (Birklé	 et	 al.	 2003).	 A	
number	 of	 functional	 roles	 for	 gangliosides	 have	 been	 proposed,	 many	 of	 which	 are	
important	 in	 neoplasia	 and	 also	 in	 the	 developing	 and	 non-neoplastic	 nervous	 tissue	
(Pilkington	et	al.	1993).	
The	ganglioside	GD3	 is	 the	most	widely	 studied	 in	neoplastic	disease	as	 it	 is	 commonly	
expressed	 in	 tumour	 tissues	 such	 as	 malignant	 melanoma	 and	 glioma	 (Hersey	 1991;	
Koochekpour	 &	 Pilkington	 1996).	 GD3	 and	 GD3A	 are	 known	 to	 be	 expressed	 in	 brain	
development	by	the	neural	stem	cells	from	which	brain	tissue	arises	(Svennerholm	et	al.	
1989;	Yanagisawa	et	al.	2011).	These	neural	stem	cells	are	common	ancestors	for	every	glial	
and	neuronal	cell	type	in	the	brain	(Kennea	&	Mehmet	2002;	Knott	et	al.	1990).		As	there	is	
a	common	ancestor,	the	neural	stem	cell,	the	expression	of	the	gangliosides	GD3	and	GD3A	
has	 been	 studied	 in	 primary	 brain	 tumours	 (Parker	 &	 Pilkington	 2005;	 Koochekpour	 &	
Pilkington	 1996;	 Gratsa	 et	 al.	 1997;	 Birks	 et	 al.	 2011).	 GD3	 has	 many	 known	 roles	 in	
neoplastic	 disease,	 for	 example	 in	 cell	 growth,	 invasion	 and	 evasion	 of	 the	 immune	
response	 (Birklé	 et	 al.	 2003).	 GD3A	 also	 has	 roles	 in	 neoplasia	 and	 has	 been	 shown	 to	
influence	cell	survival	in	several	cancers	such	as	acute	lymphoblastic	leukaemia	(Mukherjee	
et	al.	2008)	and	glioblastoma	multiforme	(Birks	et	al.	2011).		
Human	 glioma-associated	 GD3	 has	 been	 shown	 to	 be	 highly	 expressed	 by	 high	 grade	
tumour	cells	(anaplastic	astrocytoma	and	glioblastoma	multiforme)	but	not	expressed	by	
lower	grade	glial	tumours	(Koochekpour	&	Pilkington	1996).	It	has	also	been	shown	that	
expression	of	GD3	is	maintained	in	culture	even	with	prolonged	passage	(Knott	et	al.	1990).	
The	role	of	GD3	is	well	established	in	neural	development	of	the	brain	where	it	guides	the	
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migration	of	neuronal	progenitor	 cells	 as	well	 as	 causing	 the	apoptosis	of	 supernumary	
progenitors	 (Ogiso	 et	 al.	 1991).	 Expression	 of	 GD3	 is	 tightly	 regulated	 depending	 on	
developmental	stage	and	GD3	 is	also	 involved	 in	cancers	of	development.	GD3	 is	highly	
expressed	by	the	brain	tissue	and	several	studies	have	investigated	expression	in	primary	
brain	 tumours,	 particularly	 in	 glioma	 (Pilkington	 1992;	 Pilkington	 et	 al.	 1993;	 Merzak,	
Koochekpour	&	Pilkington	1995;	Merzak	et	al.	1994;	Merzak	et	al.	1995).	
The	expression	of	GD3	and	 its	acetylated	form,	GD3A	have	been	shown	to	be	altered	 in	
medulloblastoma	(Gottfries	et	al.	1990).	Expression	of	GD3	is	known	to	be	increased	in	the	
CSF	of	patients,	but	its	role	is	thus	far	unknown	in	this	setting	(Malisan	&	Testi	2002a).	There	
are	 few	studies	on	GD3	and	GD3A	expression	on	medulloblastoma	but	 there	have	been	
other	studies	on	the	role	of	these	gangliosides	in	other	cancers.		
In	melanoma	it	has	been	shown	that	GD3	expression	correlates	with	metastatic	potential	
(Cheresh	et	al.	1986)	and	in	glioma	it	has	been	shown	that	GD3	is	pro-angiogenic	asGD3	is	
a	potent	activator	of	vascular	endothelial	growth	factor	(VEGF)	(Koochekpour	&	Pilkington	
1996;	Seyfried	&	Mukherjee	2010).	The	role	of	GD3	on	VEGF	has	also	been	supported	in	
neuroblastoma	 by	 the	 use	 of	 anti-GD3	 antibodies	 which	 have	 been	 shown	 to	 reduce	
angiogenesis	in	a	rat	model	(Zeng	et	al.	2000).		
Studies	 have	 shown	 that	 GD3	 is	 involved	 in	 the	 attachment	 of	 human	melanoma	 and	
neuroblastoma	cells	to	various	extracellular	matrix	proteins,	including	laminin,	fibronectin,	
collagen,	 and	 vitronectin	 (Cheresh	 et	 al.	 1986).	 In	 glioma	 it	 has	 been	 shown	 that	
exogenously	added	gangliosides	stimulate	cell	invasion	in	vitro	and	in	addition	this	has	been	
shown	that	gangliosides	enhance	the	adhesion	of	glioma	cell	lines	to	fibronectin,	laminin,	
vitronectin	 and	 collagen	 I	 (Merzak	 et	 al.	 1994;	 Koochekpour	 et	 al.	 1995).	 In	 a	 study	 by	
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Merzak	et	al.	(1995)	invasion	in	glioma	cells	was	found	to	involve	gangliosides	and	this	was	
thought	 to	 be	 mediated	 by	 adhesion-promoting	 action	 to	 the	 basement	 membrane	
proteins	(Merzak	et	al.	1995).	It	was	also	shown	that	secretion	of	matrix	metalloproteinases	
2	and	9	was	affected	by	ganglioside	expression,	but	this	was	not	correlated	with	histological	
type	of	glioma	(Maidment	et	al.	1996).	 In	 IPNN-8	medulloblastoma	cells	of	 low	passage,	
cells	adhered	to	fibronectin,	collagen	I	and	vitronectin	(Merzak,	Koochekpour	&	Pilkington	
1995).	GD3	however	has	been	identified	as	a	ganglioside	which	inhibits	the	binding	of	cells	
to	fibronectin	so	perhaps	GD3	expression	is	low	in	IPNN-8	cells.	The	mechanism	for	this	was	
described	by	Wang	et.	al	and	was	shown	to	be	due	to	GD3	binding	to	integrin	a5b1	(Wang	
et	al.	2001).	It	is	this	blockage	of	the	integrin	via	carbohydrate-carbohydrate	interactions	
between	 the	 ganglioside	 and	 the	a5	 subunit	 of	 integrin	a5b1	which	 inhibits	 binding	 to	
fibronectin.	This	study	demonstrated	GD3	as	a	‘co-factor’	in	the	complexes	that	form	with	
ECM	proteins	and	receptors	(Cheresh	et	al.	1987).	It	is	therefore	no	surprise	that.	GD3	has	
roles	in	invasion	and	mobility	of	primary	brain	tumour	cell	lines	which	has	been	confirmed	
with	the	use	of	anti-GD3	antibodies	(Hedberg	et	al.	2000;	Gratsa	et	al.	1997).	
	GD3	 is	 also	 known	 to	 have	 roles	 in	 apoptosis	 where	 acetylation	 of	 the	 ganglioside,	
commonly	seen	in	glial	tumours,	helps	to	evade	apoptosis	(Malisan	&	Testi	2002a;	Malisan	
&	Testi	2002b;	Birks	et	al.	2011;	Colell	et	al.	2001)	(further	discussed	in	section	1.11).	
Interactions	between	tumour	cells	and	the	cells	of	the	immune	system	appear	to	be	critical	
for	tumour	growth	(Birklé	et	al.	2003).	The	hypothesis	that	gangliosides	may	be	involved	in	
the	 suppression	 of	 the	 anti-tumour	 immune	 response	 is	 supported	 by	 studies	
demonstrating	 that	 tumour	 cells	 synthesise	 and	 shed	 gangliosides	 into	 their	
microenvironments	 (Potapenko	et	al.	2007).	GD3	can	be	actively	shed	 from	the	 tumour	
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cells	 to	 the	 microenvironment	 where	 it	 can	 bind	 and	 interact	 with	 a	 wide	 variety	 of	
proteins,	including	extracellular	matrix	(ECM)	modulating	proteins	such	as	integrins	(Kong	
et	al.	1998;	Dolo	et	al.	2000;	Ohkawa	et	al.	2008).	Shed	GD3	can	also	be	incorporated	into	
the	 membrane	 of	 neighbouring	 cells,	 which	 helps	 to	 modulate	 tumour–host	 cell	
interactions	 (Olshefski	 &	 Ladisch	 1996).	 This	 process	 is	 important	 as	 this	 is	 one	 of	 the	
mechanisms	 by	 which	 evasion	 of	 the	 immune	 response	 is	 thought	 to	 occur	 in	 glioma	
(Potapenko	 et	 al.	 2007).	Many	 studies	 have	 shown	 that	 exogenous	 or	 tumour-derived	
gangliosides	inhibit	multiple	steps	in	the	cellular	immune	response	in	vitro.	For	example,	
tumour-derived	gangliosides	inhibit	the	activity	of	several	immune	cells,	including	helper	T	
cells	(Offner	et	al.	1987)	and	natural	killer	cell	cytotoxicity	(Grayson	&	Ladisch	1992)	among	
others.		
1.14.1 Cas1	
The	search	for	the	enzyme	that	catalyses	the	transfer	of	acetyl	groups	to	GD3	began	in	the	
1970s,	since	then	many	attempts	to	identify	the	gene	by	expression	and	cloning	have	failed	
(Arming	et	al.	2011).	Arming	however	used	a	bioinformatics	approach	to	identify	the	gene.	
Genetic	 evidence	 suggested	 one	 gene	was	 responsible	 for	 the	 transfer	 of	 acetyl	 group	
(Arming	et	al.	2011;	Campbell	et	al.	1994).	The	human	genome	database	was	screened	for	
proteins	 with	 unknown	 functions	 which	 were	 predicted	 to	 encode	 acetyl	 transferases	
(Arming	et	al.	2011).	Candidates	were	also	chosen	based	on	their	localization	to	the	Golgi	
membranes	where	acetylation	was	shown	to	occur	(Arming	et	al.	2011).	
From	Arming’s	bioinformatics	approach	the	human	CASD1	gene	was	identified.	This	gene	
consists	 of	 18	 exons	 and	 is	 located	 on	 chromosome	 7q21.3	 (Arming	 et	 al.	 2011).	 The	
transcript	length	is	3942	nucleotides	which	encodes	a	protein	of	797	amino	acids	(Baumann	
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et	al.	2015).	Analysis	of	the	full	length	transcript	revealed	a	signal	sequence	which	is	usually	
found	 in	 proteins	 that	 translocate	 to	 the	 ER,	 Golgi	 or	 plasma	 membrane.	 The	 protein	
consists	of	a	serine-glycine-asparagine-histidine	(SGNH)	hydrolase	domain	and	a	C-terminal	
transmembrane	 domain	 (Arming	 et	 al.	 2011).	 The	 protein	 also	 shares	 some	 sequence	
homology	to	the	viral	O-acetylesterases,	especially	around	the	active	site	residues	(Arming	
et	 al.	 2011).	 In	 fact,	 the	 amino	 acid	 sequence	 of	 CASD1	 was	 originally	 identified	 as	 a	
homologue	of	O-acetyl	esterase	from	the	influenza	C	virus	(Vlasak	et	al.	1987).	Additional	
features	of	the	enzyme	include	an	ER	export	signal	(D-X-E)	and	several	trans-Golgi	network	
(TGN)-endosome	export	signals	(Y-xx-hydrophobic	amino	acid	or	D/E-xxx-L/I)	(Baumann	et	
al.2015).	
	
Arming	et.	al	(2011)	tested	whether	Cas1	protein	was	involved	in	the	O-acetylation	of	GD3	
by	 expressing	 ST8Sia1	 and	 Cas1	 proteins	 in	 COS	 cells.	 Interestingly,	 GD3	 synthase	
expression	 alone	 was	 sufficient	 to	 increase	 both	 GD3	 expression	 and	 7-O-acetyl	 GD3	
expression	 (Arming	 et	 al.	 2011).	 This	 indicates	 that	 there	 may	 be	 an	 intrinsic	 O-
acetyltransferase	present	in	these	cells.	GD3	has	also	been	shown	to	be	capable	of	inducing	
its	own	acetylation	(Chen	et	al.	2006).	There	was	however	a	significantly	higher	expression	
of	 7-O-acetyl	 GD3	 when	 cells	 were	 co-transfected	 with	 ST8Sia1	 and	 Cas1.	 In	 both	
experiments	there	was	no	significant	change	in	the	expression	of	9-O-acetyl	GD3	(GD3A)	
indicating	that	Cas1	protein	may	catalyse	only	transfer	of	acetyl	groups	to	the	7	carbon	
position	 of	 sialic	 acid.	 Knock-down	 studies	 of	 Cas1	 using	 specific	 short	 interfering	
ribonucleic	acid	(siRNA)	did	however	significantly	reduce	the	expression	of	9-O-acetyl	GD3	
after	24	hours,	but	the	reduction	was	recovered	after	96	hours	(Chen	et	al.	2006).		
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There	is	some	controversy	as	to	the	involvement	of	Cas1	in	the	acetylation	forming	9-O-
acetyl	 GD3.	 In	 another	 study	 by	 Baumann,	 Cas1	 expression	was	 shown	 to	 increase	 the	
expression	of	9-O-acetyl	GD3	in	HEK293T,	LM-TK-	and	HAP	cells.	This	group	suggests	that	
the	 effect	 of	 Cas1	 on	 9-O-acetylation	 of	GD3	may	be	 cell-type	 specific	 (Baumann	 et	 al.	
2015).		
Due	to	these	results	it	is	likely	that	either	Cas1	protein	is	not	the	only	enzyme	involved	in	
the	acetylation	of	GD3	to	9-O-acetyl	GD3,	Arming	et.	al	(2011)	suggest	that	Cas1	stimulates	
the	expression	of	 intrinsic	acetyl	transferases	(Arming	et	al.	2011).	Another	possibility	 is	
that	the	7-O-acetyl	group	migrates	to	carbon	9	of	sialic	acid,	most	likely	via	a	‘migrase’	due	
to	the	distinct	function	of	GD3A	during	apoptosis	(Wipfler	et	al.	2011).	
In	previous	work,	it	was	hypothesized	that	O-acetyltransferase	activity	may	be	associated	
within	a	membrane-bound	complex	made	up	of	an	acetyl-CoA	transporter,	sialyltransferase	
(such	as	ST8Sia1)	and	acetyltransferase	and	potentially	an	acetylated	intermediate	(Diaz	et	
al.	1989;	Lrhorfi	et	al.	2007).	As	well	as	this	(Srinivasan	&	Schauer	2009)	suggested	that	a	
soluble	co-factor	may	also	be	required	for	activity.		
1.14.2 Sialic	acid	O-acetyl	esterase			
	
Sialic	 acid	O-acetyl	 esterase	 (SIAE)	 removes	 acetyl	 groups	 from	 the	 hydroxyl	 groups	 in	
position	9	and	4	of	sialic	acid	such	as	those	found	in	9-O-acetyl	GD3	(Mandal	et	al.	2012;	
Mahajan	&	Pillai	2016).		Human	SIAE	is	located	on	chromosome	11	at	11q24.2	(Zhu	et	al.	
2004).	Studies	have	reported	that	the	SIAE	gene	encodes	two	transcript	isoforms	(Varki	et	
al.	1986;	Higa	et	al.	1987).	The	lysosomal	variant	is	the	longer	of	the	two	proteins	but	has	
the	shortest	 transcript,	which	spans	10	exons.	The	cytosolic	variant	spans	12	exons	and	
	 88	
differs	 in	 the	5’	untranslated	 region	 (UTR),	 and	 its	 first	 coding	exon	 corresponds	 to	 the	
second	of	the	lysosomal	variant	(Orizio	et	al.	2015).	In	the	study	by	Orizio,	RNASeq	data	
was	analysed	from	the	Illumina	Human	body	map	2.0	project.	The	data	indicated	that	in	15	
of	 the	 16	 human	 tissues	 analysed,	 exon-exon	 boundaries	 correspond	 to	 the	 lysosomal	
variant,	while	there	 is	no	transcript	model	supporting	cytosolic	SIAE	(Orizio	et	al.	2015).	
Adult	human	tissue	expression	studies	of	SIAE	transcripts	also	suggest	that	expression	is	
almost	exclusively	 limited	to	the	 lysosomal	SIAE	 isoform.	 It	has	been	suggested	that	the	
cytosolic	variant	of	SIAE	arises	 from	cleavage	of	 the	 lysosomal	variant	 (Takematsu	et	al.	
1999),	but	there	is	little	in	vitro	evidence	of	this.	Despite	its	name,	the	lysosomal	isoform	
of	SIAE	was	not	 found	 in	the	 lysosomal	compartments	 in	experiments	done	by	Orizio	 in	
CHO	 cells	 (Orizio	 et	 al.	 2015).	 Other	 studies	 did	 indeed	 find	 SIAE	 localised	 within	 the	
lysosomes,	but	its	relevance	remains	unclear	(Mandal	et	al.	2012)	and	the	localisation	of	
SIAE	therefore	could	be	cell-type	dependent.	As	SIAE	has	been	found	to	be	associated	with	
the	ER	and	Golgi	the	secretion	and	glycosylation	of	SIAE	may	have	important	roles	(Surolia	
et	al.	2010;	Chellappa	et	al.	2013).		
In	2013,	catalytically	defective	variants	of	SIAE	were	described	and	linked	to	autoimmunity	
which	suggests	this	enzyme	may	also	be	involved	in	the	immune	response	(Surolia	et	al.	
2010),	 the	 primary	 structure	 of	 the	 SIAE	 protein	 is	 shown	 in	 figure	 1.7	 and	 includes	
mutation	 sites	 and	 cleavage	 sites.	 Studies	 on	 this	 enzyme	 have	 however	 resulted	 in	
contradictions	and	therefore	the	role	of	SIAE	in	physiology	is	not	well	defined	(Chellappa	et	
al.	2013).		
The	active	site	of	SIAE	was	identified	by	multiple	sequence	comparison	by	log-expectation	
(MUSCLE)	analysis	(Orizio	et	al.	2015).	The	MUSCLE	analysis	was	used	to	generate	a	multiple	
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sequence	 alignment	 with	 sequences	 from	 32	 protein	 orthologues	 of	 human	 SIAE	 and	
identified	conserved	motifs	and	regions.	The	conserved	regions	were	identified	as	possible	
candidates	 for	 catalytic	 sites	 (Orizio	 et	 al.	 2015).	As	 a	 result	 of	 this	work,	 eleven	highly	
conserved	 sequence	 blocks	were	 identified	 and	 the	 two	 essential	 residues	 for	 catalysis	
were	determined	as	S127	and	H377.	These	residues	were	confirmed	to	be	required	for	the	
catalytic	triad,	along	with	T132	by	site	directed	mutagenesis	experiments	and	molecular	
docking	(Orizio	et	al.	2015).	
Following	 on	 from	 localisation	 studies	 by	Mandal,	 (Mandal	 et	 al.	 2012),	 this	 study	 also	
investigated	the	presence	of	N-	and	O-	glycosylation	sites	and	phosphorylation	sites.	6	N-
glycosylation,	10	O-glycosylation,	and	24	phosphorylation	sites	were	identified	(Orizio	et	al.	
2015).	The	 identified	sites	are	shown	in	table	1.8	and	shown	as	part	of	the	primary	and	
tertiary	structures	in	in	figures	1.7	and	1.8.	
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Table	1.8	modification	sites	of	human	SIAE	protein,	isoform	1,	adapted	from	(Orizio	et	al.	
2015).	
Modification	 Predicted	sites	
N-glycosylation	 N107,	N138,	N267,	N290,	N401,	N422 	
O-glycosylation	 S177,	S231,	S242,	T511 	
Phosphorylation	 S30,	 Y31,	 T52,	 S74,	 S79,	 S144,	 S156,	 S158,	
S217,T221,	 S227,	 S228,	 S247,	 S255,	 T303,	
S308,	 T312,	 S328,	 S331,	 S332,	 Y349,	 S371,	
T461,	S470		
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Figure	1.7	The	primary	sequence	of	SIAE	isoforms	1	and	2.	Isoform	2	lacks	the	35	amino	
acids	shown	in	teal.	Naturally	occurring	mutations	are	shown	in	boxes,	mutations	in	
purple	boxes	give	rise	to	normally	secreted	and	catalytically	normal	variants	of	SIAE.	
Mutations	 in	 blue	 boxes	 give	 rise	 to	mutations	with	 unknown	effects	 on	 the	 SIAE	
protein.	Mutations	in	yellow	boxes	give	rise	to	SIAE	protein	that	is	associated	with	a	
pathological	 condition	 (M89V	 and	 T312M	 are	 associated	 with	 autoimmunity	 and	
K400N	with	Crohn’s	disease).	Mutations	in	pink	boxes	are	associated	with	defective	
secretion	 and	 catalytic	 activity.	 All	 post-translational	 modification	 sites	 are	 also	
shown,	N-glycosylation	sites	are	highlighted	in	red,	O-glycosylation	sites	in	blue	and	
phosphorylation	sites	in	orange.	Adapted	from	Serolia	(2010).	
	 92	
	 	
Figure	 1.8	 SIAE	 modifications	 sites	 shown	 as	 part	 of	 the	 homologous	 and	
hypothesised	structure	of	the	SIAE	protein.	N-glycosylation	sites	are	shown	in	red,	
O-glycosylation	 sites	 in	 blue	 and	 phosphorylation	 sites	 in	 orange.	 Structure	
obtained	from	the	protein	data	bank	(PDB)	and	visualised	on	Mac	PyMol.	
	 93	
Further	to	this	Orizio	et.	al	published	 in	silico	predictions	of	the	SIAE	protein.	This	group	
demonstrated	presence	of	an	N-terminal	signal	peptide	that	corresponds	to	amino	acids	
M1-A18.	Further	to	this	this	study	used	Secretome	2.0	prediction,	the	human	SIAE	protein	
had	a	high	score,	which	implicates	SIAE	as	a	secreted	protein	(Orizio	et	al.	2015).	In	in	vitro	
studies,	 Western	 blot	 analysis	 revealed	 that	 SIAE	 was	 found	 in	 both	 cell	 extracts	 and	
conditioned	media	(Surolia	et	al.	2010;	Orizio	et	al.	2015).	In	these	cases,	the	SIAE	protein	
had	a	higher	 than	expected	molecular	weight	of	62	kDa.	This	was	thought	 to	be	due	to	
glycosylation	so	cells	were	treated	with	tunicamycin	and	this	form	of	SIAE	was	no	longer	
seen,	 confirming	 glycosylation	 was	 responsible	 for	 this	 molecular	 weight	 (Orizio	 et	 al.	
2015).		
It	was	then	explored	whether	glycosylation	was	required	for	activity	of	SIAE,	and	if	it	was	
required	 for	 extracellular	 trafficking.	 In	 cell	 lysates	 and	 conditioned	media	 experiments	
SIAE	activity	was	determined	to	correlate	with	the	intensity	of	the	bands	associated	with	
the	glycosylated	form.	These	data	suggest	that	SIAE	glycosylation	is	required	for	secretion	
and	also	influences	the	activity	of	the	enzyme	(or	indeed	its	stability)	(Orizio	et	al.	2015;	
Surolia	et	al.	2010).		
1.15 Hypothesis	
We	 hypothesise	 that	 GD3	 and	 GD3A	 are	 expressed	 by	 medulloblastoma	 cells.	 By	
overexpressing	SIAE	in	medulloblastoma	cell	lines	GD3A	levels	will	decrease	leading	to	an	
increase	in	GD3.	Due	to	the	increase	in	GD3	cells	will	undergo	mitochondrially-mediated	
apoptosis	or	be	sensitised	to	treatment	with	chemotherapeutics	in	a	cell-cycle	dependent	
or	cell-cycle	independent	manner.		
	 94	
1.16 Aims	
1. To	 assess	 the	 expression	 of	 the	 regulators	 of	 the	 GD3	 acetylation	 pathway	 in	
medulloblastoma	patient	tissue	samples.	
2. To	confirm	the	expression	of	GD3	and	GD3A	in	medulloblastoma	cell	lines.	
3. To	determine	the	effects	of	SIAE	overexpression	on	the	expression	of	GD3	and	GD3A	
in	medulloblastoma	cell	lines.	
4. To	assess	the	effects	of	SIAE	overexpression	on	medulloblastoma	cell	viability.	
5. To	determine	the	effects	of	SIAE	overexpression	on	medulloblastoma	cell	response	
to	 cell-cycle	 dependent	 and	 cell-cycle	 independent	 chemotherapeutics	 currently	
used	to	treat	medulloblastoma.	
	
1.17 Objectives	
1. Using	 bioinformatics	 the	 expression	 of	 the	 regulators	 of	 the	 GD3	 acetylation	
pathway	in	medulloblastoma	patient	tissue	samples	will	be	assessed.		
2. The	expression	of	GD3	and	GD3A	in	medulloblastoma	cell	lines	will	be	explored	using	
flow	cytometry	and	immunocytochemistry.	
3. The	 effects	 of	 SIAE	 overexpression	 on	 the	 expression	 of	 GD3	 and	 GD3A	 in	
medulloblastoma	cell	lines	will	be	assessed	using	flow	cytometry.	
4. The	effects	of	SIAE	overexpression	on	medulloblastoma	cell	viability	will	be	assessed	
using	JC-1	assays	to	assess	the	mitochondrial	membrane	potential.		
5. The	 effects	 of	 SIAE	 overexpression	 on	 medulloblastoma	 cell	 response	 to	
chemotherapeutics	will	be	determined	using	MTS	viability	assays.	
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2 Materials	and	Methods	
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2.1 Cell	Lines	
	
RES256	 and	 UW402	 cells	 were	 obtained	 under	 the	 ethics	 study	 number	 13773	 at	 The	
University	 of	Washington,	 Seattle,	 headed	 by	 Dr	 John	 Silber.	 Under	 this	 study	 number	
informed	consent	for	each	of	the	patient’s	biopsy	material	or	cell	lines	was	obtained.	The	
use	of	these	cells	at	the	University	of	Portsmouth	is	possible	through	an	arranged	Material	
Transfer	Agreement	(MTA).		
For	all	other	cell	lines,	the	brain	tumour	research	centre	at	the	University	of	Portsmouth	
was	 given	 a	 favourable	 ethical	 opinion	 by	 the national	 research	 ethics	 service	 (NRES)	
committee	South	Central-	Hampshire	A	 (REC	reference	number	11/SC/0048)	 for	a	study	
titled	 ‘The	 Cellular	 and	 Molecular	 Biology	 of	 Brain	 Tumours:	 Migration,	 apoptosis,	
malignancy	and	therapeutic	applications’	which	can	be	found	in	appendix	8.		
The	cell	lines	used	in	this	project	are	briefly	described	in	table	2.1	
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Table	2.1	Table	of	cell	lines	used	throughout	this	project	including	histology,	source	and	
where	cells	were	derived	from.		
Cell	line	 Source	 Patient	 age	
and	Sex		
Histology	 Site	
RES256	 University	 of	
Washington,	
Seattle	
16	years	
Male	
Paediatric	
Medulloblastoma	
Cerebellum	
CHLA-01-
MED	
ATCC	 8	years	
Male	
Paediatric	
Medulloblastoma	
Cerebellum	
UW402	 University	 of	
Washington,	
Seattle	
Unknown	
Unknown	
Paediatric	
Medulloblastoma	
Cerebellum	
MeWo	 ATCC	 78	years	
Male	
Melanoma	 Metastatic	 site	 –	
lymph	node	
LNCaP	 ATCC	 50	years	
Male	
Prostate	
Carcinoma	
Metastatic	 site	
supraclavicular	
lymph	node	
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2.2 Maintenance	of	Cell	Lines	
	
Cell	culture	was	carried	out	in	a	class	II	Nuare	biological	safety	laminar	flow	hood.	All	cell	
lines	were	maintained	at	37oC	in	a	5	%	CO2	humidified	atmosphere	within	a	Hereaus	Hera	
Cell	incubator.		
Throughout	this	project	the	growth	and	morphology	of	each	cell	line	was	monitored	using	
an	Olympus	IX71	inverted	phase	contrast	microscope.	Images	were	captured	using	Analysis	
software	(Soft	imaging	systems).		
All	cell	lines	were	maintained	in	the	media	described	in	table	2.2	
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Table	 2.2	 Table	 of	 cell	 lines	 used	 throughout	 this	 project	 including	 base	 media	 and	
supplements	
Cell	line	 Base	media	 Supplements		
RES256	 Dulbecco’s	modified	Eagle	Media	
(DMEM)	
10%	Foetal	Bovine	Serum	(FBS)	
CHLA-01MED	 DMEM	F-12	modification	 20	 ng/mL	 Fibroblast	 Growth	 factor	
(FGF);	 Epidermal	 Growth	 Factor-1	
(EGF-2)	and	2%	(v/v)	B27		
UW402	 DMEM	 10%	FBS	
MeWo	 Eagle’s	minimum	essential	media	
(EMEM)	
10%	FBS	
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Adherent	 cultures	 were	maintained	 by	 removing	media	 and	 washing	 cells	 with	 Hank’s	
balanced	salt	solution	(HBSS;	Gibco)	to	remove	any	FBS,	which	inhibits	the	trypsin	enzyme	
found	in	TrypLE	Express.	Next,	TrypLE	Express	(Gibco),	a	dissociation	reagent,	was	added	
and	 incubated	 on	 the	 cells	 for	 up	 to	 5	minutes	 to	 dissociate	 the	 cells	 from	 the	 plastic	
surface.	 TrypLE	 Express	 was	 then	 neutralised	 with	 growth	 media	 supplemented	 with	
serum.	The	solution	was	aspirated	from	the	flask	and	centrifuged	for	5	minutes	at	300	g	
using	a	Boeco	C-28A	centrifuge.	The	supernatant	was	removed	from	the	pelleted	cells	and	
the	 cells	 resuspended	 in	 1	mL	 of	 the	 appropriate	media.	 The	 cell	 suspension	was	 then	
appropriately	diluted	and	added	to	tissue	culture	flasks	or	plates.	All	cell	lines	were	cultured	
in	monolayers	at	37oC	in	a	5	%	CO2	environment.	
Cells	were	counted	and	viability	was	determined	via	a	trypan	blue	exclusion	assay	using	a	
Countess	II	cell	counter	(Life	Technologies).	Cells	were	harvested	as	previously	described	
and	 the	 pellet	 resuspended	 in	 1	mL	 of	 appropriate	 complete	media.	 To	 plate	 cells	 for	
experimental	purposes	10	µL	of	cell	 suspension	was	mixed	with	10	µL	Trypan	Blue	 (Life	
Technologies)	 and	 loaded	 into	 a	 chamber	 of	 a	 countess	 II	 cell	 counting	 slide	 (Life	
Technologies).	Cell	viability	and	cell	count	was	determined	using	the	automatic	focusing	
setting	on	the	Countess	II	machine.	Appropriate	dilutions	were	made	for	experiments	by	
using	the	following	formula.		
!"#$%&	(&##)	*+#$,&*	+-	.	/&0$+/&*	)&&*+-1	*&-)+,23$%4&/	"5	6+74#&	(&##) 	=		 µL	of	cell	suspension	to	use	
CHLA-01-Med	suspension	cultures	were	passaged	by	centrifuging	at	300	g	using	a	Boeco	C-
28A	 centrifuge,	 cells	 were	 diluted	 for	 subsequent	 cultures	 in	 75	 %	 fresh	 media,	 25	 %	
conditioned	media	in	suspension	culture	vessels	(Greiner).	
	 101	
2.3 Freezing	of	Cell	Lines	
	
Cells	to	be	frozen	down	for	long-term	storage	were	harvested	as	above.	The	pelleted	cells	
however	were	re-suspended	in	1	mL	recovery	cell	culture	freezing	medium	containing	the	
cryoprotectant	dimethyl	sufoxide	(DMSO,	Gibco)	and	aliquotted	into	cryovials	(Nunc).	The	
cryovials	 were	 placed	 into	 a	 Mr.	 Frosty	 container	 (Thermo)	 and	 placed	 into	 -80	 OC	
overnight.	 This	 allows	 vials	 to	 be	 cooled	 slowly	 (1oC	 per	 minute).	 Cryovials	 were	 then	
transferred	and	added	to	the	vapour	phase	of	liquid	nitrogen	(-196oC).		
When	cells	are	resurrected	from	liquid	nitrogen	storage	they	are	thawed	quickly	at	37oC	in	
a	water	bath.	Cells	are	then	added	drop-wise	to	9	mL	fresh	complete	media	and	centrifuged	
for	5	minutes	at	300	g	using	a	Boeco	C-28A	centrifuge.	The	supernatant	was	removed	to	
remove	 residual	 cytotoxic	 DMSO	 and	 the	 cells	 were	 added	 drop-wise	 to	 T-25	 flasks	
containing	5	mL	complete	media	appropriate	to	the	cell	line.	All	cell	lines	were	cultured	in	
monolayers	at	37oC	in	a	5	%	CO2	environment.	
2.4 Human	Authentication	of	Cell	Lines	
	
Deoxyribonucleic	acid	(DNA)	fingerprint	analysis	was	carried	out	on	each	cell	line	to	ensure	
its	authenticity	as	published	by	(An	et	al.	2014).	Total	genomic	DNA	(gDNA)	was	extracted	
from	 cultured	 cells	 using	 QIAamp	 DNA	 mini	 kit	 (Qiagen).	 Short	 tandem	 repeat-based	
multiplex	polymerase	chain	reaction	(PCR)	was	then	carried	out	using	2	ng	template	gDNA	
by	a	MyCycler	thermal	cycler	(Bio-Rad).	The	PCR	program	was	run	as	shown	in	figure	2.1	
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Figure	 2.1	 Thermal	 cycling	 conditions	 for	 human	 authentication	 of	 cell	 lines.	 The	 PCR	
program	above	allows	sufficient	amplification	of	each	STR	fragment	unique	to	each	cell	
line.	The	amplified	products	are	then	compared	using	an	Agilent	2100	bioanalyser	and	
unique	genotypes	for	each	cell	line	identified.		Adapted	from	An	et.	al,	2014	
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Primers	used	were	from	the	StemElite	ID	system	kit	and	used	to	amplify	9	human	short-
tandem	repeat	(STR)	loci,	including	D21S11,	TH01,	TPOX,	vWA,	CSF1PO,	D16S539,	D7S820,	
D13S317,	and	D5S818,	as	well	as	amelogenin	for	gender	identification.	These	markers	are	
selected	from	the	set	of	core	STR	loci	that	has	been	approved	for		human	identity	testing.	
A	no	template	negative	control	PCR	reaction	was	included	in	each	run	to	ensure	specific	
amplification.	Amplified	alleles	from	the	short-tandem	repeat	PCR	and	a	DNA	ladder	were	
resolved	using	a	2100	Bioanalyser	 (Agilent)	using	 the	DNA	1000	kit	 (Agilent).	Data	were	
analysed	using	Agilent	2100	expert	software.	All	samples	were	run	in	triplicate.		
2.5 Routine	Mycoplasma	Testing	
	
Mycoplasmas	 are	 a	 species	 of	 bacteria	 that	 are	 resistant	 to	many	 classes	 of	 antibiotics	
commonly	 used	 in	 laboratories,	 and	 undetectable	 by	 phase	 contrast	 microscopy.	
Mycoplasmas	affect	cell	behaviour	on	many	levels,	including	gene	expression,	growth	and	
metabolism	so	it	is	critical	for	cultures	to	remain	uncontaminated.	Contamination	of	cell	
lines	with	mycoplasma	is	difficult	to	detect	and	they	cannot	be	removed	through	sterile	
filtering.		
Cell	 cultures	 were	 routinely	 tested	 for	Mycoplasma	 infections	 every	 two	 weeks	 using	
MycoAlert	 PLUS	Mycoplasma	Detection	Kit	 (Lonza).	 The	Mycoplasma	assay	exploits	 the	
activity	of	enzymes	found	in	all	six	of	the	most	prevalent	Mycoplasma	species	and	are	not	
found	 in	eukaryotic	 cells.	Viable	Mycoplasma	 is	detected,	 if	present,	 in	 the	conditioned	
media	of	cell	cultures.	The	Mycoplasmas,	if	present,	are	lysed	and	react	with	the	MycoAlert	
substrate	in	which	the	conversion	of	ADP	to	ATP	is	catalysed.	The	ATP	converted	into	a	light	
signal	using	the	luciferase	enzyme	in	the	MycoAlert	reagent.	By	measuring	the	level	of	ATP	
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in	the	sample	both	before	and	after	the	addition	of	the	MycoAlert	substrate,	a	ratio	can	be	
obtained	which	indicates	the	of	presence	or	absence	of	infection.		
The	Mycoplasma	assay	procedure	required	1.5	mL	of	conditioned	media	in	which	the	cells	
were	incubated	for	a	minimum	of	24	hours.	The	media	was	then	centrifuged	at	200	g	for	5	
minutes	at	room	temperature	using	an	Eppendorf	5415r	microcentrifuge.	A	100	µL	aliquot	
of	 cell	 suspension	was	added	 to	a	white	 flat-bottomed	96	well	plate	 (Gibco).	A	positive	
control,	MycoAlert	assay	control	set	(Lonza),	was	added	to	a	control	well,	this	consisted	of	
50	µL	assay	buffer	(Lonza)	and	50	µL	of	positive	control	(Lonza).	A	negative	control	of	100	
µL	assay	buffer	was	also	added	to	well	of	the	plate.	100	µL	MycoAlert	reagent	was	added	
to	each	well	and	 incubated	for	5	minutes	at	room	temperature.	Read	A	was	then	taken	
before	100	µL	of	MycoAlert	Substrate	was	then	added	to	every	well	and	incubated	for	10	
minutes	at	room	temperature.	Reading	B	was	then	taken.	Readings	were	taken	on	a	BMG	
labtech	 POLARstar	Optima	 plate	 reader.	 A	 ratio	 taken	 of	8&7*+-1	98&7*+-1	:	 yields	 a	 ratio,	which	
indicated	presence	or	absence	of	infection,	a	ratio	of	greater	than	1	indicated	infection	(i.e.	
active	mycoplasma	enzymes).	No	mycoplasma	infections	were	detected	using	this	method	
in	the	cells	used	throughout	this	project.	
2.6 Antibodies	
	
The	antibodies	used	throughout	this	project	are	shown	in	table	2.3.	
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Table	2.3	Antibodies	used	throughout	this	project,	concentrations	and	diluents	are	listed	
in	materials	and	methods	as	per	technique.		
Antigen	 Species	and	isotype	 Company	sourced	from	
GD3	 Mouse	anti-human	IgG	 Millipore	(MAB2053)	
GD3A	 Mouse	anti-human	IgM	 Thermo	Fisher	(MA1-34707)	
SIAE	 Sheep	anti-human	IgG	 Custom	 made	 (see	 section	
2.7)	
Beta	Actin	 Mouse	anti-human	IgG	 Sigma	(A4700)	
Alexafluor	488		 Goat	 anti-mouse	 IgG	 and	
IgM	
Life	 Technologies	 (A-11029	
and	A-21042)	
Alexafluor	568		 Goat	 anti-mouse	 IgG	 and	
IgM	
Life	 Technologies	 (A-
11031and	A-21043)	
Infrared	700/800	CW	 Goat	 anti-mouse	 and	
Donkey	anti-goat	IgG	
Licor	 (926-32214	 and	 926-
68071)	
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2.7 SIAE	Antibody	Production	
	
Several	commercial	SIAE	antibodies	that	had	been	raised	against	the	whole	SIAE	peptide	or	
an	84	amino	acid	section	that	included	alpha	helices	and	beta	sheets	were	tested	without	
success.	We	decided	to	design	and	produce	a	custom	polyclonal	SIAE	antibody	to	overcome	
this	problem.	Specialist	technician	Mrs	Katie	Loveson	designed	an	immunogenic	candidate	
SIAE	 peptide	 using	 well-established	 software	 (NHLBI-AbDesigner).	 With	 help	 from	 Alta	
Bioscience	 Ltd	 potential	 peptides	 were	 reviewed.	 A	 17	 amino	 acid	 peptide	 sequence	
(SSDLSKKSSDDGFPQIR)	 was	 selected	 for	 optimal	 immunogenicity	 and	 minimal	 cross-
reactivity.	The	SIAE	peptide	was	used	to	produce	antibodies	in	sheep	by	National	health	
service	 (NHS)	 Scotland,	 sheep	were	 bled	 and	 the	 antibody	was	 purified	 for	 use	 in	 this	
project.	This	antibody	was	validated	by	Western	blot	analysis,	 carried	out	by	Mrs.	Katie	
Loveson.		
2.8 Flow	Cytometry	
	
The	 quantitative	 expression	 of	 several	 antigens	 was	 determined	 using	 flow	 cytometry.	
Antigens	 were	 either	 intra-	 or	 extracellular	 and	 are	 distinguishable	 through	 a	
permeabilisation	 step	 described	 below.	Methodology	 remained	 the	 same	 regardless	 or	
previous	treatment	of	the	cells.	Expression	was	determined	for	each	antigen	three	times	in	
triplicate,	in	parallel	to	controls.		
Cells	were	cultured	in	1.5	mL	media	and	treated	as	per	experiment,	cells	were	seeded	at	
250,000	cells	per	well.	Cells	were	harvested	using	a	cell	scraper;	the	1.5	mL	cell	suspension	
was	centrifuged	for	5	minutes	at	300	rcf	in	an	Eppendorf	5145R	centrifuge	at	4oC	to	pellet	
the	cells.	The	supernatant	was	aspirated	and	cells	resuspended	in	1	mL	ice-cold	phosphate	
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buffered	saline	(PBS;	Sigma)	supplemented	with	5	%	normal	goat	serum	(NGS;	Biosera)	to	
wash	the	cells	and	prevent	internalisation	of	extracellular	antigens.	Cells	were	once	again	
pelleted	and	the	supernatant	was	removed	using	the	same	conditions	previously	described.	
For	 intracellular	antigens	the	cells	were	permeablised	by	resuspending	in	250	µL	of	cold	
cytofix/cytoperm	 solution	 (BD	 Biosciences)	 and	 incubating	 at	 4oC	 for	 20	 minutes.	 The	
cytofix/cytoperm	 solution	 disrupts	 cell	 membranes	 in	 a	 reversible	 manner	 so	 for	
intracellular	 antigen	analysis	 the	 cells	were	 then	kept	 in	 the	presence	of	0.1	%	 saponin	
(Sigma).	 Cells	 were	 pelleted	 to	 remove	 cytofix/cytoperm	 solution	 by	 centrifuging	 as	
previously	described.	Cells	were	then	washed	in	500	µL	of	cold	PBS	supplemented	with	5	%	
NGS	and	0.1	%	saponin,	cells	were	pelleted	by	centrifuging	as	described	previously,	 the	
supernatant	was	aspirated.		For	extracellular	antigen	analysis	permeabilisation	steps	were	
omitted	and	cells	were	not	incubated	with	saponin	for	any	of	the	subsequent	steps.		Cells	
were	resuspended	in	appropriate,	optimised,	concentrations	of	primary	antibody	in	cold	
PBS	supplemented	with	1	%	NGS	and	0.1	%	saponin	at	4oC	for	30	minutes.	Dilutions	for	flow	
cytometry	 were	 anti-GD3	 1:50	 (20	 µg/mL)	 and	 anti-9-O-acetyl	 GD3	 1:10	 (10	 µg/mL).	
Autofluorescent,	no	primary	antibody	and	isotype	controls	were	included	at	this	stage.	Cells	
were	 pelleted	 to	 remove	 primary	 antibody	 solutions	 by	 centrifuging	 as	 previously	
described.	Cells	were	then	washed	with	500	µL	of	cold	PBS	supplemented	with	5	%	NGS	
and	0.1	%	saponin	was	added	to	each	sample	and	cells	were	pelleted	by	centrifuging	as	
described	previously,	the	supernatant	was	aspirated.	Cell	pellets	were	then	resuspended	in	
appropriate	isotype	and	species	alexafluor-conjugated	secondary	antibody	(diluted	1:500)	
and	incubated	for	15	minutes	at	4oC.	Cells	were	pelleted	to	remove	secondary	antibody	
solutions	by	centrifuging	as	previously	described.	500	µL	of	cold	PBS	supplemented	with	5	
%	NGS	was	 added	 to	 each	 sample	 and	 cells	were	pelleted	by	 centrifuging	 as	 described	
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previously,	 the	supernatant	was	aspirated.	Cells	were	then	resuspsended	 in	300	µL	cold	
PBS	supplemented	with	2	%	NGS	and	0.01	%	sodium	azide	(Sigma),	500	µL	for	controls	and	
filtered	using	20	µm	nylon	mesh	filter	(Millipore).	A	5	µL	volume	of	propridium	iodide	(PI;	
Sigma)	was	added	to	each	extracellular	antigen	sample.	PI	binds	to	the	DNA	of	non-viable	
cells,	 allowing	 their	 exclusion	 in	 the	 gating	 procedure.	 This	 step	 was	 omitted	 for	
intracellular	antigen	samples.	Samples	were	analysed	on	a	multi-parameter	fluorescence-
activated	cell	sorting	(FACS)	Calibur	flow	cytometer.	Acquisition	and	analysis	of	data	was	
carried	out	using	CellQuest	Pro	Software.	
2.9 Immunocytochemistry	
	
To	qualitatively	analyse	the	expression	of	antigens	within	the	cell	and	on	the	cell-surface	
immunocytochemistry	was	used.	Each	experiment	was	performed	three	times	in	triplicate	
and	included	isotype	controls	and	no	primary	antibody	controls.		
Cells	were	 seeded	at	200,000	cells	per	well	onto	sterile	glass	 coverslips	 in	6	well	plates	
(Greiner)	 and	 were	 allowed	 to	 adhere	 for	 24	 hours	 at	 37oC	 in	 a	 5	 %	 CO2	 humidified	
atmosphere.	 Cells	 were	washed	with	 PBS	 and	 fixed	 using	 4	%	 paraformaldehyde	 (PFA;	
Sigma)	in	PBS	(Sigma).	Cells	were	then	washed	and	permeabilised	using	0.01	%	Triton	X-
100	 (Sigma)	 in	 PBS	 for	 intracellular	 antigens	 and	 incubated	 for	 10	 minutes	 at	 4oC,	 for	
extracellular	antigens	this	was	omitted.	Cells	were	then	washed	three	times	in	PBS.	Non-
specific	binding	was	blocked	for	1	hour	at	room	temperature	using	500	µL	NGS	in	PBS.	After	
this	 block	 buffer	 was	 aspirated	 and	 each	 sample	 was	 incubated	 with	 500	 µL	 of	 the	
appropriate	primary	antibody	(anti-GD3	1:50	(20	µg/mL	and	anti-9-O-acetyl	GD3	1:100	(1	
µg/mL)	 diluted	 in	 PBS	 containing	 1	%	NGS	 for	 1	 hour	 at	 room	 temperature.	 Cells	were	
washed	three	times	with	PBS.	Alexafluor	conjugated	secondary	antibodies	(diluted	1:500)	
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were	 then	 added	 to	 each	 sample	 using	 the	 appropriate	 species	 and	 isotype.	 A	 500	 µL	
aliquot	of	secondary	antibody	in	PBS	containing	1	%	NGS	was	added	to	each	sample	and	
incubated	 at	 4oC	 for	 30	 minutes.	 Cells	 were	 then	 washed	 three	 times	 in	 PBS.	 To	
counterstain	nuclei,	100	µL	of	10	µg/mL	hoechst	blue	(Sigma)	was	incubated	with	the	cells	
for	10	seconds.	Cells	were	washed	three	times	in	PBS.	Cells	were	mounted	onto	slides	using	
a	drop	of	VectaShield	mounting	medium	(Vector	Labs).	Cells	were	then	imaged	using	the	
Zeiss	 Axioimager	 ZI	 epifluorescence	 microscope	 equipped	 with	 a	 Hamamatsu	 digital	
camera	and	Velocity	image	software	(Improvision).		
2.10 Immunofluorescent	staining	of	wild-type	mouse	brain	sections	
	
P5	and	P60	wild-type	mouse	brains	were	used	for	ganglioside	staining	of	the	post-partum	
brain	(P5)	in	which	migration	of	the	granule	neuron	precursors	(GPCs)	was	still	taking	
place,	and	the	P60	mature	brain	where	the	external	granule	layer	was	not	present	(and	
therefore	the	GPCs	had	ceased	to	migrate).	The	staining	was	carried	out	to	determine	
where	staining	of	the	gangliosides	occurred,	and	if	this	occurred	in	regions	of	the	
cerebellum	where	medulloblastoma	is	thought	to	occur.		
The	mouse-on-mouse	immunodetection	kit	was	used	to	stain	mouse	brain	tissue	with	
anti-ganglioside	antibodies.	This	kit	was	designed	by	Vector	Labs	to	localise	mouse	
primary	antibodies	on	mouse	tissues	and	reduce	the	endogenous	immunoglobulin	
staining	of	the	tissue.	High	background	staining	of	tissues	is	therefore	reduced	using	this	
kit	by	using	Vector	Labs	blocking	agent.	
Perfused	and	frozen	P5	and	P60	mouse	brains	were	kindly	harvested	by	cervical	
dislocation	and	provided	by	Dr	James	Hallet	and	Dr	Andrea	Rivera	from	the	University	of	
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Portsmouth.	Frozen	brain	sections	were	mounted	using	cryo-M-bed	(fisher)	onto	a	cork	
board	(fisher)	in	the	correct	orientation	for	cutting	sagittal	sections.	The	brain	tissue	was	
allowed	to	cool	to	-20	oC	for	cutting	and	50	µm	sections	were	cut	using	a	Leica	CM3050C	
cyrostat.	Slices	were	placed	into	a	24	well	plate	containing	PBS	+	0.5	%	sodium	azide	for	
preservation	prior	to	staining.		
To	 determine	 ganglioside	 expression	 in	 the	wild-type	mouse	 frozen	 brain	 sections	 first	
sections	were	fixed	with	4	%	paraformaldehyde	(sigma)	for	30	minutes.	Each	subsequent	
step	was	 carried	 out	 in	wells	 of	 a	 24	well	 tissue	 culture	 plate	 (Greiner).	 Sections	were	
allowed	 to	 air	 dry	 after	 before	 being	washed	 twice	 for	 two	minutes	 each	 in	 PBS.	 Next	
sections	were	blocked	for	1	hour	in	mouse-on-mouse	blocking	reagent	(vector	labs)	and	
once	again	washed	twice	in	PBS	for	two	minutes	each.	Tissue	sections	were	then	incubated	
for	5	minutes	in	mouse-on-mouse	diluent	(vector	labs)	before	the	excess	was	removed	and	
the	primary	antibody	 (optimized	anti-GD3	(1:5	 (0.2	µg/mL);	Millipore)	or	anti-9-O-acetyl	
GD3	(1:50	(2	µg/mL);	Thermo)	were	added	and	incubated	on	the	sections	for	1	hour	along	
with	diluent	only,	and	no	primary	antibody	controls.	The	sections	were	then	washed	twice	
for	two	minutes	each	 in	PBS	and	appropriate	secondary	antibodies	(diluted	1:500)	were	
added	and	incubated	for	30	minutes.	Sections	were	washed	twice	in	PBS	for	two	minutes	
each.	 Cell	 nuclei	 were	 counterstained	 using	 100	 µL	 of	 10	 µg/mL	 hoechst	 blue	 (Sigma).	
Sections	were	incubated	with	Hoechst	blue	for	10	seconds	and	were	were	washed	twice	in	
PBS	for	two	minutes	each.	Brain	sections	were	transferred	onto	glass	slides	using	a	paint	
brush	and	finally	were	mounted	onto	slides	using	a	drop	of	VectaShield	mounting	medium	
(Vector	 Labs).	 Cells	 were	 then	 imaged	 using	 the	 Zeiss	 Axioimager	 ZI	 epifluorescence	
microscope	 equipped	 with	 a	 Hamamatsu	 digital	 camera	 and	 Velocity	 image	 software	
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(improvision).		
2.11 Cloning		
	
pCMV-N3,	pCMV-N3-SIAE	and	pCMV-N3-SIAEHis	cloning	vectors	were	kindly	provided	by	
Professor	 Reinhard	 Vlasak,	 University	 of	 Salzbug,	 Austria.	 Vector	 maps	 and	 sequence	
homology	for	these	constructs	can	be	found	in	Appendix	1.		
For	inducible	system	transfections,	constructs	were	purchased	from	Clontech	Takara.	A	tet-
responsive	bicistronic	expression	system	was	purchased	(#631166)	and	cloned	into	using	
InFusion	Plus	HD	Eco	Dry	(Clontech	#638912).	An	overview	of	this	process	 is	outlined	 in	
figure	2.2.	Plasmid	maps	can	be	found	in	Appendix	3.	
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		 Figure	2.2	An	overview	of	the	ligase-independent	InFusion	Plus	HD	cloning	protocol.	
To	generate	plasmids	containing	genes	of	interest	the	parent	plasmid	first	linearised	
using	restriction	enzymes	appropriate	for	the	multiple	cloning	site.	The	resulting	
linearised	plasmid	is	then	gel-purified.	Genes	of	interest	are	amplified	using	primers	
designed	with	15	bp	overhangs	complementary	to	the	multiple	cloning	sites	used.	
The	gene	of	interest	and	the	linearised	plasmid	are	then	joined	together	using	the	
InFusion	HD	enzyme.	During	the	reaction	sticky	ends	are	generated	by	the	InFusion	
enzyme	which	digests	15	bps	from	the	ends	of	both	the	gene	and	the	 linearised	
plasmid.	The	DNA	then	re-joins	through	complementary	base	pairing	in	an	enzyme-
independent	manner.	
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In	order	to	clone	into	pTRE3G-TetOn3G,	the	backbone	was	first	linearised	using	restriction	
endonucleases	 that	 had	unique	 sites	within	 the	 construct.	 For	 cloning	 of	 the	 enhanced	
green	fluorescent	protein	(EGFP)	gene	into	multiple	cloning	site	2	(MCS2)	the	restriction	
endonucleases	MluI	 (New	 England	 Biolabs	 #R3198S)	 and	 BamHI	 (New	 England	 Biolabs	
#R3136S)	were	used.		
To	linearise	the	pTRE3G-IRES	plasmid	the	following	conditions	were	used	at	37oC	for	three	
hours	using	a	heat	block,	table	2.4	and	run	on	a	1%	TAE	agarose	gel	for	90	mins	at	80	V	
(figure	2.3).	
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Table	2.4	Components	used	for	linearization	of	pTRE3G-IRES	backbone	vector	for	cloning.	
Component	 Amount	(µL)	
Restriction	enzyme	(BamHI/MluI)	 1	each	
DNA	 1	µg		
10	X	NEB	cut	smart	buffer		 5			
Total	Reaction	volume	 50	(made	up	to	50	µL	in	ddH2O)	
	
	
	
	
	
	
	
	 	
1	 2	 3	 4	 5	
Figure	2.3	pTRE3G-IRES	construct	is	linearised	by	restriction	endonuclease	digestion	run	
on	1%	TAE	agarose	and	run	at	80	V	for	90	mins.	20	µL	of	sample	was	added	to	each	lane	
(1)	DNA	molecular	marker	 (2)	Undigested	 supercoiled	 plasmid	 pTRE3G-IRES	 runs	more	
quickly	than	 linearised	plasmid	due	to	the	compact	size	generated	by	supercoiling	(this	
however	means	it	cannot	be	accurately	sized)	(3-5)	Linearised	pTRE3G-IRES	is	confirmed	
by	electrophoresis	and	is	the	correct	size	for	purification	(4002	bp).		
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The	bands	were	excised	from	the	agarose	gel	using	a	scalpel	and	spin-column	purified	using	
Nucleospin	Gel	and	PCR	clean	up	kit	(Clontech).	The	weight	of	the	gel	slice	was	determined	
and	for	each	100	mg	of	agarose	gel	200	μL	Buffer	NTI	(Clontech)	was	added.	The	samples	
were	then	incubated	for	10	minutes	at	50oC	on	a	heat	block	with	vortexing	every	2	minutes	
to	ensure	the	agarose	gel	had	dissolved.	A	700	μL	aliquot	of	dissolved	product	was	then	
loaded	onto	a	Nucleospin	column	and	centrifuged	at	11000	g	for	30	seconds,	this	step	was	
repeated	until	all	of	the	sample	had	been	loaded	onto	the	column.	The	membrane	was	then	
washed	using	700	μL	of	buffer	NT3	(Clontech)	and	centrifuged	for	30	seconds	at	11000	g.	
The	wash	step	was	repeated	to	ensure	chaotropic	salt	carry	over.	The	column	was	then	
centrifuged	for	1	minute	to	ensure	complete	removal	of	ethanol.		The	DNA	was	then	eluted	
using	20	μL	of	buffer	NE	(Clontech)	by	incubating	at	70oC	for	5	minutes.	The	sample	was	
centrifuged	at	40	g	for	1	minute	and	then	11000	g	for	1	minute	to	elute	DNA.		
Once	the	plasmid	backbone	was	linearised	and	purified	the	EGFP	gene	was	amplified	out	
of	the	parental	vector	using	infusion	primers.	These	primers	were	designed	to	have	15	bp	
overhangs	that	are	complementary	to	the	plasmid	backbone	for	ligase	independent	cloning	
the	following	primers	for	EGFP	(Eurofins	genomics)	are	shown	in	table	2.5.		
To	amplify	out	the	gene	the	following	PCR	master	mix	was	prepared	on	ice,	components	
are	 shown	 in	 table	 2.6.	 The	 contents	 of	 the	 tube	 were	 mixed	 by	 flicking	 and	 briefly	
centrifuged	to	bring	the	contents	to	the	bottom	of	the	tube.	The	sample	was	placed	in	a	
BioRad	thermal	cycler,	conditions	shown	in	table	2.7.	
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Table	 2.5	Primers	with	 InFusion	 cloning	overhangs	 for	 cloning.	 15	base	pair	 overhang	
regions	allow	ligase	independent	incorporation	of	genes	into	the	linearised	plasmid.	
Primer	 Sequence	
Mlul/BamHI_EGFPF	 GCC	GGA	TAT	CAC	GCG	TAT	GGT	GAG	CAA	GGG	CGA	GGA	GCT	G	
Mlul/BamHI_EGFPR	 CAG	TTA	CAT	TGG	ATC	CTT	ACT	TGT	ACA	GCT	CGT	CCA	TGC	C	
	
	
Table	2.6	Components	of	PCR	 reactions	 for	amplification	of	 genes	 from	parent	vector	
constructs.			
Component	 Amount		
CloneAmp	HiFi	PCR	premix	 12.5	µL	
Forward	Primer	 10	pmol	
Reverse	primer	 10	pmol	
Template		 1	µg	
Nuclease-free	water	 To	25	µL	
	
	
Table	2.7	Thermal	cycling	conditions	for	amplifying	genes	from	parent	constructs	
Temperature	/	oC	 Time	/	seconds	
98	 10	
55	 15	
72	 8	(5	sec	/	kb)	
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The	PCR	product	was	then	run	on	a	1%	agarose	TAE	gel	which	was	run	at	80	V	for	90	minutes	
and	visualised	using	safe	view	stain	and	visualised	using	a	Syngene	G	box	(Syngene).	Finally,	
the	product	was	spin	column	purified	as	previously	described.	To	 join	 the	gene	and	the	
linearised	backbone	together	an	Infusion	Plus	HD	Eco	Dry	cloning	kit	was	used	(Clontech).	
The	following	reaction	was	set	up	 in	the	provided	InFusion	 lyophilised	reaction	tubes	as	
shown	in	table	2.8.	
The	PCR	reactions	were	incubated	for	15	minutes	at	37oC,	followed	by	15	minutes	at	50oC	
using	a	Biorad	Thermal	Cycler,	and	placed	on	ice.	The	resulting	DNA	was	then	transformed	
and	plasmid	DNA	purified	as	described	below.		
To	ensure	 the	EGFP	gene	had	been	 incorporated,	 the	 resulting	DNA	was	digested	once	
again	with	MluI	and	BamHI	and	the	insert	sized	on	an	agarose	gel	as	shown	in	figure	2.4.	
The	 resulting	construct	was	pTRE3G-IRES-EGFP	and	was	 further	cloned	 into	 to	generate	
pTRE3G-IRES-EGFP-SIAE	and	pTRE3G-IRES-EGFP-SIAE_S127A	by	digestion	with	EagI	and	SalI	
enzymes	unique	to	multiple	cloning	site	1	(MCS1).		
The	 Primers	 used	 to	 amplify	 the	 SIAE	 and	 S127A	 genes	 from	 their	 parent	 plasmids	 are	
shown	in	table	2.9.		
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Table	2.8	 InFusion	Plus	HD	Eco	Dry	reactions	for	both	pTRE3G-IRES-EGFP	and	pTRE3G-
IRES-EGFP-SIAE	and	pTRE3G-IRES-EGFP-SIAE-S127A	reactions.		
Reaction	
Component	
Cloning	Reaction	 Negative	
control	reaction	
Positive	control	reaction	
Purified	 PCR	
fragment	
100	ng	 0	ng	 2	µL	of	control	 insert	
(Clontech)	
Linearised	vector	 50	ng		 1	µL	 1	uL	of	 control	 pU19	
vector	(Clontech)	
Deionised	water	 To	10	µL	 To	10	µL	 To	10	µL	
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Figure	 2.4	 EGFP	 incorporation	 into	 the	 pTRE3G-IRES	 constructs	 is	 confirmed	 with	
digestion	of	plasmid	DNA	with	MluI	and	BamHI.	The	products	of	the	digest	were	run	on	
a	1%	TAE	agarose	gel	at	80	V	for	90	minutes.	(1)	DNA	molecular	marker	(2)	undigested	
supercoiled	plasmid	DNA	was	run	as	a	control	for	the	linearization	reaction	(3)	Empty	
lane	(4)	Purified	EGFP	DNA	(750	bp)	(5-9)	Unsuccessful	incorporation	of	the	EGFP	gene	
shown	by	no	presence	of	EGFP	at	750	bp	despite	digestion	with	MluI	and	BamHI.	(10)	
Successful	incorporation	of	the	EGFP	gene	as	shown	by	presence	of	a	digest	product	at	
750bp	(blue	arrow).	
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Table	2.9	Primers	used	for	the	amplification	of	SIAE	and	SIAE-S127A	genes	including	15	
bp	 overhang	 regions	 complementary	 to	 linearised	 pTRE3G-IRES-EGFP	 to	 allow	 ligase-
independent	cloning.		
Primer	 Sequence	
SalI/EglI_SIAEF	 CCC	TCG	TAA	AGT	CGA	CAT	GGT	CGC	GCC	GGG	GCT	TGT	ACT	C	
SalI/EglI_SIAER	 GGA	GAG	GGG	CCG	GCC	GTC	ATT	TAG	CAA	CAT	TGC	TCT	GAT	G	
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The	cloning	process	was	repeated	as	 for	EGFP,	using	SIAE	and	S127A	purified	genes.	To	
ensure	the	insertion	of	the	gene	into	the	construct,	KpnI	digests	were	carried	out	as	the	
KpnI	site	is	unique	within	the	construct	and	linearises	the	backbone	through	the	SIAE	gene	
insert	 as	 shown	 in	 figure	 2.5.	 Digest	 conditions	 are	 shown	 in	 table	 2.10.	 If	 insert	 was	
present,	the	product	could	be	sized	appropriately	for	insertion	of	the	gene	when	run	on	a	
1%	TAE	agarose	gel	for	90	minutes	at	80	V	(figure	2.6).		
The	constructs	were	then	sequenced	by	Eurofins	genomics	using	Eurofins	genomics	primers	
to	confirm	insertion	of	the	gene	resulted	in	the	correct	sequence,	confirmed	in	appendix	3.	
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Table	2.10	Components	used	for	linearization	of	pTRE3G-IRES-EGFP-SIAE	and	SIAE-
S127A	vectors	to	confirm	successful	integration	of	the	genes.	
Component	 Amount	(µL)	
Restriction	enzyme	(KpnI)	 1	
DNA	 1	µg		
10	X	NEB	cut	smart	buffer		 5			
Total	Reaction	volume	 50	(made	up	to	50	µL	in	ddH2O)	
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Figure	2.5	Linearisation	of	the	pTRE3G-IRES-EGFP-SIAE	construct	
demonstrates	integration	of	the	gene	as	the	restriction	site	only	
occurs	within	the	SIAE	gene	itself.		
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Figure	2.6	Confirmation	of	the	insertion	of	the	SIAE	gene	into	pTRE3G-IRES-EGFP	vector.	(1)	DNA	
molecular	marker,	(2-3)	Empty	lanes.	(Even	lanes)	Supercoiled	plasmid	DNA	to	confirm	linearity.	
(Odd	 lanes)	KpnI	digested	plasmid	DNA.	Arrows	show	products	of	 restriction	digest	by	KpnI	
(present	only	in	the	SIAE	sequence,	confirming	presence	of	inserted	gene	with	a	band	at	1193	
bp;	blue	arrows).	
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2.11.1 	Transformation	and	Preparation	of	Plasmid	DNA	
	
To	transform	Stellar	competent	E.coli	(Clontech)	50	ng	of	plasmid	DNA	was	required.	Each	
plasmid	was	diluted	to	the	appropriate	concentration	in	nuclease-free	water.	A	1	µL	aliquot	
was	added	to	50	µL	of	defrosted	stellar	cells	on	ice.	The	cells	were	incubated	with	plasmid	
on	ice	for	30	mins.	The	cells	were	then	placed	on	a	heat	block	for	50	seconds	at	42oC	(heat	
shock).	For	recovery	cells	were	 incubated	for	5	minutes	on	 ice.	A	425	µL	aliquot	of	SOC	
media	was	then	added	to	each	tube	and	they	were	placed	into	the	shaking	incubator	for	1	
hour	at	37	OC.	After	the	recovery	incubation	the	whole	aliquot	of	cells	were	plated	in	aseptic	
conditions	onto	the	appropriate	selection	antibiotic	on	Luria-Bertani	(LB)-agarose	plates.	
All	 plasmids	 were	 plated	 on	 50	 µg/mL	 ampicillin.	 The	 plates	 were	 incubated	 at	 37oC	
overnight	 to	allow	colonies	 to	 form.	The	next	day	plates	were	sealed	with	parafilm	and	
stored	at	4oC	until	colony	selection.		
A	5	mL	volume	of	 sterile	 LB	broth	was	added	 to	universal	 tubes	 (one	per	 construct).	A	
concentration	of	50	µg	of	ampicillin	was	added	to	the	LB	broth	in	appropriate	tubes.	Single	
colonies	were	then	selected	using	sterile	pipette	tips	and	placed	into	the	media	(in	aseptic	
conditions).	The	tubes	were	then	taped	loosely	shut	to	allow	gas	exchange	and	incubated	
for	16	hours	at	37oC	in	a	rocking	incubator.		
When	 transformation	was	complete	and	an	overnight	culture	had	been	grown,	glycerol	
stocks	 were	 prepared.	 A	 total	 volume	 of	 1.125	 mL	 of	 bacteria	 culture	 was	 added	 to	
duplicate	sterile	screw	top	eppendorf	tubes.	A	volume	of	375	µL	of	sterile	60	%	glycerol	
(Sigma)	was	 added.	 The	 tubes	were	 vortexed	 and	 snap-frozen	 in	 liquid	 nitrogen	 for	 10	
minutes	before	being	stored	at	-80oC.		
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Plasmid	DNA	was	then	isolated	from	the	E.coli	using	a	plasmid	PureYield	Minicolumn	kit	
(Promega).	 A	 volume	 of	 1.5	mL	 of	 bacterial	 culture	 was	 centrifuged	 for	 30	 seconds	 at	
maximum	speed	(16900	g)	in	an	Eppendorf	5415r	microcentrifuge.	The	supernatant	was	
discarded	before	an	additional	1.5ml	of	bacterial	culture	was	added	to	the	same	tube	and	
centrifuged	again	 for	30	 seconds	at	maximum	speed.	A	600	μL	aliquot	of	nuclease-free	
water	was	added	cell	pellet,	and	the	cells	re-suspended.	The	cells	were	then	lysed	using	
lysis	buffer	(Promega)	for	3	minutes	at	room	temperature	with	5	inversions	to	mix.	The	lysis	
buffer	was	then	neutralised	using	350	μL	cold	neutralisation	solution	(Promega)	and	the	
supernatant	 transferred	 to	 a	 PureYield™	Minicolumn	without	 disturbing	 the	 cell	 debris	
pellet.	 The	 minicolumn	 was	 then	 placed	 into	 a	 Collection	 Tube,	 and	 centrifuged	 at	
maximum	speed	for	15	seconds.	The	flow-through,	was	discarded	and	200μl	of	Endotoxin	
Removal	Wash	(ERB;	Promega)	was	added	to	the	minicolumn	to	wash	the	DNA.	This	was	
then	centrifuged	at	maximum	speed	for	15	seconds.	400μl	of	Column	Wash	Solution	(CWC;	
Promega)	was	 then	 added	 to	 the	minicolumn	 and	 centrifuged	 at	maximum	 speed	 in	 a	
microcentrifuge	 for	 30	 seconds	 to	 ensure	 the	 complete	 removal	 of	 ethanol	 which	 can	
interfere	with	transfection.	The	minicolum	was	then	transferred	to	a	1.5ml	microcentrifuge	
tube	and	DNA	was	eluted	using	30	μL	of	nuclease-free	water,	this	was	incubated	at	at	room	
temperature	for	one	minute	before	centrifugation	for	15	seconds	at	full	speed	to	elute	the	
plasmid	DNA.	Plasmid	DNA	was	stored	at	–20°C.	
	
Cells	were	seeded	 in	a	single	well	of	a	6-well	plate	at	a	density	 sufficient	 to	 reach	near	
confluence	at	48	h	after	transfection	(200,000	cells).	Then	pCMV-Tet3G	was	transefected	
into	cells	using	Xfect	transfection	reagent.		
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After	48	h,	the	confluent	well	was	divided	into	4	x	10	cm	dishes.	After	an	additional	48	h,	
G-418	 was	 added	 at	 the	 selection	 concentration	 that	 was	 determined	 from	 kill	 curves	
(appendix	 5).	 The	medium	was	 replaced	 every	 four	 days	 to	 ensure	 presence	 of	 G-418	
remained	constant.	Cells	that	have	not	integrated	the	plasmid	begin	to	die	after	3–5	days.	
After	 2	weeks,	 G418-resistant	 colonies	 begin	 to	 appear.	When	 the	 colonies	were	 large	
enough	to	transfer,	colonies	were	picked	and	transferred	into	separate	wells	of	a	24-well	
plate.	When	confluent,	the	clones	from	each	well	were	split	 into	three	wells	of	a	6-well	
plate	for	testing	and	maintenance.	
For	each	clone	to	be	tested,	two	wells	of	the	six	well	plates	were	used	for	induction	tests	
by	 seeding	at	200,000	cells/well	again.	The	 remaining	well	of	each	clone	was	used	as	a	
‘stock	plate’	for	propagation	if	needed	after	testing.	The	wells	that	were	seeded	were	then	
transfected	 with	 5	 μg	 of	 pTRE3G-Luc	 using	 Xfect	 transfection	 reagent	 as	 previously	
described.	 After	 4	 h,	 the	 culture	 medium	 was	 replaced	 with	 fresh	 medium	 containing		
1	 µg/mL	 doxycycline	 to	 one	 of	 the	 duplicate	 wells,	 while	 leaving	 the	 second	 well	
doxycycline-free.	 After	 24	 h,	 an	 assay	 for	 luciferase	 activity	was	 carried	 out	 (described	
below)	and	the	fold-induction	calculated	to	determine	the	best	clones.		
Clones	with	the	highest	 fold	 induction	(ratio	of	maximal	to	basal	gene	expression)	were	
used	for	propagation	and	further	testing.		
Stocks	of	each	promising	clone	were	made	as	soon	as	possible	after	expanding	the	culture	
as	described	in	section	2.1.3.	
The	Tet3G-expressing	cell	line	was	once	again	plated	at	200,000	cells	per	well	in	three	wells	
of	a	6-well	plate.	Using	Xfect	transfection	reagent	pTRE3G-IRES-EGFP,	pTRE3G-IRES-EGFP-
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SIAE	and	pTRE3G-IRES-EGFP-SIAE-S127A	constructs	were	 transfected	at	2	µg	each	along	
with	100	ng	of	a	linear	puromycin	selection	marker.		
After	48	h	cells	were	divided	4	x	10	cm	dishes.	After	an	additional	48	h,	puromycin	was	
added	at	the	selection	concentration	that	was	determined	by	kill	curve	analysis.	Medium	
was	replaced	with	fresh	complete	medium	supplemented	with	puromycin	every	four	days.	
Cells	that	have	not	integrated	the	plasmid	should	to	die	after	3–5	days.	After	2	weeks,	drug-
resistant	colonies	begin	to	appear.	When	the	colonies	were	large	enough	to	transfer	they	
were	moved	into	separate	wells	of	a	24-well	plate.	When	confluent,	the	cells	were	split	into	
three	wells	of	a	6-well	plate	for	testing	and	maintenance	as	before	and	assayed	for	SIAE	
expression.		
Stocks	 were	 then	made	 of	 each	 promising	 clone	 as	 soon	 as	 possible	 after	 testing	 and	
expanding.		
2.12 Stable	and	Transient	Transfection	with	pCMV-N3-SIAE		
	
To	 transfect	 cells	 with	 pCMV-N3,	 pCMV-N3-SIAE	 and	 pCMV-N3-SIAE-His	 constructs	
JetPrime	reagent	was	used	(Polyplus	transfection).	Plasmids	were	kindly	provided	by	Prof.	
Reinhard	Vlasak.	Cells	were	seeded	at	200,000	cells	per	well	in	6	well	plates	(Greiner)	in	full	
media,	24	hours	before	being	transfected		using	2	µg	plasmid	DNA	per	well.	DNA	was	first	
diluted	in	200	µL	per	well	of	JetPrime	buffer,	vortexed	and	briefly	centrifuged.	A	4	µL	aliquot	
of	 JetPrime	reagent	per	well	was	 then	added	to	 the	tube	which	was	then	vortexed	and	
briefly	centrifuged	before	incubating	for	10	minutes	at	room	temperature.	The	DNA	was	
then	added	in	a	drop-wise	manner	to	appropriate	wells	with	gentle	swirling.	The	cells	were	
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incubated	at	37oC	in	a	5	%	CO2	environment	for	four	hours	before	media	was	changed	to	
prevent	toxicity.		
2.13 Stable	Transfection	–	Inducible	System	Constructs	
	
For	 transfection	 with	 pCMV-TetOn3G,	 pTRE3G-Luc,	 pTRE3G-IRES-EGFP,	 pTRE3G-IRES-
EGFP-SIAE	 and	 pTRE3G-IRES-EGFP-SIAE-S127A	 constructs	 Xfect	 Transfection	 reagent	
(Clontech)	was	used.		
Cells	were	plated	for	transfection	24	hours	prior	to	addition	of	DNA	complexes.	Adherent	
cells	were	plated	at	200,000	cells	per	well	of	a	6	well	plate	(Griener)	 in	1	mL	full	media.	
Suspension	cells	were	plated	at	1	x	106	cells	per	well	in	3	mL	growth	media	in	one	well	of	a	
6	well	plate	(Greiner).	 	Xfect	polymer	was	vortexed	and	briefly	centrifuged	to	ensure	no	
separation	of	components	had	occurred.		
A	volume	containing	2	µg	plasmid	DNA	(or	5	µg	for	pTRE3G-Luc)	was	diluted	in	100	µL	Xfect	
buffer	per	well.	The	solution	was	mixed	by	vortexing	and	briefly	centrifuged	and	0.3	µL	per	
1	µg	DNA	of	Xfect	Polymer	was	then	added	and	the	components	mixed	by	vortexing,	and	
then	briefly	 centrifuged.	The	DNA	mix	was	 then	 incubated	at	 room	 temperature	 for	10	
minutes	to	allow	nanoparticle	complexes	to	form.	A	100	µL	aliquot	of	DNA	complex	mix	
was	then	added	drop-wise	to	cells	with	gentle	swirling.	The	cells	were	incubated	at	37oC	in	
a	5	%	CO2	environment	for	four	hours	before	media	was	changed	to	prevent	toxicity.		
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2.14 EGFP	transfection	efficiency	assay	
	
pEGFP-N3,	pEGFP-N3-SIAE	and	pEGFP-N3-SIAE-His	constructs	each	express	an	enhanced	
green	fluorescent	protein	(EGFP)	tag.	This	tag	can	be	detected	using	the	EGFP	transfection	
efficiency	assay	protocol	and	analysed	on	the	Nucleocounter	3000	(Chemometec).		
Cells	 were	 transiently	 transfected	 with	 each	 construct	 as	 previously	 described	 and	
harvested	using	trypLE	express	(Life	technologies)	as	previously	described.	A	volume	of	96	
μL	of	each	cell	sample	was	added	to	a	microcentrifuge	tube	and	2	μL	of	500	μg/mL	Hoechst	
33342	 was	 added	 and	 mixed	 by	 pipetting	 to	 counterstain	 nuclei.	 The	 cells	 were	 then	
incubated	at	37oC	for	15	minutes	using	a	heat	block.	After	the	incubation	period	2	μL	of	500	
μg/mL	propridium	iodide	was	added	and	mixed	by	pipetting	to	determine	the	dead	cell	
population.	 A	 30	 μL	 sample	 was	 loaded	 into	 a	 nucleocounter	 A2	 chamber	 slide	
(Chemometec)	and	analysed	using	Nucleoview	software	(Chemometec).	
2.15 Luciferase	assay	
	
Cells	were	transfected	as	previously	described.	The	cells	were	then	washed	once	in	2	mL	
PBS	in	the	culture	vessel,	or	if	a	suspension	culture	is	being	tested,	centrifuged	at	300	g	for	
5	 minutes	 in	 an	 Eppendorf	 5415r	 microcentrifuge,	 washed	 in	 1	 mL	 PBS	 and	 again	
centrifuged	at	300	g	for	5	minutes.		500	µL	of	passive	lysis	buffer	(promega)	was	added	to	
each	well.	The	plate	was	then	placed	on	a	rocker	at	room	temperatureat	a	slow	sped	for	15	
mintues.	The	lysate	was	then	collected	and	stored	in	1.5	mL	eppendorf	tubes	at	-80oC.	A	20	
µL	aliquot	of	cell	lysate	was	added	in	triplicate	to	wells	of	a	white-walled	flat	bottom	plate	
(Greiner).	Then,	100	µL	volume	per	well	of	buffer	LARII	(Promega)	was	added	and	luciferase	
activity	measured	on	a	BMG	labtech	POLARstar	Optima	plate	reader	using	a	program	that	
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provides	a	2-second	pre-read	delay,	 followed	by	a	10-second	measurement	period.	The	
fold-induction	 was	 calculated	 as	 the	 fold-change	 between	 clones	 in	 the	 absence	 and	
presence	of	doxycycline.		
2.16 Clone	Selection	
	
In	order	to	select	transfected	clones	from	a	heterogeneous	population	of	transfected	and	
not-transfected	cells	selective	antibiotics	are	used.	For	pCMV-N3,	pCMV-N3-SIAE,	pCMV-
N3-SIAE-His	 and	 pCMV-TetOn3G	 G-418	 (BioChrom)	 was	 used.	 For	 pTRE3G-IRES-EGFP,	
pTRE3G-IRES-EGFP-SIAE	and	pTRE3G-IRES-EGFP-SIAE-S127A	puromycin	(Life	Technologies)	
was	used.		
In	order	to	determine	the	concentration	of	antibiotic	required	to	kill	cells	 that	have	not	
integrated	plasmid	kill	curves	were	carried	out.		
The	seeding	density	of	cells	was	determined	previously	by	seeding	cells	at	various	densities	
and	conducting	MTS	assays	and	imaging	cells	to	determine	when	a	monolayer	of	cells	was	
formed.	This	seeding	density	was	then	used	for	subsequent	experiments	and	was	cell	line	
dependent.		
To	determine	a	concentration	of	antibiotic,	various	concentrations	of	G-418	or	puromycin	
were	incubated	with	cells	that	had	not	been	transfected	before	MTS	assays	and	cell	imaging	
was	carried	out.	For	G-418,	a	concentration	that	kills	more	than	50	%	of	the	cells	within	5	
days	and	all	cells	within	14	days	was	selected.	For	puromycin	a	concentration	was	selected	
that	killed	greater	than	50	%	of	cells	within	3	days	and	all	cells	within	5	days	was	selected.		
All	media	was	changed	every	4	days	 to	ensure	antibiotic	was	always	present	 in	 the	cell	
culture	media.		
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To	carry	out	an	MTS	assay	media	was	changed	to	100	µL	media	without	antibiotics.	20	µL	
of	CellTiter	96	AQueous	One	solution	reagent	(Promega)	was	added	to	each	well.	Plates	were	
incubated	at	37oC	for	3	hours.	The	absorbance	was	then	read	at	490	nm	using	the	BMG	
labtech	POLARstar	Optima	plate	reader.	Cells	were	imaged	to	verify	MTS	results.		Data	for	
clone	selection	for	RES256	cells	can	be	found	in	appendix	5.	
2.17 Lysis	of	cells		
	
Cells	were	cultured	and	 treated	as	per	experimental	protocol.	For	 total	protein	analysis	
cells	were	lysed	using	Mammalian	Protein	Extract	Reagent	(M-PER;	Thermo).		
For	Western	blot	analysis,	small	volumes	of	lysate	were	required	for	SIAE	detection.	In	this	
case,	cells	were	harvested	using	cell	scrapers	and	centrifuged	at	300	g	using	a	Boeco	C-28A	
centrifuge.	The	cell	pellet	was	washed	in	ice-cold	PBS	to	remove	phenol	red,	which	interacts	
with	the	downstream	protein	assay	(BCA	Assay)	and	transferred	to	1.5	mL	Eppendorf	tubes	
and	centrifuged	at	300	g	for	5	minutes	at	5oC	using	an	Eppendorf	5415r	microcentrifuge	to	
pellet	cells.	Cells	were	lysed	in	M-PER	reagent	(750	µL	per	T-75	culture	flask)	supplemented	
with	1	X	protease	and	phosphatase	inhibitor	cocktail	(Thermo)	for	5	minutes	on	ice.	The	
lysates	 were	 centrifuged	 at	 maximum	 speed	 (16,900	 g)	 using	 an	 Eppendorf	 5415r	
microcentifuge	 for	 10	 minutes	 at	 4oC	 to	 remove	 cell	 debris.	 The	 pellet	 and	 lysate	
supernatant	were	then	separated;	the	lysate	was	aliquotted	to	avoid	freeze-thaw	cycles	for	
down-stream	assays	and	stored	at	-20oC.		
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2.17.1 	Determination	of	Protein	Content	in	Cell	Lysates	(BCA	Assay)	
The	bicinchoninic	acid	(BCA)	assay	is	a	colorimetric	detection	and	quantitation	method	for	
total	 protein.	 The	 assay	 combines	 two	 reactions,	 protein	 reduction	 of	 Cu2+	 to	 Cu1+	 and	
colourimetic	detection	of	Cu1+	by	bicinchoninic	acid.		
The	first	step	of	the	assay	is	chelation	of	copper	with	protein	in	an	alkaline	solution	to	form	
a	 light-blue	complex,	 the	biuret	reaction.	Peptides	containing	three	or	more	amino	acid	
residues	for	a	coloured	chelate	complex	with	copper	(cupric)	 ions	in	an	alkaline	solution	
containing	sodium	potassium	tartrate.	The	second	step	involves	bicinchoninic	acid	(BCA)	
which	reacts	with	the	reduced	copper	ions	formed	in	step	1.	This	forms	a	purple	reaction	
product	which	results	from	the	chelation	of	two	molecules	of	BCA	with	one	Cu1+	ion.	The	
BCA/copper	 complex	 gives	 a	 strong	 linear	 absorbance	 at	 562	 nm	 that	 increases	 with	
increasing	protein	concentration.		
This	method	is	strongly	influenced	by	the	amino	acid	residues	cysteine	or	cystine,	tyrosine,	
and	tryptophan	in	the	amino	acid	sequence	of	the	protein.	However,	unlike	the	Coomassie	
dye-binding	method,	the	universal	peptide	backbone	also	contributes	to	colour	formation,	
helping	to	minimize	variability	caused	by	the	different	compositions	of	proteins.	
	
A	protein	standard	curve	was	generated	using	2	mg/mL	stock	bovine	serum	albumin	(BSA)	
diluted	to	the	appropriate	concentrations	using	lysis	buffer.	The	following	dilutions	were	
made	using	table	2.11	
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Table	2.11	Dilutions	for	the	BCA	assay	protein	standards.	This	table	was	used	to	generate	
a	standard	curve	for	BCA	assays.	The	final	concentration	of	BCA	protein	will	be	used	to	
determine	the	total	protein	concentration	in	the	samples.	
Standard	 Volume	 of	 lysis	 buffer	
(μL)		
Volume	and	Source	of	BSA	
(μL)	
Final	 BSA	 concentration	
(μg/mL)	
A	 0	 300	 of	 stock	 (2	 mg/mL	
BSA)	
2000	
B	 125	 375	of	stock	 15000	
C	 325	 325	of	stock	 1000	
D	 175	 175	of	vial	B	solution	 750	
E	 325	 325	of	vial	C	dilution	 500	
F	 325	 325	of	vial	E	dilution	 250	
G	 325	 325	of	vial	F	dilution		 125	
H	 400	 100	of	vial	G	dilution	 25	
I	 400	 0	 0	
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The	BCA	working	reagent	(WR;	50	parts	of	bicinchoninic	acid	1	part	copper	(II)	sulphate)	
was	prepared	using	the	following	formula.		
(#	standards	+	#	samples	to	be	tested)	x	(#	replicates)	x	(volume	of	WR	per	sample	(200	μL))	=	total	volume	required	
A	volume	of	10	μL	of	each	unknown	sample	and	standard	was	pipetted	in	triplicate	into	a	
clear	flat-bottomed	96-well	plate	(Greiner).	200	μL	of	the	WR	was	then	added	to	each	well	
and	the	plate	covered	and	incubated	at	37°C	for	30	minutes.		
The	plate	was	then	cooled	to	room	temperature	and	absorbance	measured	at	562	nm	on	
the	Optima	BMG	labtech	POLARstar	plate	reader.		
The	 concentration	 of	 protein	 was	 then	 determined	 using	 a	 standard	 curve	 and	 linear	
regression.		
2.18 Western	Blot	
	
Expression	of	antigens	was	confirmed	at	the	protein	level	by	Western	blot	analysis.		
Cells	were	seeded	in	cell	culture	flasks	and	were	incubated,	and	treated	appropriately	for	
any	 given	 experiment.	 Each	 experiment	was	 performed	 in	 triplicate.	 After	 the	 required	
incubation	 period,	 cells	were	 lysed	 and	 protein	 concentration	 determined	 as	 described	
above.	If	conditioned	media	was	loaded	onto	the	gel	then	cells	were	serum	starved	over	
48	hours	(as	a	step-down	from	10%	to	5	%	for	6	hours,	2%	overnight,	1%	for	6	hours	and	
then	0%).	The	media	was	then	harvested	and	centrifuged	at	1,000	rpm	for	5	minutes	to	
remove	cells.	This	supernatant	was	used	for	conditioned	media	gels	described	below.		
A	 10%	 polyacrylamide	 sodium	 dodecyl	 sulphate	 (SDS)	 gel	 (Thermo)	 was	 placed	 into	 a	
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BioRad	Miniprotean	gel	rig	(BioRad),	wells	were	washed	with	Tris-HCl	running	buffer	(2.5	
mM	Trizma	base;	19.2	mM	Glycine;	0.1	%	Sodium	dodecyl	Sulphate).	Samples	were	diluted	
with	lysis	buffer	(M-PER,	Thermo)	and	5	X	Llameli	buffer	(Sigma)	supplemented	with	lysis	
buffer	 and	β-mercaptoethanol	 (Sigma)	 at	 an	 appropriate	 concentration	 and	 volume	 for	
sodium	dodecyl	 sulphate	 polyacrylamide	 gel	 electrophoresis	 (SDS-PAGE).	 Samples	were	
briefly	vortexed	and	heated	at	95oC	for	5	minutes	to	break	down	disulphide	bonds	allowing	
the	linear	running	of	sample.		
A	volume	of	5	μL	of	Precision	Plus	Protein	molecular	weight	standard	(Bio-Rad)	was	loaded	
on	to	the	gel	 followed	by	appropriate	volume	of	sample.	Where	wells	were	unfilled,	an	
appropriate	volume	of	lysis	buffer	and	loading	buffer	were	loaded	to	ensure	no	curvature	
of	bands	in	the	gel.	The	gel	was	run	for	around	90	minutes	at	100	V.		
The	gel	was	then	removed	from	the	rig	and	plates	and	allowed	to	equilibrate	in	transfer	
buffer	(2.5	mM	Trizma	base;	19.2	mM	glycine)	for	15	minutes.	PVDF	membrane	(Millipore)	
was	 hydrated	 for	 15	 seconds	 in	methanol	 (Sigma)	 and	 placed	 into	 transfer	 buffer	 until	
needed.	In	order	to	transfer	the	protein	from	gel	to	PVDF	membrane,	the	sandwich	method	
was	used.	Mini-Blot	filter	paper	(Bio-Rad)	and	2	sponges	were	soaked	in	transfer	buffer	and	
assembled	 in	 the	 sandwhich	 cassette.	 The	 assembly	was	 carried	with	 a	 sponge	 on	 the	
cathode	side	of	the	plate,	then	one	page	of	blotting	paper,	the	gel,	then	the	membrane,	
followed	by	another	blotting	paper	page	and	finally	the	sponge.	This	was	added	to	the	rig	
with	an	ice	pack	and	a	magnetic	stirrer	and	transferred	at	100	V	for	90	minutes.		
If	conditioned	media	was	 loaded	 into	the	gel,	 the	membrane	was	stained	for	5	minutes	
with	Ponceau	S	(Sigma)	and	washed	with	distilled	water	3	times	for	five	minutes	each.	If	
cell	lysates	were	loaded	onto	the	gel	then	this	step	was	omitted.	Then	the	following	steps	
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were	carried	out.		
Before	the	membrane	could	be	probed	with	primary	antibody	it	was	necessary	to	first	carry	
out	a	blocking	step	to	reduce	the	amount	of	background	and	non-specific	binding.	Blocking	
buffer	was	added	to	the	membrane	and	incubated	for	1	hour	at	room	temperature	with	
gentle	rocking.	The	blocking	buffer	was	made	up	from	5	%	non-fat	milk	(Marvel)	dissolved	
in	Tris-buffered	saline	(TBS;	0.2	mM	Trizma	base;	1.4	mM	sodium	chloride;	pH	7.6).	The	
membrane	was	then	incubated	overnight	at	4°C	on	a	platform	shaker	with	the	appropriate	
primary	antibody	and	 the	 loading	 control	 antibody.	The	membrane	was	 then	washed	5	
times	with	 Tris-buffered	 saline	 (0.2	mM	Trizma	base;	 1.4	mM	sodium	chloride;	 pH	7.6)	
containing	 0.1%	 Tween-20	 (TBST)	 for	 five	 minutes	 each.	 The	 appropriate	 infrared	
conjugated	secondary	antibody	was	then	incubated	for	1	hour	at	room	temperature.	The	
membrane	was	then	washed	5	times	with	TBST	for	five	minutes	each.	The	membrane	was	
then	imaged	on	the	Licor	Odyssey	(Licor)	using	Image	Studio	5.0	software.		
2.19 Mitochondrial	Membrane	Potential	Assay	(JC-1	Assay)		
	
Mitochondrial	 membrane	 potential	 (ΔΨm)	 is	 an	 important	 measure	 of	 mitochondrial	
function	and	is	used	to	determine	cell	health.		
The	JC-1	assay	measures	monomers	and	aggregates	of	the	lipophilic	cationic	JC-1	dye.	The	
JC-1	dye	changes	its	fluorescent	properties	based	on	the	aggregation	of	the	probe,	shown	
as	green	and	red	fluorescence.	 In	healthy	cells,	with	polarised	mitochondrial	membrane	
potentials	 (high	ΔΨm),	 JC-1	 forms	 red	 aggregates	within	 the	mitochondria.	 In	 cells	with	
depolarised	mitochondrial	membrane	potentials	 (low	ΔΨm)	green	monomers	of	dye	are	
formed	outside	of	the	mitochondria	(figure	2.7).	A	ratio	of	red	to	green	fluorescence	is	used	
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to	determine	the	degree	of	depolarisation	of	the	sample.	DAPI	staining	is	included	for	dead	
cell	staining.	This	assay	was	carried	out	in	parallel	to	a	positive	and	a	negative	control.	Each	
experiment	was	carried	out	three	times	in	triplicate	with	help	from	Mrs.	Katie	Loveson.		
Cells	were	harvested	by	 trypsinisation	and	resuspended	1	ml	PBS	at	1	x	106	cells/mL.	A	
volume	of	12.5	μL	of	200	μg/ml	JC-1	(Satorius)	giving	a	final	concentration	of	2.5	μg/mL	was	
added	 to	each	 sample	and	 incubated	 for	10	minutes	 at	 37oC.	Cells	were	 centrifuged	at		
400	g	for	5	minutes	at	room	temperature	using	an	Eppendorf	5415r	microcentrifuge.	The	
supernatant	was	discarded	and	the	cell	pellet	washed	by	resuspending	 in	1	mL	PBS	and	
centrifuging	at	400	g	 for	5	minutes	at	room	temperature	as	before.	This	wash	step	was	
repeated.	 The	 cell	 pellet	was	 then	 resuspended	 in	 250	 μL	 of	 1	 μg/mL	 of	DAPI	 solution	
(Satorius).	The	cells	were	then	added	to	an	A2	nucleocounter	slide	(Satorius)	and	analysed	
on	 the	 Nucleocounter	 3000	 (Chemometec)	 using	 Nucleocounter	 3000	 software	
(Chemometec).	
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Figure	2.7	The	JC-1	assay	is	used	as	a	measure	of	the	mitochondrial	membrane	potential.	
Aggregates	of	dye	within	the	mitochondria	emit	red	fluorescence	and	are	indicative	of	
functioning	mitochondria.	Monomers	of	dye	outside	of	 the	mitochondrial	membranes	
emit	green	fluorescence	and	are	indicative	of	a	collapsed	membrane	potential	and	early	
apoptosis.	This	is	a	transient	event	and	therefore	must	be	used	in	combination	with	other	
methods	to	determine	apoptosis.	
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2.20 Chemotherapy	Experiments		
	
The	 agents	 chosen	 for	 chemotherapy	 experiments	 were	 cisplatin	 and	 etoposide,	 these	
were	 used	 as	 examples	 of	 cell-cycle	 non-specific	 (cisplatin)	 and	 cell-cycle	 specific	
(etoposide)	agents	currently	in	use	for	treatment	of	brain	tumours	in	children.	Etoposide	
was	 also	 chosen	 for	 its	 reported	 mechanism	 of	 action	 on	 the	 collapse	 mitochondrial	
membrane	potential	in	isolated	mitochondria	(Robertson	et	al.	2000).	As	the	mechanism	
by	 which	 GD3	 causes	 apoptosis	 is	 most	 widely	 accepted	 to	 be	 via	 the	 collapse	 of	 the	
mitochondrial	membrane	potential	it	was	thought	that	a	synergistic	or	additive	effect	of	
etoposide	with	SIAE	over-expression	may	be	seen	(Malisan	&	Testi	2002a).	
Etoposide	is	a	cell	cycle-specific	antineoplastic	drug	belonging	to	a	family	of	topoisomerase	
II	inhibitors	(Jacob	et	al.	2011).		The	cell	cycle	is	arrested	at	G2/S	phase.	Etoposide	stabilises	
the	 DNA/protein	 complex	 and	 the	 breaks	 inserted	 by	 topoisomerase	 II	 are	 therefore	
permanent.	The	inability	for	cells	to	transcribe	or	replicate	DNA	causes	apoptosis	as	the	
DNA	damage	overwhelms	the	DNA	repair	machinery.		The	primary	mechanism	of	action	of	
Etoposide	is	described	in	figure	2.8.	
Cisplatin	is	a	cell-cycle	non-specific	DNA	alkylating	drug	that	causes	DNA	adducts	between	
guanine	 residues,	 which	 causes	 apoptosis	 through	 direct	 DNA	 damage	 (Dasari	 &	
Tchounwou	2014).	The	primary	mechanism	of	action	of	Cisplatin	is	described	in	figure	2.9.	
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Figure	2.8	Mechanism	of	action	of	Etoposide.	During	transcription	and	replication	of	DNA,	
RNA	 and	 DNA	 polymerases	 cause	 tension	 on	 the	 DNA	 helix	 as	 extension	 takes	 place.		
Topoisomerase	 II	 releases	 tension	 on	 the	 DNA	 helix	 by	 creating	 transient	 double	 strand	
breaks	thereby	relieving	supercoils.	Topoisomerase	 II	 then	 joins	the	breaks	back	together.	
Etoposide	 is	a	topoisomerase	 II	 inhibitor	that	prevents	this	untangling	of	supercoiled	DNA	
and	stabilises	the	DNA	breaks.	When	cells	are	treated	with	Etoposide,	the	apoptotic	program	
can	be	initiated	due	to	failure	of	the	DNA	damage	repair	machinery	which	cannot	repair	the	
breaks	due	to	the	presence	of	the	drug.	Adapted	from	Jacob	(2011).		
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Figure	 2.9	Mechanism	of	 action	 of	 Cisplatin.	 The	 platinum	 (Pt)	 charge	 of	
cisplatin	is	stabilised	by	chloride	(Cl)	ions,	but	is	more	successfully	stabilised	
by	nitrogen	(N)	resides	found	at	the	N7	position	of	Guanine	(G).	Binding	of	
cisplatin	to	the	N7	residues	forms	adducts	and	recruits	high	motility	group-
containing	proteins	(HMGs),	which	causes	the	de-stacking	of	the	nucleotide	
bases.	This	de-stacking	cannot	be	repaired	by	the	cell	and	damages	the	DNA	
such	 that	 the	 apoptotic	 program	 is	 initiated.	 Adapted	 from	 Dasari	 &	
Tchounwou,	2014.	
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Treatment	 of	 cells	with	 chemotherapy	was	 carried	 out	 by	 plating	 EGFP,	 SIAE	 and	 SIAE-
S127A	expressing	clones	at	2,500	cells	per	well	in	100	μL	clear	media	in	96	well	plates.	Cells	
were	plated	in	the	presence	and	absence	of	doxycycline	in	order	to	determine	if	there	was	
a	difference	in	viability	between	clones	expressing	and	not	expressing	genes.	After	48	of	
doxycycline	 treatment,	 when	 SIAE	 expression	 was	 confirmed,	 cells	 were	 treated	 with	
Cisplatin	 (Sigma)	 made	 fresh	 in	 sterile	 PBS	 (Sigma)	 or	 Etoposide	 (Sigma)	 made	 in	
dimethylsulphoxide	(DMSO;	Sigma).		Concentrations	ranged	from	1	μM	to	14	μM	at	1	μM	
increases.	Untreated	cells	and	vehicle	controls	were	 included	for	each	clone	 in	order	 to	
determine	any	changes	in	viability	seen	were	due	to	drug	treatment.		Cells	were	treated	
for	 24,	 48	 and	 72	 hours	 post-chemotherapy	 addition.	 After	 each	 time	 course	 phase-
contrast	images	were	taken	to	confirm	MTS	assay	results	before	MTS	assays	were	carried	
out	as	previously	described	in	section	2.16.	These	experiments	were	carried	out	three	times	
in	triplicate	with	help	from	Mrs.	Katie	Loveson.	
2.21 Molecular	Modelling		
	
Molecular	modelling	was	carried	out	on	the	SIAE	peptide	sequence	from	the	protein	data	
bank	(PDB;	www.rcsb.org).	PDB	files	were	generated	using	homologous	structures	to	the	
human	 SIAE	 peptide	 using	 Phyre2	 (www.sbg.bio.ic.ac.uk/phyre2).	 The	 PDB	 file	 was	
uploaded	to	MacPyMol,	where	structural	annotation	and	visualisation	was	carried	out.		
2.22 Bioinformatics	
	
All	Bioinformatic	analysis	was	carried	out	using	publically	available	data	sets	from	the	R2	
database	(r2.amc.nl).	This	dataset	is	a	public	domain	for	published	datasets	to	be	uploaded.	
It	is	hosted	by	the	AMC	cancer	centre,	Netherlands.	Specific	data	sets	used	are	annotated	
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in	figures	shown	in	subsequent	chapters.	A	step-by-step	guide	on	how	data	was	obtained	
from	this	database	is	shown	in	figure	2.10.	
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Figure	2.10	Step-by-step	method	for	data	acquisition	from	the	R2	database	using	SIAE	
expression	 from	 the	Northcott	database	as	an	example.	 Steps	1-20	demonstrate	data	
visualisation	as	a	box-plot	graphic	and	acquisition	of	log2	normalised	data	for	statistical	
analysis.		
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2.23 Statistics	
	
All	statistical	analyses	were	carried	out	using	GraphPad	Prism	6.0	software.	Appropriate	
statistical	tests	are	annotated	in	figures	shown	in	subsequent	chapters.		
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3 Results	
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3.1 Introduction	
	
Medulloblastoma,	 the	 most	 common	 malignant	 childhood	 brain	 tumour,	 occurs	
predominantly	in	the	cerebellum	and	is	associated	with	poor	quality	of	life	in	survivors	due	
to	the	aggressive	nature	of	treatment	(Michiels	et	al.	1996).	Four	molecular	subgroups	of	
medulloblastoma	have	been	identified	and	have	different	molecular	and	clinical	features,	
including	varying	prognoses	(Taylor	et	al.	2012).	Patients	who	have	lower-risk	disease	or	
fall	into	the	better	prognosis	subgroups	are	considered	as	having	been	over-treated	at	the	
expense	of	their	quality	of	life.	Other	patients	who	have	high-risk	disease	or	fall	into	the	
poorer	 prognosis	 subgroups	may	 need	more	 tailored	 therapy	 to	 improve	 their	 survival	
(Gilbertson	2004).	The	refining	of	treatments	for	each	subgroup	is	just	beginning	to	emerge	
as	we	learn	more	about	this	disease.	Medulloblastoma	is	a	tumour	of	development	and	
therefore	 our	 work	 focuses	 on	 a	 pathway	 that	 functions	 in	 the	 development	 of	 the	
cerebellum	(Wechsler-Reya	&	Scott	2001a;	Svennerholm	et	al.	1991;	Miyakoshi	et	al.	2001).	
The	GD3	acetylation	pathway	 is	known	to	have	 roles	 in	brain	development	 (Liang	et	al.	
2011;	Yu	et	al.	2004)	and	 in	malignancies	such	as	high	grade	gliomas	(Birks	et	al.	2011).	
GD3,	 a	 simple	 ganglioside,	 is	 expressed	 by	 the	 granule	 neuron	 precursor	 cells	 of	 the	
developing	cerebellum	where	it	guides	their	migration	(Goldman	&	Reynolds	1996).	In	rats	
it	has	been	shown	that	upon	maturation	of	the	brain,	GD3	rapidly	accumulates	within	the	
supernumary	cells	where	it	causes	their	mitochondrially-mediatated	apoptosis	(Birks	et	al.	
2011;	Higgins	et	al.	2015;	Ogiso	et	al.	1991).	After	birth,	the	expression	of	GD3	is	virtually	
absent	(Yu	et	al.	2012;	Yu	et	al.	2004).	In	some	cancers	of	neural	crest	origin,	such	as	high	
grade	gliomas	(Birks	et	al.	2011),	melanomas	(Ohkawa	et	al.	2008),	and	as	we	show	here,	
in	medulloblastomas,	GD3	also	becomes	re-expressed.	In	acute	lymphoblastic	leukaemia	
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(ALL)	high	levels	of	GD3	have	been	shown	to	protect	from	a	pro-apoptotic	phenotype,	due	
to	 acetylation	 of	 GD3	 to	 GD3A.	 GD3A	 is	 thought	 to	 protect	 cells	 from	 GD3-mediated	
apoptosis	and	this	balance	of	GD3	and	GD3A	is	thought	to	influence	cell	survival	(Mandal	et	
al.	2012;	Mukherjee	et	al.	2008).	In	this	study	we	analysed	publically	available	data	sets	to	
conduct	bioinformatic	analysis	of	the	enzymes	involved	in	the	GD3	acetylation	pathway.	
We	also	investigated	the	expression	of	GD3	and	GD3A	by	three	medulloblastoma	cell	lines.	
As	a	proof	of	principle	we	determined	if	the	GD3	acetylation	pathway	could	be	a	potential	
therapeutic	target	for	paediatric	medulloblastoma	by	over-expressing	the	human	enzyme	
responsible	for	deacetylation	of	endogenous	sialate-O-acetyl	esterase	enzyme	(SIAE).	As	
GD3A	 expression	 plays	 a	 role	 in	 protecting	 cells	 from	 GD3-mediated	 apoptosis,	 we	
predicted	that	SIAE	would	be	expressed	in	high	levels	in	medulloblastoma	subgroups	with	
the	poorest	prognosis.	SIAE	cleaves	acetyl	groups	from	the	carbon	9	position	of	SIAE,	such	
as	 those	 found	 in	GD3A.	We	believe	 that	by	deacetylating	GD3A,	medulloblastoma	 cells	
would	be	more	susceptible	to	chemotherapeutics,	thereby	lessening	the	devastating	side-
effects	as	a	result	of	toxicity.	
3.2 Bioinformatic	characterisation	of	the	GD3	acetylation	pathway		
	
In	 order	 to	 determine	 if	 the	 GD3	 acetylation	 pathway	 was	 abnormally	 expressed	 in	
medulloblastoma,	 the	 major	 components	 were	 characterised	 using	 a	 bioinformatics	
approach.	The	major	components	of	the	pathway	are	shown	in	figure	3.1.		
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Figure	 3.1	 The	 major	 components	 of	 the	 GD3	 acetylation	 pathway.	 GD3	 is	
synthesised	from	its	precursor	ganglioside	GM3	by	the	enzyme	ST8Sia1.	The	ST8Sia1	
enzyme	adds	a	second	sialic	acid	residue	to	GM3	via	a	2,8-glycosidic	bond,	forming	
GD3	 (reaction	 1).	 GD3	 can	 be	 acetylated	 to	 9-O-acetyl	 GD3	 (GD3A),	 which	 is	
hypothesised	 to	 be	 due	 to	 the	 action	 of	 Cas1	 (Cas1	 domain	 containing	 1).	 Cas1	
transfers	acetyl	groups	from	the	donor	acetyl	CoA	to	form	7-O-acetyl	GD3.	The	7-O-
acetyl	GD3	has	been	shown	to	be	converted	to	9-O-acetyl	GD3	by	non-enzymatic	
and	enzymatic	means	(reaction	2).		9-O-acetyl	GD3	can	be	converted	back	to	GD3	
by	 the	 human	 endogenous	 deacetylation	 enzyme	 SIAE	 (Sialic	 acid	 O-acetyl	
esterase).	SIAE	cleaves	the	acetyl	group	from	GD3A	at	this	position	restoring	levels	
of	GD3	in	the	cell	(reaction	3).	Adapted	from	Yu	et	al.	2004.		
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A	 publicly	 available	 genome-wide	 transcriptional	 analysis	 of	 103	 sub-grouped	
medulloblastoma	patients	that	included	non-neoplastic	foetal	and	adult	brain	controls	was	
analysed	with	help	from	Dr	L.	Donovan	(Personal	communication,	March	2012).		
The	medulloblastoma	samples	used	for	the	bioinformatics	analysis	were	obtained	from	the	
R2	database	 (r2.amc.nl).	Tissue	samples	were	derived	 from	patients	whose	ages	ranged	
from	11	months	to	39	years,	which	encompasses	infant,	child	and	adult	patients.	Patients	
who	are	infants	are	defined	as	0-3	years	of	age;	child	patients	as	3-16	years	of	age	and	adult	
patients	as	over	the	age	of	16,	as	defined	by	Taylor	et	al.	2012.	Using	these	criteria,	the	
sample	set	was	comprised	of	15	infant	patients,	73	children	and	14	adults	(and	1	case	of	
unknown	age	at	diagnosis).	Of	 these	patients,	35	had	group	4	 tumours,	 followed	by	33	
patients	 with	 SHH	 subgroup	 tumours,	 27	 patients	 with	 group	 3	 tumours	 and	 finally	 8	
patients	with	WNT	subgroup	 tumours.	 The	distribution	of	 subgroups	was	 similar	 to	 the	
incidence	seen	in	the	clinic	(Northcott,	Korshunov,	et	al.	2012).	
3.2.1 Regulators	 of	 the	 GD3	 acetylation	 pathway	 are	 atypically	 expressed	 in	
medulloblastoma	tissue	at	the	mRNA	level	
	
GD3	synthase,	also	known	as	ST8Sia1,	is	the	enzyme	responsible	for	synthesis	of	GD3	from	
its	 precursor	 GM3.	 ST8Sia1	 mRNA	 was	 found	 to	 be	 significantly	 down-regulated	 in	
medulloblastoma	 tissue	 compared	 to	 non-neoplastic	 foetal	 and	 adult	 brain	 (p<0.0001)	
(figure	3.2A).		
Cas1	is	the	enzyme	hypothesised	to	catalyse	the	acetylation	of	GD3	to	GD3A	(reaction	2;	
figure	3.1).	High	 levels	of	acetylation	 to	GD3A	 requires	a	high	 level	of	expression	of	 the	
acetylation	enzyme.	The	expression	of	Cas1	was	shown	to	be	significantly	up-regulated	in	
medulloblastoma	samples	compared	to	foetal	and	adult	non-neoplastic	brain	(p<0.0001)	
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(figure	3.2B)	which	may	indicate	that	the	balance	of	GD3	to	GD3A	is	in	favour	of	GD3A.	This	
however	 must	 be	 taken	 into	 consideration	 along	 with	 the	 deacetylation	 enzyme	 SIAE	
(Mukherjee	et	al.	2008;	Mandal	et	al.	2012),	SIAE	cleaves	the	acetyl	groups	from	sialic	acid	
residues	at	the	carbon	4	and	carbon	9	positions,	such	as	those	found	in	GD3A	(Orizio	et	al.	
2015).	 SIAE	 catalyses	 reaction	3	 (figure	3.1)	 and	was	predicted	 to	be	of	 low	expression	
compared	to	adult	non-neoplastic	brain	where	GD3A	expression	is	known	to	be	low.	The	
expression	of	SIAE	was	significantly	down-regulated	compared	to	non-neoplastic	foetal	and	
adult	brain	samples	(p<0.0001)	(figure	3.2C).		
Taken	together	these	data	suggest	that	at	the	mRNA	level	the	expression	of	GD3	may	be	
low	in	these	samples	due	to	the	lower	than	expected	ST8Sia1	expression,	but	any	GD3	that	
is	produced	is	likely	to	be	acetylated	to	GD3A.	The	expression	of	these	enzymes	in	relation	
to	the	GD3	acetylation	pathway	is	shown	in	figure	3.2D.	
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Figure	3.2	Expression	of	GD3	pathway	components	at	the	mRNA	level	as	determined	using	a	
bioinformatics	approach.	(A)	ST8Sia1	mRNA	encoding	the	enzyme	that	converts	GM3	to	GD3,	
was	found	to	be	significantly	down-regulated	in	medulloblastoma	samples	compared	to	non-
neoplastic	 foetal	 and	 adult	 brain	 samples	 (p<0.0001).	 (B)	 Cas1	 mRNA	 encoding	 the	
hypothesised	 acetylation	 enzyme	 of	 GD3	 was	 found	 to	 be	 significantly	 up-regulated	 in	
medulloblastoma	 samples	 compared	 to	 non-neoplastic	 foetal	 and	 adult	 brain	 samples	
(p<0.0001).	 (C)	 SIAE	mRNA	 encoding	 the	 acetyl	 esterase	 enzyme	 of	 GD3	was	 found	 to	 be	
significantly	 down-regulated	 compared	 to	 non-neoplastic	 foetal	 and	 adult	 brain	 samples	
(p<00001).	(D)	The	major	components	of	the	GD3	acetylation	pathway	and	their	regulation	
as	determined	by	bioinformatics	analysis.	ST8Sia1	enzyme	which	adds	a	second	sialic	acid	
residue	to	GM3	via	a	2,8-glycosidic	bond,	forming	GD3	was	found	to	be	significantly	down-
regulated	 in	 medulloblastoma	 (reaction	 1;	 green	 arrow).	 Cas1,	 the	 acetyl	 transferase	
hypothesed	 to	 acetyate	 GD3	 to	 GD3A	 was	 found	 to	 be	 significantly	 up-regulated	 in	
medulloblastoma	(reaction	2;	green	arrow).		SIAE	(Sialic	acid	O-acetyl	esterase)	the	enzyme	
which	cleaves	the	acetyl	group	from	GD3A	was	found	to	be	significantly	down-regulated	in	
medulloblastoma	(reaction	3;	green	arrow).	Data	obtained	from	the	R2	database	using	the	
Northcott	(core	Transcript)	data	set.		The	micro-array	chip	used	for	this	data	set	was	huex10t,	
and	was	normalised	using	the	rma-sketch	scheme.	Data	was	analysed	by	one-way	analysis	
of	variance	(ANOVA)	followed	by	Tukey’s	multiple	comparisons	post	hoc	test	using	graph	
pad	prism	6	software.	n=103±	SEM	
	
	
D	
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3.2.1.1 Expression	 of	 the	 GD3	 acetylation	 pathway	 regulators	 varies	 according	 to	
molecular	subgroup	
	
Further	to	the	examination	of	medulloblastoma	patient	samples,	the	relevance	to	each	of	
the	 molecular	 subgroups	 was	 then	 explored	 using	 a	 similar	 bioinformatics	 approach.	
Northcott	 (core	 transcript)	data	 from	the	R2	database	had	been	divided	 into	subgroups	
using	nano-string	technology	before	uploading	to	the	database.	Data	was	mined	from	the	
database	for	this	study.	The	medulloblastoma	samples	used	were	the	same	103	as	those	
described	previously.	Each	gene	of	interest	was	selected	from	the	database	and	the	data	
used	to	determine	if	there	were	any	statistically	significant	log-fold	differences	in	mRNA	
expression	 of	 the	 regulators	 of	 the	 GD3	 and	 GD3A	 pathway	 between	 subgroups	 of	
medulloblastoma.		
ST8Sia1	 mRNA	 was	 lowest	 in	 the	 WNT	 subgroup	 compared	 to	 the	 highest	 level	 of	
expression	 seen	 in	 the	 SHH	 subgroup	 (figure	 3.4A).	 The	WNT	 subgroup	 expressed	 the	
lowest	amount	of	ST8Sia1	mRNA,	but	this	was	not	statistically	different	to	groups	3	and	4	
(P>0.05;	figure	3.4A).	The	SHH	subgroup	expressed	the	highest	levels	of	ST8Sia1	mRNA	in	
this	 sample	set	and	was	significantly	higher	 than	WNT,	group	3	and	group	4	expression	
(p<0.0001;	figure	3.4A).	This	data	shows	that	the	expression	of	ST8Sia1	in	group	3	samples	
was	similar	to	that	of	WNT	tumours.			
As	we	found	expression	of	ST8Sia1	to	be	surprisingly	down-regulated	in	our	original	analysis	
compared	to	non-neoplastic	foetal	and	adult	brain	samples,	we	considered	other	enzymes	
that	can	affect	the	expression	of	GD3.	As	the	expression	of	GD3	synthase	does	not	define	
the	expression	level	of	GD3,	the	expression	of	the	enzymes	that	use	GD3	as	a	substrate	
were	also	considered.	A	publication	by	Yu	in	2004	states	that	the	expression	of	a	ganglioside	
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is	not	only	dependent	on	the	expression	of	the	synthesis	enzyme,	but	also	of	the	enzyme	
that	uses	the	ganglioside	as	a	substrate	this	concept	is	further	explained	in	figure	3.3	(Yu	et	
al.	2004).	ST8Sia5,	the	enzyme	that	converts	GD3	to	GT3	and	GD2	(reaction	4;	figure	3.6)	
was	 therefore	 considered.	 This	 catalytic	 step	 is	 shown	 as	 part	 of	 the	 GD3	 acetylation	
pathway	in	figure	3.3.	ST8Sia5	is	a	more	promiscuous	enzyme	and	can	convert	GD3	into	
GT3	 by	 the	 addition	 of	 a	 sialic	 acid	 residue,	 or	 it	 can	 convert	GD3	 to	GD2	 through	 the	
addition	 of	 N-acetylgalactosamine	 (reaction	 4;	 figure	 3.6).	 This	 process	 is	 also	
demonstrated	in	figure	1.5.		
The	mRNA	expression	of	ST8Sia5	was	found	to	be	significantly	higher	in	the	WNT	subgroup	
compared	to	group	3	(p<0.0001)	and	group	4	(p<0.001)	(figure	3.4B).	These	data	suggest	
that	the	expression	of	GD3	is	more	likely	to	be	further	converted	to	GT3	and	GD2	in	the	
WNT	 subgroup	and	GD3	 is	 less	 likely	 to	 accumulate.	 This	 is	 because	 the	enzyme	which	
converts	GD3	to	GD2	and	GT3	is	expressed	at	a	higher	level	allowing	the	ganglioside	to	be	
further	modified	 into	the	more	complex	gangliosides.	The	SHH	subgroup	also	expressed	
significantly	more	ST8Sia5	compared	to	group	3	and	group	4	subgroups	 (p<0.0001)	also	
suggesting	that	in	the	SHH	subgroup	there	may	be	further	conversion	of	GD3	rather	than	
accumulation	 of	 the	 ganglioside.	 Furthermore,	 there	 were	 no	 significant	 differences	
between	ST8Sia5	mRNA	expression	in	WNT	and	SHH	subgroups	(p>0.05),	nor	were	there	
any	significant	differences	between	expression	in	group	3	compared	to	group	4	(p<0.05).		
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Figure	3.3	The	concept	of	ganglioside	biosynthesis	as	demonstrated	by	Yu	in	2004.	The	
gangliosides	 follow	pathways	of	 synthesis	 that	are	 controlled	by	 the	expression	 (and	
activity)	of	the	sialyltransferases.	The	termination	of	the	biosynthesis	pathway	and	the	
resulting	ganglioside	is	shown	in	red	boxes.	Adapted	from	Yu	et	al.	2004.		
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Figure	 3.4	 ST8SIa1	 and	 ST8Sia5	 expression	 varies	 with	 molecular	 subgroup	 of	
medulloblastoma.	 ST8Sia1	 mRNA	 expression	 was	 analysed	 using	 the	 Northcott	 (core	
transcript)	data	set	from	the	R2	database.	In	103	subgrouped	samples,	the	expression	of	
the	mRNA	encoding	ST8Sia1	showed	highest	expression	in	the	SHH	subgroup	compared	
to	WNT,	group	3	and	group	4	samples.	(B)	ST8Sia5	mRNA	expression	was	also	analysed	
using	 the	 same	dataset	 and	 shows	 that	 there	 are	 significant	 differences	 in	 expression	
between	 the	 less	 aggressive	 subgroups	 WNT	 and	 SHH	 which	 demonstrated	 higher	
expression	 compared	 to	 the	 more	 aggressive	 subgroups	 group	 3	 and	 group	 4	 which	
demonstrates	lower	expression.	Data	analysed	by	one-way	ANOVA	using	GraphPad	Prism	
6	software	(***	p<0.001;	****	p<0.0001).	Data	obtained	from	the	R2	database	using	the	
Northcott	(core	Transcript)	data	set.	Data	was	analysed	by	one-way	analysis	of	variance	
(ANOVA)	followed	by	Tukey’s	multiple	comparisons	post	hoc	test	using	graph	pad	prism	6	
software.	n=103±	SEM	
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Figure	3.5	mRNA	expression	of	the	acetylation	and	deacetylation	regulating	enzymes	of	
GD3	 in	medulloblastoma	tissue.	 (A)	Cas1	the	hypothesised	acetylation	enzyme	of	GD3	
was	 characterised	 in	 subgrouped	 samples	 and	 shows	 highest	 expression	 in	 group	 4	
disease	and	the	lowest	expression	is	seen	in	the	WNT	and	SHH	subgroup	samples.	(B)	The	
level	of	SIAE	mRNA	 (the	human	endogenous	deacetylation	enzyme	of	GD3A)	was	also	
characterised	 in	 subgrouped	 medulloblastoma	 samples	 at	 the	 mRNA	 level.	 The	
expression	of	SIAE	was	highest	in	the	WNT	subgroup	compared	to	all	other	subgroups.	
Data	obtained	from	the	R2	database	using	the	Northcott	(core	Transcript)	data	set.	Data	
was	 analysed	by	 one-way	 analysis	 of	 variance	 (ANOVA)	 followed	by	 Tukey’s	multiple	
comparisons	post	hoc	test	using	graph	pad	prism	6	software.	(*	p<0.05;	**	p<0.01;	****	
p<0.0001).	n=103±	SEM	
	
A	 B	
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Figure	 3.6	 A	 summary	 of	 the	mRNA	expression	of	 the	 regulating	 enzymes	 of	 the	GD3	
acetylation	 pathway	 by	molecular	 subgroup.	 The	 expression	 of	 GD3	 is	 determined	 by	
ST8Sia1,	 the	enzyme	which	converts	GM3	 to	GD3,	and	 the	enzyme	 that	uses	GD3	as	a	
substrate,	 ST8Sia5	 (reaction	 4).	 ST8Sia1	 expression	 was	 found	 to	 be	 low	 (green	 box;	
reaction	1)	and	we	confirmed	similar	expression	 in	each	 subgroup	except	SHH	disease	
which	expressed	the	highest	level	of	ST8Sia1	mRNA.	We	also	confirmed	lowest	expression	
of	ST8Sia5		in	groups	3	and	4,	the	more	aggressive	disease	subgroups	(green	box,	reaction	
4).	We	could	not	however	determine	 if	 the	expression	was	up	or	down-regulated	with	
respect	 to	 non-neoplastic	 brain	 tissue	 as	 this	 data	 was	 not	 available	 (dotted	 arrows	
represent	 unknown	 relationship	 to	 non-neoplastic	 brain	 controls)	 and	 we	 therefore	
cannot	 conclude	 that	mRNA	 levels	 of	 ST8Sia5	 are	 down-regulated	 in	medulloblastoma	
samples.	 We	 also	 confirmed	 higher	 expression	 of	 Cas1,	 the	 hypothesised	 acetylation	
enzyme	 of	 GD3	 in	 group	 3	 and	 group	 4	 disease	 compared	 to	WNT	 and	 SHH	 samples,	
suggesting	that	there	may	be	higher	levels	of	GD3A	expression	in	these	subgroups	(green	
box;	 reaction	 2).	 In	 agreement	 with	 this,	 the	 mRNA	 levels	 of	 SIAE	 (the	 deacetylation	
enzyme	of	GD3A)	show	low	levels	of	SIAE	mRNA	in	group	3	and	group	4	disease,	and	in	this	
case	 in	SHH	disease	as	well,	suggesting	that	GD3A	may	be	expressed	 in	higher	 levels	 in	
these	 subgroups.	 Data	 obtained	 from	 the	 R2	 database	 using	 the	 Northcott	 (core	
Transcript)	data	set.			
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In	order	 to	determine	 if	 the	 regulation	of	GD3	acetylation	was	 atypically	 expressed	we	
characterised	the	acetylation	and	deacetylation	enzymes	Cas1	and	SIAE	(figure	3.5).	We	
found	the	mRNA	expression	of	Cas1	to	be	significantly	up-regulated	in	medulloblastoma	
compared	to	non-neoplastic	foetal	and	adult	brain	controls	we	further	explored	this	to	see	
if	this	enzyme	had	a	different	expression	level	between	medulloblastoma	subgroups.	Cas1	
expression	(if	this	is	 indeed	the	enzyme	that	is	responsible	for	GD3	acetylation	to	GD3A)	
should	therefore	correlate	with	GD3A	expression.		
From	this	study	the	expression	of	Cas1	mRNA	was	shown	to	be	lowest	in	WNT	and	SHH	
subgroups	 (figure	 3.5A).	 Expression	 of	 Cas1	 mRNA	 was	 significantly	 lower	 in	 the	WNT	
subgroup	compared	to	group	3	 (p<0.05)	and	group	4	 (p<0.001).	SHH	subgroup	tumours	
expressed	significantly	less	Cas1	mRNA	than	group	4	tumour	samples	(p<0.0001)	but	not	
group	3	(p>0.05),	indicating	a	similar	level	of	Cas1	mRNA	expression	in	these	subgroups.	
Group	4	subgrouped	samples	expressed	the	highest	level	of	Cas1	mRNA,	which	was	also	
significantly	higher	than	group	3	(p<0.05).		
As	the	highest	levels	of	expression	of	Cas1	were	seen	in	groups	3	and	4,	this	suggests	that	
there	 may	 be	 the	 highest	 levels	 of	 GD3A	 in	 these	 subgroups,	 if	 Cas1	 is	 the	 enzyme	
responsible	for	acetylation	of	GD3,	supporting	our	hypothesis	that	the	balance	of	GD3	to	
GD3A	in	these	cells	is	in	favour	of	GD3A.	
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In	figure	3.2,	our	bioinformatics	analysis	showed	that	the	mRNA	expression	of	SIAE	is	up-
regulated	in	medulloblastoma	samples	compared	to	non-neoplastic	foetal	and	adult	brain	
controls.	 We	 therefore	 further	 analysed	 the	 mRNA	 expression	 of	 SIAE	 by	 molecular	
subgroup	in	order	to	determine	if	the	expression	of	SIAE	(and	therefore	GD3)	correlates	
with	subgroup.	In	this	data	set	the	highest	expression	of	SIAE	mRNA	was	found	in	the	WNT	
subgroup	(figure	3.5B).	The	WNT	subgroup	which	expressed	SIAE	mRNA	significantly	more	
than	SHH	(p<0.0001),	group	3	(p<0.02)	and	group	4	subgroups	(p<0.0001).	There	were	no	
significant	 differences	 found	 between	 any	 other	 subgroup	 demonstrating	 that	 the	
expression	of	SIAE	mRNA	was	similar	between	SHH,	group	3	and	group	4.	
3.2.2 Characterisation	of	GD3	acetylation	pathway	 regulators	by	metastatic	 stage	of	
medulloblastoma	
	
At	diagnosis,	patients	with	medulloblastoma	are	typically	grouped	according	to	the	Chang’s	
staging	system	(Chang	et	al.	1969),	in	order	for	this	classification	to	be	applied	to	a	patient	
magnetic	resonance	imaging	(MRI)	and	a	lumbar	puncture	(LP)	are	carried	out	(Phi	et	al.	
2011).	Using	MRI	scans	tumour	mass	location	can	be	determined.	Using	cerebral	spinal	fluid	
(CSF)	obtained	from	LP,	it	can	be	determined	if	tumour	cells	are	present.	Using	Chang’s	M	
staging	system,	the	expression	of	each	of	the	known	GD3	acetylation	pathway	regulators	
was	 examined	 according	 to	 metastatic	 stage	 (Gilbertson	 2004).	 Chang’s	 M	 staging	 is	
outlined	in	table	3.1.	We	predicted,	based	on	our	hypothesis,	that	the	most	aggressive	and	
metastatic	medulloblastomas	would	have	deregulated	GD3	pathway	enzymes	which	would	
be	regulated	in	favour	of	GD3A	synthesis.	
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Table	 3.1	 Chang’s	 M	 stage	 classification	 of	 medulloblastoma	 patients	 modified	 from	
Chang	et	al.	1969.		
	
	 	
M	stage	 	
M0	 No	gross	subarachnoid	or	haematogenous	
metastasis.	
M1	 Tumour	cells	found	in	cerebral	spinal	fluid	
on	microscopic	analysis.	
M2	 Gross	nodular	seeding	in	the	cerebellum,	
cerebral	subarachnoid	space,	or	in	third	or	
fourth	ventricles.		
M3	 Gross	nodular	seeding	in	spinal	arachnoid	
space.	
M4	 Extraneural	metastasis.	
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For	 this	 study,	 publically	 available	 data	 was	 mined	 from	 the	 R2	 database	 using	 the	
Heidelberg	data	set,	this	microarray	was	carried	out	on	a	custom	chip	set	and	normalised	
using	 the	 4hm44k	 scheme.	 64	 patient	 samples	 were	 analysed.	 Age	 information	 was	
unfortunately	not	available	for	this	data	set.	Of	the	patients	analysed	45	were	classified	as	
having	M0	disease,	5	patients	were	classified	as	having	M1	disease,	4	patients	were	classified	
as	having	M2	disease	and	the	remaining	9	patients	were	classified	as	M3.	No	patients	in	this	
cohort	had	extraneural	metastasis	(M4	disease).		
ST8Sia1	 which	 synthesises	 GD3	 from	 GM3	 (reaction	 1;	 figure	 3.1).	 ST8Sia1	 was	 down-
regulated	as	shown	by	negative	transformed	log-fold	values	(figure	3.7A).	The	expression	
of	ST8Sia1	appeared	to	be	correlated	with	metastatic	stage	from	M1	to	M3,	however	the	
highest	 level	 of	 expression	 seen	 in	 M0.	 There	 was	 however	 no	 significant	 difference	
between	metastatic	stages	(figure	3.7A).		
ST8Sia5,	 the	 enzyme	 that	 uses	 GD3	 as	 a	 substrate	 for	 conversion	 to	 GT3	 or	 GD2	 was	
significantly	higher	in	M0	disease	compared	to	M3	(p<0.05),	showing	that	expression	of	this	
mRNA	decreases	with	increasing	M	stage	(figure	3.7B).		
Cas1	is	the	enzyme	that	is	hypothesised	to	acetylate	GD3	to	GD3A.	The	expression	of	Cas1	
at	 the	 mRNA	 level	 is	 shown	 to	 increase	 with	 increasing	 M	 stage	 (figure	 3.8A).	 The	
expression	of	Cas1	 is	 significantly	higher	 in	 the	M3	stage	compared	 to	M0	 (p<0.05).	The	
expression	of	SIAE,	the	deacetylation	enzyme	of	GD3A,	is	decreased	at	the	mRNA	level	with	
increasing	M	 stage	 and	 is	 shown	 to	 be	 lowest	 in	M3	 disease	 compared	 to	M0	 and	M1	
(p<0.05;	 figure	 3.8B).	 SIAE	 and	 Cas1	 mRNA	 expression	 appear	 to	 inversely	 correlate,	
particularly	in	M3	disease.	
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Figure	 3.7	 mRNA	 levels	 of	 ST8Sia1	 and	 ST8Sia5	 according	 to	 metastatic	 stage.	
Expression	 of	 ST8Sia1,	 the	 enzyme	 that	 synthesises	 GD3	 from	 GM3,	 was	 similar	
between	 all	metastatic	 stages	 as	 there	was	 not	 significant	 difference	 in	 expression	
between	 any	 metastatic	 stage.	 (B)	 mRNA	 expression	 of	 ST8Sia5	 appears	 to	 be	
correlated	 with	 metastatic	 stage	 of	 disease.	 There	 is	 a	 general	 trend	 that	 with	
increasing	metastatic	stage	there	is	a	lower	expression	of	ST8Sia5	mRNA.	There	was	
statistically	however	only	significantly	less	mRNA	expressed	in	M3	samples	compared	
to	M0.	Data	obtained	from	the	R2	database	using	the	Heidelberg	data	set.	Data	was	
analysed	 by	 one-way	 analysis	 of	 variance	 (ANOVA)	 followed	 by	 Tukey’s	 multiple	
comparisons	post-hoc	test	using	graph	pad	prism	6	software.	(*	p<0.05).	n=64	±	SEM		
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Figure	3.8	mRNA	expression	of	Cas1	and	SIAE	according	to	Metastatic	stage.	(A)	Analysis	
of	Cas1	mRNA,	the	hypothesised	acetylation	enzyme	of	GD3A,	showed	that	expression	
correlated	with	metastatic		stage	as	the	higher	the	expression	of	Cas1	mRNA,	the	higher	
the	metastatic	stage.	However,	the	only	significantly	different	metastatic	stages	were	M0	
and	M3	where	M3	expression	was	significantly	higher	than	M0.	(B)	mRNA	expression	of		
SIAE,	the	deacetylation	enzyme	of	GD3A,	was	highest	in	M1	disease.	The	mRNA	expression	
of	SIAE	was	significantly	lower	in	M3	disease	compared	to	M1	and	M2.	Data	obtained	from	
the	R2	database	using	the	Heidelberg	data	set.	Data	was	analysed	by	one-way	analysis	of	
variance	(ANOVA)	followed	by	Tukey’s	multiple	comparisons	post	hoc	test	using	graph	
pad	prism	6	software.	(*	p<0.05).	n=64	±	SEM		
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3.2.3 Summary	
	
Although	 the	 expression	 of	 the	 regulating	 enzymes	 of	 this	 pathway	 requires	 further	
investigation	at	the	protein	level,	studies	using	publicaly	available	mRNA	expression	data	
shed	some	light	on	the	regulation	of	these	enzymes	in	medulloblastoma.	
The	bioinformatics	data	supports	the	idea	that	the	GD3	acetylation	pathway	is	atypically	
expressed	in	medulloblastoma	tissue.		
The	expression	of	ST8Sia1	is	significantly	down-regulated	at	the	mRNA	level	in	this	study	
(p<0.001),	but	is	not	the	only	enzyme	involved	in	GD3	synthesis	so	may	not	correlate	with	
the	 expression	 of	 GD3	 when	 analysed	 alone.	 Cas1	 is	 significantly	 up-regulated	 in	 the	
medulloblastoma	 samples	 in	 this	 dataset	 (p<0.001)	 and	 inversely	 correlates	 with	 SIAE	
expression	which	may	indicate	that	the	balance	of	GD3	to	GD3A	is	in	favour	of	GD3A	in	these	
tumour	samples.	
When	the	medulloblastoma	data	set	was	analysed	with	respect	to	molecular	subgroup	the	
expression	of	ST8Sia1	was	seen	to	be	highest	in	the	SHH	subgroup	which	was	significantly	
higher	than	WNT,	group	3	and	group	4	(p<0.0001).	This	prompted	us	to	explore	the	mRNA	
expression	of	ST8Sia5	to	determine	if	GD3	was	being	used	as	a	substrate	to	generate	the	
more	complex	gangliosides	in	these	cells.	ST8Sia5	expression	was	found	to	be	significantly	
higher	 in	 the	 WNT	 subgroup	 compared	 to	 group	 3	 (p<0.0001)	 and	 group	 4	 (p<0.001)	
suggesting	that	the	more	aggressive	subgroups	would	be	more	likely	to	have	higher	levels	
of	GD3.	This	was	also	the	case	for	the	SHH	subgroup	which	expressed	significantly	more	
ST8Sia5	 mRNA	 than	 group	 3	 and	 group	 4	 samples	 (p<0.0001).	 Taken	 together,	 the	
concomitant	low	expression	of	ST8Sia1	and	ST8Sia5	suggest	that	 in	the	better	prognosis	
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subgroups	(WNT	and	SHH),	 the	GD3	synthesised	could	be	further	converted	to	complex	
gangliosides	 than	 group	 3	 and	 group	 4	 tumours,	 however	 this	 would	 need	 further	
exploration	to	confirm	this	hypothesis.		
In	 terms	 of	medulloblastoma	 subgroups,	 data	 also	 show	 the	 highest	 level	 of	 Cas1	 and	
lowest	 expression	 of	 SIAE	 are	 found	 in	 group	 3	 and	 group	 4	medulloblastomas.	 This	 is	
supportive	 of	 the	 hypothesis	 that	 the	 balance	 of	 GD3	 to	 GD3A	 is	 in	 favour	 of	 GD3A,	
particularly	in	the	more	aggressive	subgroups	of	disease.	When	this	data	was	examined	in	
relation	 to	metastatic	 stage	 the	prediction	 that	with	 increasing	M	 stage	GD3	and	GD3A	
expression	would	increase,	in	favour	of	GD3A	was	also	supported.		
The	 bioinformatics	 data	 show	 that	 ST8Sia1	 expression	 was	 generally	 correlated	 with	
increasing	M	stage	(although	highest	 in	M0	disease)	but	expression	was	not	significantly	
different	between	the	stages.	ST8Sia5	expression	was	also	examined	and	was	decreased	
with	increasing	M	stage,	the	expression	of	ST8Sia5	was	found	to	be	lowest	in	M3	disease	
compared	 to	M0	 (p<0.05).	 The	expression	of	Cas1	and	SIAE	were	 found	 to	be	 inversely	
correlated,	particularly	 in	M3	disease.	 The	data	 suggest	 that	with	 increasing	M	stage	of	
disease	the	expression	of	GD3	to	GD3A	is	likely	to	be	in	favour	of	GD3A	as	the	expression	of	
Cas1	is	up-regulated,	the	expression	of	SIAE	is	concomitantly	down-regulated.	
In	 summary,	 these	 findings	 support	 the	 idea	 that	 GD3	 is	 likely	 to	 be	 re-expressed,	
particularly	in	the	higher	risk	disease	groups	(groups	3	and	4,	and	high	M	stage)	and	is	also	
likely	to	be	acetylated	to	GD3A	in	medulloblastoma.	Therefore,	we	characterised	the	GD3	
and	 GD3A	 expression	 in	 medulloblastoma	 cell	 lines	 to	 compliment	 the	 bioinformatics-
derived	 information.	 As	 a	 proof	 of	 principle	 study,	 we	 investigated	 the	 potential	 of	
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exploiting	this	pathway	in	order	to	determine	if	by	increasing	the	deacetylation	of	GD3A,	
render	medulloblastoma	cells	are	rendered	more	susceptible	to	chemotherapy.		
3.3 Characterisation	of	GD3	and	GD3A	expression	in	medulloblastoma	cell	
lines		
3.3.1 Introduction	
	
The	expression	of	GD3	and	GD3A	has	been	shown	to	be	 in	delicate	balance	 in	 favour	of	
GD3A	 in	 cancers	 such	 as	 acute	 lymphoblastic	 leukaemia	 (Mukherjee	 et	 al.	 2008)	 and	
glioblastoma	 multiforme	 (Birks	 et	 al.	 2011).	 In	 this	 part	 of	 the	 study	 we	 aimed	 to	
characterise	these	gangliosides	in	three	medulloblastoma	cell	lines	(RES256,	UW402	and	
CHLA-01-Med)	 in	order	to	determine	the	relevance	of	this	pathway	in	this	tumour	type.	
Based	 on	 bioinformatics	 data,	 the	 expression	 of	 GD3	 and	 GD3A	 may	 be	 expressed	 by	
medulloblastoma	 cells.	 There	 may	 also	 be	 a	 balance	 in	 favour	 of	 GD3A	 in	 the	
medulloblastoma	cell	lines	as	suggested	by	information	gathered	from	bioinfomatic	studies		
of	SIAE,	the	deacetylation	enzyme,	and	the	up-regulation	of	Cas1,	the	acetylation	enzyme	
of	GD3.		
3.3.2 GD3	and	GD3A	are	expressed	by	medulloblastoma	cell	lines	
	
In	order	to	test	our	hypotheses	that	GD3	and	GD3A	are	expressed	by	medulloblastoma	cells,	
expression	of	GD3	and	GD3A	in	three	cell	lines	was	characterised	using	flow	cytometry	and	
immunocytochemistry.		
Expression	 levels	 were	 determined	 by	 directly	 assaying	 GD3	 and	 GD3A	 to	 determine	
expression	of	the	products,	not	the	mRNA	of	the	synthesis	enzymes.	Flow	cytometry	was	
used	 to	determine	quantitative	expression	of	both	antigens	 as	 a	percentage	of	 the	 cell	
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population,	 and	 was	 further	 confirmed	 with	 qualitative	 immunocytochemistry.	 A	
representative	example	of	positive	staining	is	shown	in	figure	3.9A.		
The	 expression	 of	 cell	 surface-associated	 and	 intracellular	 GD3	 and	 GD3A	 were	
characterised	 and	 compared	 in	medulloblastoma	 cell	 lines	 using	 flow	 cytometry.	 Three	
medulloblastoma	cell	lines	RES256,	UW402,	and	CHLA-01-Med	were	used	and	compared	
to	 that	of	a	positive	control	cell	 line,	MeWo,	a	metastatic	melanoma	cell	 line	known	to	
express	both	antigens	(Kniep	et	al.	2006)	(figure	3.9).	Due	to	the	fact	that	gangliosides	are	
synthesised	both	within	the	cell	and	(to	a	lesser	extent)	on	the	cell	surface,	as	well	as	and	
trafficked	(Sorice	et	al.	2012)	both	the	expression	within	the	cell	and	on	the	cell	surface	was	
examined.		
Analysis	of	intracellular	GD3	and	GD3A	showed	that	the	population	of	cells	expressing	GD3	
was	similar	for	RES256,	UW402	and	CHLA-01-Med	(56.7%,	61.3%	and	45.1%	respectively;	
figure	 3.9B).	 The	 percentage	 of	 the	 cells	 expressing	GD3A	was	 also	 found	 to	 be	 similar	
between	the	cell	lines	(85.4%,	74.4%	and	79.4%	respectively;	figure	3.9B).	When	comparing	
GD3	to	GD3A	by	each	individual	cell	line,	the	balance	of	the	gangliosides	is	shown.	The	only	
cell	line	to	have	a	higher	population	of	GD3A	positive	cells	compared	to	GD3	positive	cells	
was	CHLA-01-Med	(figure	3.9B;	p<0.01).	This	however	may	not	be	necessary	for	protection	
against	high	levels	of	GD3	as	previous	studies	have	shown	that	GD3A	can	protect	from	GD3	
mediated	apoptosis	at	 low	 levels	 (Kniep	et	al.	2006).	Expression	of	both	antigens	 in	 the	
positive	 control	 cell	 line	MeWo	was	 49.0%	GD3	 and	 79.5%	GD3A	also	 demonstrating	 a	
balance	in	favour	of	GD3A	in	this	cell	 line,	although	the	difference	in	expression	was	not	
significant.		
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When	examined	on	the	cell	surface,	expression	of	GD3	was	found	to	be	higher	than	that	of	
GD3A	in	the	medulloblastoma	cell	lines.	This	was	not	found	in	the	MeWo	cell	line	whose	
expression	of	GD3	was	93.8%	and	expression	of	GD3A	was	91.7%	(figure	3.9C).	In	both	the	
UW402	and	CHLA-01-Med	cell	 line	there	 is	a	significant	difference	 in	the	balance	of	cell	
surface	GD3	to	GD3A	with	UW402	(62.2%	GD3	compared	to	17.5%	GD3A)	(p<0.01),	and	the	
CHLA-01-Med	cell	 line	(77.1%	GD3	compared	to	0.6%	GD3A)	(P<0.001)	(figure	3.9C).	The	
expression	of	GD3	and	GD3A	for	RES256	cells	was	55.0%	and	36.0%	respectively.	These	data	
are	in	agreement	with	published	work	showing	that	GD3	requires	internalisation	to	become	
acetylated	(Chen	et	al.	2006)	and	therefore	the	low	levels	of	GD3A	on	the	cell	surface	are	
not	surprising.		
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Figure	3.9	Expression	of	GD3	and	GD3A	was	confirmed	by	flow	cytometry	using	a	positive	
control	cell	line	MeWo,	known	to	express	both	antigens	at	high	levels.	(A)	Examples	of	flow	
cytometry	 histograms	 demonstrating	 expression	 of	 GD3	 and	 GD3A.	 Purple	 filled	 peaks	
represent	negative	control	samples	from	which	gating	was	carried	out,	red	peaks	represent	
positive	staining.	Histograms	represent	one	technical	replicate	from	one	experiment.	 	 (B)	
Intracellular	 expression	 of	 GD3	 and	 GD3A	 from	 three	 independent	 experiments	
demonstrates	a	higher	level	of	GD3A	expression	(red	bars)	compared	to	GD3	(green	bars)	in	
CHLA-01-Med,	a	group	4	cell	line.		(C)	Cell	surface	expression	of	GD3	and	GD3A	shows	a	higher	
expression	 of	 GD3	 (green	 bars)	 compared	 to	 GD3A	 expression	 (red	 bars)	 and	 shows	 a	
significantly	higher	level	of	GD3	expression	in	UW402	and	CHLA-01-Med	cells.	Data	analysed	
by	unpaired	two-tailed	t-test	using	Graph	Pad	Prism	6	software	(**	p<0.01;	***	p<0.001)	n=3	
±	SEM	
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To	 further	 confirm	 the	 expression	 of	 GD3	 and	 GD3A	 in	 medulloblastoma	 cell	 lines,	
immunocytochemistry	 was	 used	 (figure	 3.10).	 This	 technique	was	 used	 to	 qualitatively	
evaluate	expression	and	validate	flow	cytometry	data.		
Immunocytochemistry	revealed	that	intracellular	expression	of	GD3A	(red)	was	higher	than	
that	of	GD3	(green).	There	was	some	degree	of	co-localisation	with	these	two	antigens.	Co-
localisation	studies	cannot	be	conclusive	in	this	manner	however	due	to	the	influence	of	
fixation	methods	on	the	localisation	of	the	gangliosides	(Schwarz	&	Futerman	1997).	The	
expression	of	these	antigens	is	confirmed	by	immunocytochemistry	but	not	compared	to	
flow	cytometry	data	which	reports	the	percentage	of	the	population	expressing	antigen,	
not	 the	 expression	of	 the	 antigens	 on	 a	 single	 cell	 basis.	 It	 is	 therefore	not	 possible	 to	
conclude	which	of	the	cell	lines	expresses	the	highest	levels	of	GD3A	in	this	way	as	the	whole	
population	of	cells	would	be	required.	
Ganglioside	expression	was	also	examined	in	the	wild-type	mouse	cerebellum.	Two	ages	
(P5	and	P60)	of	mice	were	chosen	to	represent	two	stages	of	development.	The	P5	mouse	
brain	is	at	a	point	in	time	where	the	GPCs	are	at	their	peak	of	migration,	the	expression	of	
the	gangliosides	GD3	and	GD3A	should	therefore	be	at	peak	expression	during	these	times.	
The	P5	mouse	brain	represents	a	32-36	week	foetal	brain.	As	we	know	that	the	expression	
of	GD3	and	GD3A	is	present	on	medulloblastoma	tumour	cells,	we	stained	the	cerebellums	
of	these	mice	to	determine	the	location	of	ganglioside	positive	staining	(figure	3.11).	We	
then	used	this	information	to	determine	which	of	the	subgroups	of	medulloblastoma	could	
arise	based	on	the	location	of	GD3	and	GD3A	staining	and	the	age	of	the	mouse.	The	P60	
mouse	was	a	control	for	a	time	when	the	brain	should	only	express	low	levels	of	both	GD3	
and	GD3A,	the	P60	mouse	represents	a	human	brain	over	the	age	of	20	years.		
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Staining	of	the	post-natal	day	5	wild-type	mouse	cerebellum	shows	that	high	levels	of	GD3	
expression	are	found	in	the	internal	granule	layer	(IGL)	(figure	3.11A,	green).	Staining	was	
shown	to	be	cellular	as	there	is	localisation	surrounding	counterstained	nuclei.	The	majority	
of	the	cells	in	the	IGL	express	GD3	in	this	area	of	the	cerebellum.	Also	in	the	P5	wild-type	
mouse	cerebellum	is	a	high	level	of	GD3A	expression	shown	in	red,	staining	is	intense	and	
present	in	a	high	percentage	of	the	cell	populations.	Staining	is	also	seen	in	projections	in	
the	EGL	(figure	3.11A).		Staining	in	the	P60	cerebellum	was	diminished	significantly	(figure	
3.11B).	Little	GD3	staining	was	present	throughout	the	internal	granule	layer	(IGL)	and	the	
PL	in	P60	samples.	Only	low	intensity	GD3	staining	was	seen	in	the	molecular	layer	(figure	
3.11B).	GD3A	staining	in	the	P60	wild-type	mouse	brain	showed	much	the	same	pattern	as	
the	GD3	staining,	with	most	being	present	at	low	intensity	in	the	molecular	layer	(figure	
3.11B),	 there	 was	 however	 some	 background	 fluorescence	 in	 this	 instance	making	 the	
actual	staining	intensity	of	GD3A	difficult	to	determine.	
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Figure	3.10	Expression	of	GD3	and	GD3A	is	confirmed	by	immunocytochemistry	in	fixed	cell	
lines.	MeWo,	a	positive	control	cell	line	confirms	intracellular	expression	of	GD3	(green)	
and	GD3A	(red)	with	some	co-localisation	of	the	antigens	(yellow).	On	the	cell	surface	there	
is	also	expression	of	both	antigens.	Expression	of	GD3A	is	seen	throughout	the	cytoplasm	
of	RES256	cells	with	faint	GD3	staining	also	seen.	On	the	cell	surface	the	RES256	cell	line	
shows	a	higher	degree	of	GD3	staining	compared	to	GD3A.	In	UW402	cells	there	is	a	similar	
staining	to	RES256	cells,	with	more	GD3A	expressed	intracellularly	compared	to	on	the	cell	
surface	where	GD3	 is	more	highly	expressed.	 In	CHLA-01-Med	cells	GD3	and	GD3A	are	
expressed	in	similar	levels	whereas	GD3A	appears	to	be	expressed	more	highly	on	the	cell	
surface	compared	to	GD3.	Cell	images	taken	using	a	Zeiss	Axioimager	ZI	epifluorescence	
microscope	equipped	with	a	Hamamatsu	digital	camera	and	velocity	imaging	software.	40	
X	magnification,	scale	bar	100	µm.	n=3		
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Figure	3.11	Expression	of	GD3	and	GD3A	in	the	post–natal	day	5	and	day	60	wild-type	mouse	
cerebellum.	(A)	The	post-natal	day	5	cerebellum	shows	a	low	level	of	background	fluorescence	
when	stained	with	secondary	antibody	only,	the	areas	of	the	cerebellum	are	highlighted	as	
the	 internal	 granule	 layer	 (IGL);	 the	 purkinje	 cell	 layer	 (PL;	 arrow	head);	and	 the	 external	
granule	layer	(EGL).	High	levels	of	GD3	expression	(green)	are	seen	in	the	internal	granule	layer	
(IGL).	Staining	is	cellular	as	shown	by	localisation	surrounding	counterstained	nuclei	(blue).	
There	is	a	large	population	of	cells	expressing	GD3	in	this	area	of	the	cerebellum	demonstrated	
by	the	20	X	magnification	image.	Also	in	the	P5	wild-type	mouse	cerebellum	is	a	high	level	of	
GD3A	staining	(red).	There	is	also	very	little	background	fluorescence	shown	in	the	controls.	
Staining	is	intense	throughout	the	cell	bodies	and	the	projections	as	seen	in	the	EGL	at	40	X	
magnification.	 (B)	 Staining	 in	 the	 P60	 cerebellum	 is	 diminished	 significantly.	 Little	 GD3	
staining	is	present	thoughout	the	internal	graule	layer	(IGL)	and	the	PL	in	P60	samples	and	is	
seen	at	low	intensity	in	the	molecular	layer	only.	GD3A	staining	shows	much	the	same	pattern	
as	the	GD3	staining	with	most	being	present	at	low	intensity	in	the	molecular	layer,	there	is	
however	 background	 fluorescence	 in	 this	 instance	making	 the	 actual	 staining	 intensity	 of	
GD3A	difficult	 to	determine.	 taken	using	a	Zeiss	Axioimager	ZI	epifluorescence	microscope	
equipped	 with	 a	 Hamamatsu	 digital	 camera	 and	 velocity	 imaging	 software.	 40	 X	
magnification,	scale	bar	100	µm.	n=3		
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3.3.3 Conclusion	
	
The	expression	of	GD3	and	GD3A	was	confirmed	in	each	of	the	medulloblastoma	cell	lines	
we	used.	This	data	suggests	that	a	balance	between	GD3	and	GD3A	exists	within	these	cells	
and	that	this	balance	is	in	favour	of	GD3A	within	the	cell	and	in	favour	of	GD3	on	the	cell	
surface.		The	deacetylation	of	GD3A	has	been	shown	in	previous	studies	to	influence	cell	
survival	(Birks	et	al.	2011).	We	therefore	hypothesised	that	through	overexpression	of	SIAE,	
the	human	endogenous	deacetylation	enzyme,	that	the	balance	of	GD3A	to	GD3	could	be	
shifted	in	favour	of	GD3	and	therefore	apoptosis	(figure	3.12).		
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Figure	3.12	Our	hypothesis,	the	balance	of	GD3	and	GD3A	is	in	favour	of	GD3A	as	shown	in	
medulloblastoma	cell	cultures,	and	as	suggested	by	bioinformatic	analysis.	Our	aim	is	to,	
through	SIAE	over-expression,	to	shift	the	balance	in	favour	of	GD3.	We	hypothesise	that	
by	over-expression	of	SIAE,	high	levels	of	pro-apoptotic	GD3	levels	will	be	restored	and	that	
this	may	influence	cell	viability	and	sensitise	cells	to	commonly	used	chemotherapeutics.	
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3.4 SIAE	overexpression	studies	
	
After	 confirming	GD3	and	GD3A	expression	 in	 the	 three	medulloblastoma	cell	 lines,	 the	
highest	expressing	cell	line	of	intracellular	GD3A	(RES256)	was	selected	for	over-expression	
of	SIAE.	This	cell	 line	was	also	chosen	for	its	rapid	proliferation	rate	and	relative	ease	of	
transfection	compared	to	UW402	and	CHLA-01-Med.	
An	 inducible	 system	was	used	 to	 control	 SIAE	 transcript	 expression.	 These	experiments	
were	 designed	 to	 test	 our	 hypothesis	 that	 over-expression	 of	 SIAE	 would	 result	 in	 an	
increase	 in	 GD3A	 deacetylation.	 This	 GD3A,	 when	 deacetylated,	 was	 hypothesised	 to	
increase	 the	 pool	 of	 GD3	 which	 may	 then	 result	 in	 a	 collapse	 of	 the	 mitochondrial	
membrane	 potential	 and	 increase	 apoptosis.	 We	 also	 hypothesised	 that	 SIAE	 over-
expression	may	make	medulloblastoma	cells	more	susceptible	to	apoptosis	when	treated	
with	chemotherapeutics.		
In	standard	stable	over-expression	experiments	clones	failed	to	expand	(appendix	1).	We	
also	carried	out	transient	transfections	using	these	constructs	(appendix	2)	and	although	
we	 cannot	 conclude	 from	 this	 data	 that	 SIAE	 overexpression	 was	 toxic	 to	 cells,	 we	
concluded	that	a	well	described	inducible	system	approach	would	provide	us	with	a	model	
to	directly	 test	our	hypothesis	 that	SIAE	overexpression	 leads	 to	deacetylation	of	GD3A.		
pCMV-TetOn3G	 and	 pTRE3G-IRES	 construct	 backbones	 were	 therefore	 purchased	 from	
Clontech	and	the	SIAE	gene	(or	the	catalytic	mutant	SIAE-S127A)	as	well	as	an	EGFP	gene	
were	cloned	into	them	using	InFusion	HD	Dry	cloning	(Clontech)	described	in	chapter	2.	
Gene	inserts	were	confirmed	by	size	(by	restriction	digests,	appendix)	and	by	sequencing	
using	SIAE	primers	(appendix	3).		
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The	 catalytic	 mutant	 SIAE-S127A	 has	 been	 described	 by	 several	 groups	 who,	 when	
investigating	 the	 possible	 sites	 for	 the	 catalytic	 triad	 of	 SIAE,	 conducted	 site-directed	
mutagenesis	 studies	 that	 demonstrated	 serine	 127	 (S127)	 as	 a	 conserved	 and	 critical	
residue	 for	 esterase	 activity	 (Surolia	 et	 al.	 2010;	Orizio	 et	 al.	 2015).	 These	 studies	 also	
demonstrated	 that	when	 the	 serine	 residue	was	mutated	 to	 an	 alanine	 (S127A),	wildly	
changing	the	properties	of	the	amino	acid	within	the	triad,	catalytic	activity	was	decreased	
significantly	to	almost	negligible	levels	(Surolia	et	al.	2010).	It	is	important	to	note	that	while	
this	group	describe	many	germline	SIAE	mutations	and	their	activities,	the	S127A	variant	
has	not	been	found	endogenously	and	was	used	as	an	artificial	control	for	these	studies.		
When	cloning	the	SIAE	and	SIAE-S127A	genes	into	the	pTRE3G-IRES-EGFP	constructs,	it	was	
important	to	ensure	the	sequence	was	incorporated	correctly	(appendix	3).	Of	particular	
importance	was	the	point	mutation	encoding	the	serine	to	alanine	substitution	in	the	SIAE-
S127A	plasmid	(figure	3.13,	black	circle).	The	mutation	from	GAG	to	GGC	encodes	the	serine	
to	 alanine	 mutation	 and	 is	 shown	 at	 positions	 378-380	 of	 the	 cDNA	 sequence	
(corresponding	to	amino	acid	127).		
The	 incorporation	of	 the	EGFP,	 SIAE	and	SIAE-S127A	genes	was	 successful	 as	 shown	by	
sequencing	 (appendix	 3),	 these	 plasmids	were	 then	 used	 for	 down-stream	 transfection	
experiments.		
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Figure	 3.13	 Sanger	 sequencing	 demonstrates	 that	 SIAE	 and	 SIAE-S127A	 genes	were	
successfully	 cloned	 into	 the	 pTRE3G-IRES-EGFP	 plasmids.	 The	 mutation	 encoding	
S127A,	 a	 mutation	 of	 the	 catalytic	 triad	 of	 SIAE	 is	 shown	 in	 the	 black	 circle	 and	
corresponds	to	position	127	of	the	amino	acid	sequence.	
SIAE_Reference	_Sequence		
SIAE_Plasmid	
SIAE-S127A_Plasmid	
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3.5 The	Tet-On	3G	inducible	system	
	
The	Tet-On	3G	system	is	a	well	described	inducible	gene	expression	system	for	mammalian	
cells.	 There	 are	 two	 elements	 to	 the	 Tet-On3G	 system.	 The	 Tet-On	 3G	 transactivator	
protein,	which	has	a	high	sensitivity	to	doxycycline,	and	the	PTRE3G	inducible	promoter.	The	
PTRE3G	promoter	allows	for	very	low	basal	expression	and	high	expression	of	the	genes	of	
interest	after	induction.	Within	the	tet-responsive	construct	pCMV-TetOn3G,	there	are	7	
repeats	of	a	19	base	pair	tet	operator	sequence	which	is	 located	upstream	of	a	minimal	
CMV	 promoter.	 In	 the	 presence	 of	 doxycycline,	 Tet-On	 3G	 protein	 undergoes	 a	
conformational	 change	 that	 allows	 binding	 to	 the	 PTRE3G	 promoter	 (figure	 3.14).	 The	
doxycycline	 concentration	 for	 induction	 of	 gene	 expression	 is	 far	 below	 cytotoxic	
concentrations	for	cell	culture	studies	(1	µg/mL).		
In	these	studies,	cells	are	transfected	with	pCMV-TetOn3G	and	pTRE3G-IRES-EGFP-(SIAE	or	
SIAE-S127A).	The	cells	therefore	express	a	Tet-On	3G	transactivator	protein	and	contain	
two	genes	of	interest,	EGFP	and	either	SIAE	(wild-type)	or	SIAE-S127A.	Expression	is	under	
the	control	of	the	TRE3G	promoter	(PTRE3G	).	The	genes	of	interest	are	expressed	only	in	the	
presence	of	doxycycline,	and	are	not	expressed	as	fusion	proteins.		This	is	achieved	as	the	
construct	contains	an	internal	ribosomal	entry	site	(IRES),	which	allows	the	generation	of	
two	proteins	from	the	same	mRNA	transcript	shown	in	figure	3.15.	
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Figure	3.14	The	Tet-On	3G	inducible	expression	system.	Cells	are	stably	transfected	with	two	
constructs,	pCMV-TetOn3G,	which	produces	Tet-On	3G	protein;	and	an	inducible	construct	
containing	an	internal	ribosomal	entry	site	(IRES)	and	cloned	genes	of	interest.	Tet-On	3G	
protein	is	then	expressed	by	the	Tet-On	3G	transfected	clone.	When	expressed,	Tet-On	3G	
protein	 undergoes	 a	 conformational	 change	 in	 the	 presence	 of	 doxycycline-	 driving	
transcription.	In	the	absence	of	doxycycline	the	Tet-On3G	protein	expressed	by	Tet-On	stable	
cell	lines	is	unable	to	bind	to	PTRE3G	and	transcription	does	not	take	place.	In	the	presence	of	
doxycycline,	the	Tet-On	3G	protein	undergoes	a	conformational	change	that	allows	promoter	
binding	of	the	pTRE3G-IRES	tet-responsive	construct	and	drives	transcription	of	cloned	genes	
of	interest.	
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Figure	 3.15	 Two	 proteins	 are	 expressed	 from	 one	 mRNA	 transcript	 using	 an	 internal	
ribosomal	entry	site.	The	Tet-On	3G	inducible	system	contains	an	internal	ribosomal	entry	
site	(IRES)	under	the	control	of	a	tet-responsive	promoter	(PTRE3G).	Gene	expression	is	only	
initiated	 in	 the	 presence	 of	 Tet-On	 3G	 protein	 bound	 to	 doxycycline,	 allowing	
transcription.	Two	proteins	are	produced	simultaneously	from	one	mRNA	transcript	by	the	
use	of	the	IRES	that	is	flanked	by	the	two	multiple	cloning	sites	containing	cloned	genes	
(SIAE	and	EGFP	or	SIAE-S127A	and	EGFP).	Translation	initiation	usually	occurs	at	the	5’	cap	
however	the	IRES	allows	ribosomes	to	bind	at	a	second	location	allowing	the	proteins	to	
be	expressed	separately.	Adapted	from	Tet-On	user	guide	(Clontech)	
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3.6 Generating	and	screening	a	Tet-responsive	cell	line	
	
RES256	 cells	 were	 first	 stably	 transfected	 with	 the	 pCMV-TetOn3G	 construct	 (map,	
appendix	3)	as	described	in	chapter	2.	After	clonal	selection	with	selective	antibiotic	and	
picking	of	colonies,	24	clones	were	screened	for	expression.	Cells	were	tested	for	induction	
of	expression	using	 transient	expression	with	a	Tet-responsive	 luciferase	construct.	This	
assay	allows	the	functionality	of	the	Tet-On	3G	protein	to	be	tested.	The	Tet-On	3G	protein	
drives	expression	of	a	luciferase	gene	and	the	basal	level	of	expression	can	be	determined.	
To	achieve	this	cells	were	transfected	with	pTRE3G-Luc	(map,	appendix	4)	as	described	in	
chapter	2	and	cultured	in	the	presence	and	absence	of	doxycycline	for	48	hours	according	
to	manufactures	instructions.	Cells	were	lysed	using	the	lysis	buffer	provided	with	the	Dual	
Luciferase	 kit	 (Promega).	 The	 assay	was	 carried	out	 and	 luminescence	of	 the	 luciferase	
protein	 recorded.	 Fold-induction	 of	 expression	 was	 confirmed,	 and	 the	 clones	 which	
demonstrated	the	lowest	basal	expression	and	the	highest	induction	of	expression	were	
propagated	(appendix	4).	
The	 clones	 with	 the	 highest	 fold-induction	 of	 luciferase	 gene	 expression	 were	 then	
transfected	with	pTRE3G-IRES-EGFP	(empty	vector	control),	pTRE3G-IRES-EGFP-SIAE	(wild-
type)	 or	 pTRE3G-IRES-EGFP-SIAE-S127A	 (catalytic	 mutant)	 plasmids.	 Following	 the	
transfection	of	SIAE	genes,	potential	clones	were	screened	for	EGFP	expression	with	and	
without	doxycycline	treatment	(1	µg/mL)	using	ICC	(figure	3.16).	Expression	of	EGFP	was	
confirmed	and	these	clones	were	propagated.	The	next	step	was	to	ensure	that	SIAE	(or	
SIAE-S127A)	was	expressed	at	the	protein	level.	
To	determine	the	level	of	SIAE	protein	expression,	Western	blot	analysis	was	conducted.	
Cells	were	incubated	in	the	presence	and	absence	of	doxycycline	for	48	hours	and	lysed	
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using	M-PER	supplemented	with	protease	and	phosphatase	inhibitors	described	in	chapter	
2.	The	protein	content	of	the	lysates	was	determined	using	the	colorimetric	bicinchoninic	
acid	 assay	 (BCA	 Assay;	 Thermo).	 Protein	 was	 separated	 using	 polyacrylamide	 gel	
electrophoresis	 and	 transferred	 to	 a	 PVDF	 membrane	 and	 prepared	 for	 Western	 blot	
analysis	using	an	in-house	anti-SIAE	antibody	(described	in	chapter	2).	Two	wild-type	clones	
that	 expressed	 SIAE	 were	 analysed,	 along	 with	 empty	 vector	 control	 (EGFP)	 and	 the	
catalytic	mutant	cell	line	S127A	(figure	3.16).	
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Figure	3.16	EGFP	gene	expression	is	induced	in	the	presence	of	doxycycline.	RES256	cells	
were	screened	for	EGFP	gene	expression	in	the	first	instance	to	reduce	clone	numbers	
for	 SIAE	 expression	 screens.	 Clones	 expressing	 EGFP	 in	 the	 presence	 of	 doxycycline	
(green)	that	showed	little	expression	in	the	absence	of	doxycycline	were	chosen	for	SIAE	
expression	screening.	(EGFP	–	green,	nuclei	-	blue)	10	X	objectives.	SIAE	clone	2	is	shown	
as	an	example.	Cell	images	taken	using	a	Zeiss	Axioimager	ZI	epifluorescence	microscope	
equipped	 with	 a	 Hamamatsu	 digital	 camera	 and	 velocity	 imaging	 software.	 40	 X	
magnification,	scale	bar	100	µm.	n=3	
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In	 RES256	 cell	 lysates	 SIAE	 expression	was	 confirmed	by	Western	blot	 analysis	 and	 the	
expression	appeared	to	be	tightly	controlled	(as	demonstrated	by	the	absence	of	construct	
leakiness).	 This	 further	 confirmed	 the	 results	 from	 the	 luciferase	 assay	 that	 the	
conformational	change	of	the	TetOn	3G	protein	was	under	tight	control	(appendix	4.2).	The	
predicted	molecular	weight	of	SIAE	 in	 its	active	 form	 is	a	glycoprotein	with	a	molecular	
weight	of	62	kDa	as	described	by	Orizio	et.	al.	Interestingly,	the	intensity	of	expression	of	
the	proteins	expressed	by	SIAE	and	SIAE-S217A	clones	appears	to	be	somewhat	different	
(figure	3.17).	Two	immunoreactive	bands	for	each	clone	are	shown	when	gene	expression	
is	 induced	with	doxycycline	addition.	The	largest	molecular	weight	band	has	a	predicted	
size	of	62	kDa	as	determined	by	ImageStudio	software	(Licor	Biosciences),	this	is	the	same	
molecular	weight	 reported	by	Orizio	et.	al	as	active	glycoprotein.	The	second	molecular	
weight	 band,	 which	 is	 more	 intense	 in	 wild-type	 expressing	 clones,	 has	 a	 predicted	
molecular	weight	of	32	kDa.	Initially	we	thought	that	the	blot	may	be	showing	heavy	and	
light	chains	of	the	antibody	we	used,	however	as	we	did	not	see	these	bands	in	our	EGFP	
expressing	 cell	 lines,	 nor	 in	 lanes	 loaded	 with	 cells	 not	 treated	 with	 doxycycline,	 we	
disregarded	this.	Another	explanation	for	the	expression	of	a	32	kDa	protein	was	that	the	
processing	of	was	somehow	different.	The	protein	loading	of	each	clone	is	confirmed	as	
equal	between	off	and	on	using	a	beta-actin	loading	control	(figure	3.17).			
	 	
195	
	 	
	
Figure	3.17	SIAE	expression	is	induced	by	RES256	clones	in	the	presence	of	doxycycline.	Cells	
were	 cultured	 in	 the	 presence	 and	 absence	 of	 doxycycline	 for	 48	 hours	 and	 lysed	 using	
mammalian	 protein	 extraction	 reagent	 containing	 protease	 and	 phosphatase	 inhibitors.	
Protein	was	quantified	using	bicinchoninic	acid	assay	(BCA	assay)	and	was	then	loaded	and	
resolved	 using	 sodium	 dodecyl	 sulphate	 polyacrylamide	 gel	 electrophoresis	 (SDS-PAGE).	
Resolved	 protein	was	 then	 transferred	 onto	 a	 polyvinylidene	 fluoride	 (PVDF)	membrane,	
blocked	with	1	%	non-fat	milk	and	probed	with	an	in-house	anti-SIAE	primary	antibody	and	
conjugated	fluorescent	secondary	antibody.	 	SIAE	was	expressed	by	 two	wild-type	clones,	
SIAE	1	and	SIAE	2,	and	by	the	catalytic	mutant,	S127A,	importantly	only	when	the	cells	were	
cultured	with	doxycycline	for	48	hours.	Two	bands	were	present	on	each	blot.	The	protein	at	
approximately	62	kDa	represents	the	glycosylated	active	form	of	SIAE.	The	second	band	at	
around	32	kDa	 is	probably	 the	 result	of	 cleavage.	Equal	protein	 loading	between	samples	
from	each	clone	are	confirmed	with	beta	actin	(red	bands).	Less	protein	was	loaded	in	the	
S127A	samples	due	to	protein	concentration	of	the	lysate.		Image	acquired	using	the	Licor	
Odyssey	Clx	equipped	with	ImageStudio	5	software.	Image	representative	of	n=3	
Beta	actin	42	kDa	-	
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We	 also	 considered	 whether	 the	 62	 kDa	 protein	 might	 be	 secreted.	 Orizio	 et.	 al	
demonstrated	 that	 the	 62	 kDa	 glycoprotein	 can	 be	 secreted	 in	 a	 cell-type	 dependent	
manner.	 This	 publication	 also	 demonstrated	 that	 the	 catalytic	 mutant	 secreted	 more	
enzyme	than	wild-type	in	their	cell	lines	so	we	hypothesised	that	our	mutant	would	do	the	
same.	In	order	to	test	this,	we	first	serum-depleted	the	cells	over	48	hours.	We	then	treated	
with	 doxycycline	 for	 48	 hours	 as	 for	 pervious	 experiments.	 Conditioned	 media	 was	
harvested	and	analysed	by	Western	blot	analysis	(figure	3.18).	Protein	loading	was	adjusted	
and	 confirmed	 with	 Ponceau	 S	 staining	 (figure	 3.18B).	 The	 conditioned	 media	 studies	
demonstrated	 that	 the	 SIAE-S127A	 mutant	 clone	 secreted	 enzyme	 (figure	 3.18A).	 The	
molecular	weight	of	the	secreted	protein	was	confirmed	as	62	kDa,	in	line	with	Orizio	et	al.	
this	protein	was,	therefore,	confirmed	as	the	fully	glycosylated	enzyme.	As	the	wild-type	
SIAE	expressing	clones	did	not	secrete	enzyme	at	detectable	levels,	this	may	explain	the	
difference	 in	band	 intensities.	 In	 light	of	 this	we	 further	explored	 the	32	kDa	molecular	
weight	band	to	elucidate	what	it	could	be.		
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Figure	3.18	SIAE	as	a	secreted	enzyme.	Cells	were	serum	starved	over	a	course	of	48	hours,	
after	 which	 media	 was	 supplemented	 with	 (or	 without)	 doxycycline	 for	 48	 hours.	
Conditioned	 media	 was	 then	 loaded	 and	 resolved	 using	 sodium	 dodecyl	 sulphate	
polyacrylamide	gel	electrophoresis	 (SDS-PAGE).	Resolved	protein	was	then	transferred	
onto	a	polyvinylidene	 fluoride	(PVDF)	and	(B)	 stained	with	ponceau	s	 to	ensure	equal	
loading.	 (A)	 The	membrane	was	 then	blocked	 and	probed	with	 an	 in-house	 anti-SIAE	
primary	antibody	 and	 conjugated	 fluorescent	 secondary	antibody.	 	 SIAE	was	 secreted	
only	by	by	the	catalytic	mutant,	S127A,	importantly	only	when	the	cells	were	cultured	
with	 doxycycline	 for	 48	 hours.	 The	 protein	 at	 approximately	 62	 kDa	 represents	 the	
glycosylated	active	form	of	SIAE.	Image	acquired	using	the	Licor	Odyssey	Clx	equipped	
with	ImageStudio	5	software.	n=3	
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Orizio	et.	al	described	a	cleaved	SIAE	product	with	a	molecular	weight	of	49	kDa,	while	our	
molecular	weight	was	32	kDa	we	considered	cleavage	products	as	an	option	for	identifying	
this	band.	In	further	support	of	this	analysis	of	the	peptide	sequence	of	SIAE	by	protparam	
(http://web.expasy.org/protparam/)	suggests	that	SIAE	is	an	unstable	protein.		
We	first	entered	the	SIAE	sequence	into	peptide	cutter	software	which	recognises	cleavage	
sites	within	the	SIAE	protein.	When	narrowing	the	searches	of	the	protein	sequence	that	
gave	rise	to	similar	molecular	weights	shown	 in	 figure	3.17	and	that	also	conserved	the	
antibody	recognition	site,	one	candidate	was	 identified,	caspase	1	 (figure	3.19).	Peptide	
cutter	software	demonstrated	that	caspase	1	could	cleave	SIAE	once	to	give	rise	to	a	236	
amino	acid	and	a	287	amino	acid	product.	The	cleavage	product	containing	the	antibody	
recognition	sequence	was	predicted	to	be	27	kDa	 in	molecular	weight.	By	Western	blot	
analysis	 we	 showed	 the	 cleavage	 product	 to	 have	 a	 molecular	 weight	 of	 32	 kDa;	 this	
difference	 could	 be	 explained	 as	 the	 protein	 sequence	 contains	 4	N-glycosylation,	 2	O-
glycosylation	and	12	phosphorylation	sites	that	are	not	considered	by	the	software.		
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Figure	3.19	Cleavage	sites	of	SIAE	resulting	in	fragment	sizes	similar	to	32	kDa.	To	determine	if	
cleavage	of	SIAE	protein	could	be	a	result	of	protein	cleavage,	giving	rise	to	the	32	kDa	band	seen	
on	western	blot	analysis	of	SIAE	peptide	cutter	software	was	used.	The	full	SIAE	sequence	was	
uploaded	to	peptide	cutter	software.	This	software	demonstrates	one	potential	cleavage	site	
giving	 rise	 to	a	27	kDa	 fragment	 containing	 the	antibody	 recognition	 sequence	 (highlighted).	
Although	a	lower	molecular	weight	to	the	32	kDa	band	observed	in	figure	3.16,	post-translational	
modification	is	not	taken	into	consideration	when	sizing	the	fragment.	The	candidate	enzyme	
peptide	cutter	software	suggests	that	caspase	1	may	be	able	to	cleave	the	SIAE	sequence	in	one	
place	(shown	above),	resulting	in	this	27	kDa	fragment.	Caspase	1	cleaves	towards	the	C-terminal	
side	of	the	position	marked	above.	Caspase	1	may	be	activated	in	SIAE	wild-type	expressing	cells	
in	the	presence	of	doxycycline	and	will	be	the	subject	of	further	work	beyond	the	scope	of	this	
project.	
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Caspase	 1,	 also	 known	 as	 interleukin	 1b	 converting	 enzyme	 (ICE)	 is	 involved	 in	 the	
conversion	of	the	interleukin	to	its	active	form	(Denes	et	al.	2012).	Interleukin	1b	(IL-1b)	is	
a	key	mediator	of	the	inflammatory	response,	but	has	also	been	shown	in	rodents	to	have	
roles	in	neuronal	cell	apoptosis	(via	activation	of	caspase	3	and	bid	cleavage)	however	this	
link	has	yet	to	be	confirmed	in	human	brain.	An	outline	of	the	roles	of	caspase	1	is	shown	
in	 figure	 3.20.	We	 hypothesise	 that	 the	wild-type	 SIAE	 enzyme	 is	 capable	 of	 activating	
caspase	1	and	therefore	the	enzyme	is	being	cleaved,	we	also	hypothesise	that	this	may	
not	occur	with	the	SIAE-S127A	mutant	as	it	may	not	have	the	ability	to	activate	caspase	1.	
If	this	hypothesis	was	true	it	could	explain	the	difference	in	intensity	between	62	kDa	and	
32	kDa	products	detected	by	Western	blot.	Further	work	outside	the	scope	of	this	project	
will	be	required	to	test	this	hypothesis.			
In	order	to	determine	if	the	potential	cleavage	site	for	caspase	1	within	the	SIAE	amino	acid	
sequence	is	possibly	accessible	due	to	folding	of	the	SIAE	protein,	molecular	modelling	was	
used.	Using	the	Phyre	2	database,	homologous	sequences	to	the	SIAE	gene	were	used	in	
order	to	generate	a	hypothesised	structure	(as	a	crystal	structure	for	SIAE	is	not	yet	known).	
The	 database	 generated	 a	 structure	 of	 74%	 of	 the	 SIAE	 sequence	with	 >90%	 accuracy	
indicating	a	good	quality	in	the	prediction.	The	Phyre	2	software	also	generated	a	protein	
database	file	(PDB	file)	which	was	modelled	using	MacPyMol	to	visualise	the	hypothesised	
protein	 structure	 (figure	 3.21).	 Using	MacPyMol,	 the	 sequence	 of	 antibody	 recognition	
(figure	3.21,	green),	the	active	site	residue	mutated	in	in	the	S127A	mutant	(figure	3.21,	
red)	 and	 the	potential	 caspase	1	 cleavage	 site	 (figure	3.21,	 pink)	were	highlighted.	 The	
structural	 model	 (although	 not	 complete)	 provides	 good	 evidence	 that	 the	 caspase	 1	
cleavage	site	is	assessable	to	caspase	1	as	it	is	located	on	the	surface	of	the	protein	and	is	
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not	buried	in	its	structure.	While	the	cleavage	site	is	present	in	both	the	mutant	and	the	
native	protein	sequences,	activation	of	the	caspase	1	protein	may	be	required	in	order	for	
the	protein	to	be	cleaved.		
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Figure	 3.20	 A	 summary	 of	 caspase	 1	 pathways.	 Caspase	 1	 has	 roles	 in	 inflammation,	
cytoskeletal	modulation	(via	actin),	metabolism	(caspase	1	is	a	positive	regulator	of	lipid	
metabolism)	and,	cell	death.	Neuronal	cell	death	via	caspase	1	has	been	shown	in	rodents	
but	not	in	human	central	nervous	system	tissue.	Caspase	1	can	act	via	caspase	2,	3,	7,	
Calpastatin,	 X-linked	 inhibitor	 of	 apoptosis	 (XIAP)	 and	 BH3	 interacting-domain	 death	
agonist	 (Bid).	 If	 caspase	 1	 has	 a	 role	 in	 neuronal	 cell	 death	 it	 may	 play	 a	 role	 in	
medulloblastoma	 as	 it	 is	 a	 tumour	 of	 the	 granule	 neuron	 precursor	 cells,	 this	 would	
however	require	further	exploration.	Adapted	from	Denes	et	al.	2012.	
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Figure	 3.21	 A	 homologous	 SIAE	 structural	 model	 predicts	 the	 caspase	 1	 cleavage	
sequence	is	accessible	to	caspase	1.	(A-B)	The	predicted	SIAE	model	is	based	on	the	amino	
acid	 sequence	 of	 human	 SIAE	 and	 is	 based	 on	 known	 structures	 with	 homologous	
sequences	to	SIAE	generated	by	the	protein	fold-recognition	server	Phyre2.	MacPyMol	
was	used	 to	generate	 the	 image	of	SIAE	which	 is	based	on	Phyre2	prediction.	Phyre2	
shows	 74%	 of	 the	 protein	 was	modelled	 with	 >90%	 confidence	 giving	 the	 structures	
above.	With	a	confidence	of	>90%	the	program	states	that	the	overall	fold	of	the	protein	
(and	 the	 core	 of	 the	 protein)	 is	 modelled	 at	 high	 accuracy	 (2-4Å	 root-mean-square	
deviation	of	atomic	positions	(rmsd)	from	the	native,	true	structure)	however,	surface	
unstructured	loops	may	deviate	from	the	actual	structure.	(A)	Surface	structure	of	SIAE	
as	modelled	by	MacPyMol	using	 a	Phyre	2	 generated	 sequence	 shows	 the	 active	 site	
serine	 residue	 (red),	 the	 in-house	 antibody	 recognition	 sequence	 (green)	 and	 the	
potential	caspase	1	cleavage	site	(pink).	(B)	The	hypothesed	surface	structure	of	SIAE	is	
modelled	 with	 alpha	 helicies	 shown,	 as	 the	 caspase	 1	 site	 is	 part	 of	 an	 alpha	 helix	
structure	it	is	modelled	with	high	confidence	and	while	we	cannot	definitively	say	that	
the	caspase	1	site	is	accessible	to	enzyme,	its	location	within	an	alpha	helix	makes	it	is	
likely	that	this	site	will	be	accessible	to	the	enzyme.		
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While	preliminary	and	in	need	of	further	investigation,	this	data	may	help	to	explain	data	
described	 below	 in	which	we	 tested	 the	 deacetylation	 of	GD3A	 and	 the	 role	 of	 SIAE	 in	
response	 to	 chemotherapeutic	 agents.	 The	 role	of	 SIAE	 and	 its	 catalytic	mutant	will	 be	
discussed	further	in	chapter	4.		
Since	we	had	confirmed	SIAE	expression	and	determined	that	our	constructs	did	not	leak	
expression	of	SIAE	without	doxycycline	addition,	the	resulting	cell	 lines	were	cultured	in	
the	presence	of	doxycycline	for	48	hours	according	to	the	manufacturer’s	instructions	to	
induce	 gene	 expression.	 These	 cell	 lines	 were	 then	 harvested	 for	 assays	 in	 order	 to	
determine	changes	in	the	GD3	and	GD3A	expression	as	well	as	cell	viability	and	response	to	
chemotherapy.		
In	 order	 to	 determine	 if	 SIAE	 overexpression	 results	 in	 a	 reduction	 of	 GD3A	 (which	
potentially	reflects	the	activity	of	the	enzyme	being	expressed)	flow	cytometry	was	used.		
Intracellular	GD3	and	GD3A	were	analysed	in	order	to	determine	if	SIAE	expression	resulted	
in	cleavage	of	the	acetyl	group	from	GD3A	and	thereby	increasing	the	pool	of	GD3.	When	
analysed,	GD3A	expression	did	not	significantly	reduce	with	expression	of	wild-type	SIAE	by	
either	clone	1	or	clone	2	 (p>0.05;	 figure	3.22A).	The	 lack	of	 significant	changes	 in	GD3A	
status	when	SIAE	protein	expression	was	induced	by	the	addition	of	doxycycline	was	not	
anticipated.	We	therefore	considered	possible	explanations	for	this	unexpected	result.	In	a	
publication	by	Chen	et.	al	GD3	was	shown	to	be	capable	of	 inducing	its	own	acetylation	
machinery	(Chen	et	al.	2006).	If	this	is	indeed	happening	in	this	case,	the	deacetylation	of	
GD3A	to	GD3	may	be	recovered	by	induction	of	the	acetylation	machinery.	This	published	
phenomenon	is	reported	to	take	place	6	hours	after	GD3’s	synthesis	(in	this	case	GD3	would	
be	‘synthesised’	by	cleavage	of	the	acetyl	group	from	GD3A).	In	further	work	this	could	be	
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explored	with	 a	 time	 course	 experiment	 to	 determine	when	GD3A	 cleavage	was	 taking	
place,	if	at	all.		
Another	possible	explanation	for	this	lack	of	significant	changes	in	GD3A	expression	is	that	
the	SIAE	enzyme	 is	being	cleaved	by	 the	cells	as	shown	 in	 figure	3.17	or	 is	 failing	 to	be	
processed	to	its	fully	glycosylated	and	active	form	sufficiently	to	significantly	 impact	the	
expression	of	GD3A.	The	trafficking	of	GD3	and	GD3A	may	also	play	a	role	in	the	observed	
changes	in	the	ganglioside	expression	levels.	These	possibilities	will	need	to	be	explored	
with	further	laboratory	work.		
The	empty	vector	control	however	did	express	significantly	 less	GD3A	upon	 induction	of	
expression	 (p<0.05;	 figure	3.22A)	however	 this	was	not	 reflected	by	an	 increase	 in	GD3	
expression	 (figure	3.22B)	 suggesting	 that	 this	may	not	be	due	 to	 catalytic	activity	of	an	
acetyl	esterase	and	the	reason	for	this	is	unknown.	
When	GD3	expression	was	analysed,	there	were	some	interesting	differences.	In	the	wild-
type	SIAE	expressing	clone	2	cultured	in	the	presence	of	doxycycline	there	was	a	significant	
increase	in	the	expression	of	GD3	compared	to	cells	cultured	in	the	absence	of	doxycycline	
(p<0.05;	 figure	3.22B).	This	 indicates	 that	although	 there	was	no	significant	decrease	 in	
GD3A	expression	there	was	an	effect	of	SIAE	overexpression	on	the	cells	in	clone	2.	Despite	
this,	the	increase	in	GD3	expression	in	SIAE	expressing	clone	1	failed	to	reach	significance.	
Further	to	this	the	expression	of	GD3	followed	an	opposite	trend	in	SIAE-S127A	expressing	
cells	 with	 a	 lower	 (although	 not	 significantly	 lower)	 level	 of	 GD3	 expression	 than	 cells	
cultured	 in	 the	 absence	 of	 doxycycline	 suggesting	 that	 SIAE-S127A	 may	 not	 only	 be	
catalytically	 different	 but	 also	 has	 a	 different	 role	 (figure	 3.22B).	 An	 increase	 in	 GD3	
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expression	did	not	occur	with	the	empty	vector	control	EGFP	expressing	cell	line	despite	
the	changes	in	GD3A	expression	(p>0.05;	figure	3.22B).		
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Figure	3.22	GD3	expression	is	increased	with	SIAE	over-expression	in	RES256	cells.	Intracellular	
changes	in	GD3	and	GD3A	expression	with	induction	of	SIAE	gene	expression	were	examined	by	
flow	cytometry	(A)	The	expression	of	GD3A	was	not	significantly	lower	with	induction	of	SIAE	in	
neither	 clone	1	nor	 clone	2	as	hypothesised.	 In	 catalytic	mutant	SIAE-S127A	expressing	 cells	
GD3A	was	not	decreased	either,	however,	in	empty	vector	EGFP	expressing	controls	GD3A	was	
significantly	decreased.	In	order	to	determine	if	GD3A	cleavage	was	occurring,	the	expression	of	
GD3	was	also	examined.	If	cleavage	of	GD3A	did	occur,	an	increase	in	GD3	would	be	expected	as	
the	pool	of	GD3	would	be	 increased	with	 the	 removal	of	acetyl	 groups	 from	GD3A.	 (B)	GD3	
expression	 was	 significantly	 increased	 in	 SIAE	 clone	 2	 in	 wild-type	 expressing	 RES256	 cells	
compared	to	controls	indicating	that	GD3A	cleavage	may	be	occurring.	This	was	not	the	case	in	
clone	1,	nor	the	catalytic	mutant	cell	 line	SIAE-S127A	which	did	not	have	an	 increase	 in	GD3	
expression	which	likely	means	that	GD3A	cleavage	was	not	occurring.	The	wild-type	expressing	
cells	expressed	more	GD3	than	the	catalytic	mutant	cell	line	in	the	presence	of	doxycycline.		In	
EGFP	expressing	cells	 there	was	no	 increase	 in	GD3	expression,	which	may	 indicate	that	the	
reduction	in	GD3A	expression	may	be	due	to	something	other	than	cleavage	of	the	acetyl	group.	
Samples	 were	 analysed	 using	 a	 multi-parameter	 fluorescence-activated	 cell	 sorting	 (FACS)	
Calibur	flow	cytometer	and	data	was	acquired	using	CellQuest	Pro	software.	Data	analysed	by	
paired	t-test	using	Graph	Pad	Prism	6	software	(*	p<0.05;	**	p<0.01)	n=3	data	presented	as	mean	
±	SEM.		
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3.6.1 The	effect	of	SIAE	expression	on	mitochondrial	membrane	potential	
	
The	 expression	 of	 GD3	 is	 known	 to	 be	 associated	 with	 collapse	 of	 the	 mitochondrial	
membrane	potential	(Malisan	&	Testi	2002a).	Depolarisation	of	mitochondrial	membrane	
potential	is	a	marker	for	early	apoptosis,	and	is	known	to	occur	after	a	threshold	of	GD3A’s	
protection	from	GD3	mediated	apoptosis	is	overcome	(Birks	et	al.	2011).	To	explore	this,	
the	JC-1	assay	was	used	to	determine	if	this	threshold	had	been	met	by	the	increase	in	GD3	
shown	by	flow	cytometry	when	wild-type	SIAE	expression	was	induced	(figure	3.23).	
Upon	 induction	 of	 gene	 expression	 there	 was	 a	 significant	 increase	 in	 mitochondrial	
membrane	depolarisation,	indicative	of	early	apoptosis	with	the	wild-type	SIAE	(clone	1)	
expressing	cell	line	(p<0.001;	figure	3.23).	This	change	in	depolarisation	is	a	transient	event	
and	is	reversible	which	may	explain	why	this	change	is	not	seen	in	clone	2.	This	increase	in	
membrane	depolarisation	is	shown	by	an	increase	in	the	concentration	of	green	monomers	
of	JC-1	dye	compared	to	red	aggregates	which	accumulate	in	polarised	mitochondria.	
This	significant	change	in	depolarisation	was	not	seen	in	cells	with	induced	expression	of	
SIAE	 clone	 2	 nor	 the	 catalytic	 mutant	 SIAE-S127A,	 nor	 the	 empty	 vector	 control	 EGFP	
(p>0.05;	figure	3.23).		
Despite	the	significant	increase	in	depolarisation	with	induction	of	SIAE	expression	in	SIAE	
clone	 1,	 the	 starting	 membrane	 polarisation	 of	 these	 cells	 appears	 very	 high	 (i.e.	 the	
samples	are	mostly	depolarised	at	the	start	of	the	experiment).	This	means	that	this	data	
cannot	 be	 relied	 on	 for	 an	 accurate	 conclusion	 on	 the	 effects	 of	 SIAE	 expression.	 The	
reasons	for	this	will	be	discussed	in	chapter	4.	
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Figure	3.23	The	mitochondrial	membrane	potential	is	depolarised	by	SIAE	over-
expression	 in	 RES256	 cells.	 Polarisation	 of	 the	 mitochondrial	 membrane	
potential	was	determined	using	the	JC-1	assay.	Percentage	change	in	membrane	
polarisation	was	determined	between	cells	cultured	in	the	presence	and	absence	
of	doxycycline	and	presented	as	a	percentage	change.	Expression	of	wild-type	
SIAE	significantly	depolarises	the	mitochondrial	membrane	potential	in	clone	1l	
RES256	 cells	 	 and	was	 significantly	more	 depolarised	 than	 each	 of	 the	 other	
clones.	Depolarisation	did	not	occur	in	RES256	SIAE	wild-type	expressing	clone	2.	
The	EGFP	and	SIAE-S127A	expressing	clones	did	not	have	a	significant	reduction	
of	the	mitochondrial	membrane	potential.	Data	obtained	using	Nucleocounter	
3000	and	acquired	using	NucleoView	software.	Data	analysed	by	unpaired	two-
tailed	 t-test	using	graph	pad	prism	6	 software	*	p<0.05;	**	p<0.01),	n=3	data	
presented	as	mean	±	SEM	
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3.6.2 SIAE	overexpression	in	conjunction	with	current	chemotherapeutics	
	
The	 effects	 of	 aggressive	 treatment	 of	medulloblastoma	 on	 the	 developing	 brain	 often	
result	 in	 life-long	 treatment	 induced	 side	 effects	 such	 as	 neurocognitive	 deficits	 and	
endocrine	disorders	(Millard	&	De	Braganca	2015).	It	may	provide	benefit	to	patients	if	the	
dose	of	 chemotherapy	 could	be	 lowered,	without	 compromising	 survival.	We	 therefore	
examined	 if	 SIAE	 overexpression	 could	 make	 RES256	 cells	 more	 sensitive	 to	
chemotherapeutics	in	either	a	synergistic	or	additive	way.		Two	drugs	that	are	commonly	
used	 in	 medulloblastoma	 treatment	 regimens	 were	 chosen	 for	 testing,	 cisplatin	 and	
etoposide.		
Etoposide	 is	 a	 drug	 that	 prevents	 transcription	 and	 DNA	 replication	 in	 a	 cell-cycle	
dependent	manner.	 It	 works	 via	 inhibition	 of	 topoisomerase	 II.	 Topoisomerase	 II	 is	 an	
enzyme	that	unwinds	DNA	to	allow	transcription	and	DNA	replication	by	causing	transient	
double	strand	DNA	breaks.	These	breaks	 relieve	 the	 tension	on	DNA	generated	by	DNA	
polymerase.	 Etoposide	 prevents	 the	 re-ligation	 of	 the	 double	 strand	 DNA	 breaks	 by	
topoisomerase	II.	The	double	strand	DNA	breaks	are	maintained	with	drug	binding	and	this	
causes	apoptosis	as	transcription	and	replication	of	DNA	cannot	take	place.	The	mechanism	
of	action	is	described	in	more	detail	in	chapter	2.	
Cisplatin	 was	 also	 used	 to	 determine	 if	 SIAE	 overexpression	 sensitised	 RES256	 cells	 to	
treatment.	 Cisplatin	 is	 a	 cell-cycle	 non-specific	 DNA	 alkylating	 drug	 that	 causes	 DNA	
adducts	 (mostly)	 between	 guanine	 residues.	 This	 causes	 apoptosis	 through	 direct	 DNA	
damage,	as	well	as	binding	and	recruiting	proteins	that	generate	kinks	 in	the	DNA	helix.	
These	kinks	prevent	any	further	transcription	or	replication	of	the	DNA.	The	mechanism	of	
action	is	further	described	in	chapter	2.	
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In	 order	 to	 test	 our	 hypothesis	 that	 SIAE	 overexpression	 makes	 RES256	 cells	 more	
susceptible	to	cell	death	when	treated	with		etoposide	or	cisplatin,	cells	were	treated	with	
a	 range	 of	 concentrations	 of	 drug	 (or	 vehicle	 control)	 in	 the	 presence	 and	 absence	 of	
doxycycline.	Cells	were	pre-treated	for	48	hours	with	(or	without)	doxycycline	to	allow	gene	
expression	 to	 be	 induced	 before	 the	 chemotherapeutic	 was	 added.	 Doxycycline	 was	
maintained	in	the	media	throughout	the	experiment	where	appropriate.	MTS	assays	were	
then	 carried	 out	 after	 24,	 48	 and	 72	 hours	 after	 treatment	 to	 determine	 if	 treatments	
caused	a	reduction	in	cell	viability.	Western	blots	were	carried	out	in	parallel	to	confirm	
SIAE	and	SIAE-S127A	protein	expression	throughout	the	experiment.	Data	for	each	clone	
and	time	point	is	shown	in	figure	3.24	for	cisplatin	and	3.25	for	etoposide.		
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Figure	3.24	RES256	clones	are	treated	with	cisplatin	after	induction	of	gene	expression	using	
doxycycline.	(A)	24	hour	treatment	with	cisplatin	shows	that	no	change	in	viability	is	seen	
with	 induction	 of	 gene	 expression	 in	 any	 of	 the	 four	 clones.	 (B)	 48	 hour	 treatment	with	
cisplatin	 shows	no	changes	 in	viability	with	expression	of	EGFP.	A	 significant	decrease	 in	
viability	was	seen	with	3	µM	cisplatin	treatment	in	SIAE	clone	1.	This	effect	was	not	seen	
with	 increased	 concentrations	 of	 cisplatin,	 nor	was	 it	 seen	 in	 SIAE	 clone	 2.	 The	 catalytic	
mutant	S127A	interestingly	showed	a	significant	decrease	in	cell	viability	when	treated	with	
4,	11	and	12	µM	cisplatin.	(C)	72	hour	treatment	with	cisplatin	showed	a	significant	increase	
in	cell	viability	in	vehicle	control	treated	and	7	µM	treated	cells	EGFP	expressing	cells.	The	
reason	 for	 this	 increase	 in	 cell	 viability	 is	 unknown.	 Wild-type	 SIAE	 expressing	 clone	 1	
showed	only	a	significant	reduction	in	cell	viability	with	13	µM	treatment	with	cisplatin	but	
this	effect	was	not	seen	in	SIAE	expressing	clone	2.	Once	again	the	catalytic	mutant	S127A	
shows	a	significantly	reduced	cell	viability	with	3,	11,	12	and	13	µM	cisplatin	treatment.	(*	
p<0.05;	**	p<0.01;	***	p<0.001)	data	presented	as	mean	±	SEM	Data	analysed	by	unpaired	
two-tailed	t-test	using	GraphPad	Prism	6	software	n=3		
C	
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Figure	 3.25	 RES256	 clones	 are	 treated	 with	 etoposide	 after	 induction	 of	 gene	
expression	 using	 doxycycline.	 (A)	 24	 hour	 treatment	 with	 etoposide	 shows	 no	
significantly	changes	in	cell	viability	in	any	of	the	four	clones	except	EGFP	expressing	
cells	 treated	 with	 1	 µM	 etoposide,	 this	 effect	 however	 is	 not	 maintained	 with	
increasing	 concentrations	 of	 drug.	 (B)	 48	 hour	 treatment	 with	 etoposide	 shows		
significant	decreases	in	viability	in	EGFP	expressing	clones	treated	with	11,	12	and	13	
µM	etoposide.	No	significant	decreases	 in	viability	was	seen	with	 induction	of	SIAE	
expression	in	clone	1.	However,	in	clone	2	there	were	significant	decreases	in	viability	
when	cells	were	treated	with	1	and	4	µM	etoposide.	This	effect	was	not	maintained	
with	increasing	concentrations	of	etoposide.	The	catalytic	mutant	S127A	showed	no	
significant	 decreases	 in	 cell	 viability	 when	 treated	 with	 etoposide.	 (C)	 72	 hour	
treatment	with	etoposide	showed	no	significant	changes	in	cell	viability	in	any	of	the	
four	clones	except	EGFP	expressing	cells	treated	with	1	µM	etoposide,	however	this	
was	 not	 maintained	 with	 increased	 concentrations.	 (*	 p<0.05;	 **	 p<0.01)	 data	
presented	as	mean	±	SEM	Data	analysed	by	unpaired	two-tailed	t-test	using	GraphPad	
Prism	6	software	n=3		
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Cisplatin	did	not	significantly	reduce	RES256	cell	viability	with	induction	of	empty	vector	
control	expression,	nor	with	SIAE	wild-type	or	mutant	expression	at	24	hours	(figure	3.24A).	
After	48	hours	of	cisplatin	treatment	there	was	a	significant	reduction	in	viability	with	3	μM	
cisplatin	 in	 wild-type	 SIAE	 clone	 1	 (p<0.001)	 but	 this	 effect	 was	 not	 concentration-
dependent	 and	was	 not	maintained	with	 higher	 doses	 (figure	 3.24B).	 There	was	 also	 a	
significant	reduction	in	cell	viability	of	S127A	expressing	cells	with	cisplatin	treatment	with	
4	and	11	μM	(p<0.05;	figure	3.24B)	and	with	12	μM	cisplatin	(p<0.01;	figure	3.24B).	After	
72	hours	of	 cisplatin	 treatment	 there	was	 a	 significant	difference	 in	 EGFP	 viability	with	
vehicle	control	(p<0.05;	figure	3.24C)	and	7	μM	cisplatin	treatment	(p<0.05;	figure	3.24C).	
There	was	also	a	significant	reduction	in	viability	with	13	μM	cisplatin	treatment	in	SIAE	
clone	1	(p<0.05;	figure	3.24C).	There	were	also	significant	differences	between	3,	11	and	
13	μM	cisplatin	treatment	(p<0.05;	figure	3.24C)	and	12	μM	cisplatin	treatment	(p<0.001;	
figure	3.24C)	in	the	SIAE-S127A	expressing	clone.			
Etoposide	significantly	reduced	RES256	cell	viability	with	induction	of	empty	vector	control	
expression	at	24	hours	of	treatment	with	7	and	12	μM	(p<0.05;	figure	3.25A)	and	with	13	
μM	treatment	 (p<0.01;	 figure	3.25A).	 In	SIAE	wild-type	expressing	cells	 (clone	2)	12	μM	
etoposide	treatment	also	had	a	significant	difference	with	gene	expression	(p<0.01;	figure	
3.25A).	 SIAE	 2	 and	 SIAE-S127A	 mutant	 expression	 at	 24	 hours	 however	 were	 not	
significantly	different	 (figure	3.25A).	After	48	hours	of	etoposide	treatment	 there	was	a	
significant	reduction	in	viability	with	11	μM	etoposide	in	EGFP	expressing	clones	(p<0.005;	
figure	3.25B)	and	with	13	μM	treatment	(p<0.01;	figure	3.25B).	There	was	also	a	significant	
reduction	in	cell	viability	with	etoposide	treatment	at	1	and	4	μM	(p<0.05;	figure	3.25B).	
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After	72	hours	of	 cisplatin	 treatment	 there	was	a	 significant	difference	1	μM	etoposide	
treated	cells	(p<0.05;	figure	3.25C)		
Together	 this	 suggests	 that	 SIAE	 expression	 may	 have	 an	 effect	 on	 cell	 survival	 when	
treated	with	cisplatin	and	etoposide,	particularly	with	48	and	72	hr	treatments.	This	data	
will	be	analysed	further	in	section	3.6.3	to	see	if	there	is	a	change	in	IC50	with	treatment	of	
cisplatin	 or	 etoposide	 and	 induction	 of	 gene	 expression,	 particularly	 as	 (although	 not	
always	significant)	there	is	a	general	trend	for	a	reduction	of	viability	with	induction	of	gene	
expression	at	these	time	points.		
3.6.3 Changes	in	IC50	with	chemotherapy	treatments	
	
As	chemotherapy	treatments	appeared	to	have	significant	effects	on	cell	viability	at	48	and	
72	hours	with	induced	gene	expression	(figures	3.24	and	3.25)	we	examined	if	there	were	
significant	changes	in	IC50	with	treatment.	We	kept	in	mind	that	there	was	a	general	trend	
towards	 reduced	 cell	 viability	 with	 induction	 of	 gene	 expression	 and	 therefore	
hypothesised	 that	 the	 IC50s	 may	 reduce	 with	 induction	 of	 expression.	 The	 IC50	 is	 the	
concentration	of	(inhibitory)	drug	(or	antagonist)	required	for	a	50	%	reduction	in	response.	
In	this	case	the	concentration	of	chemotherapeutic	required	for	a	50	%	reduction	in	cell	
viability.	IC50	data	for	each	time	point	and	clone	shown	in	figures	3.26	and	3.27	can	be	found	
in	appendix	7.		
Cisplatin	IC50s	were	determined	at	each	time	point	and	it	was	shown	to	only	significantly	
affect	the	mutant	SIAE-S127A	clone	at	48	hours	of	treatment,	significantly	reducing	the	IC50	
from	4.1	(±0.6)	to	3.1	(±0.5)	μM	(p<0.05;	figure	3.26B).	Data	is	normalised	and	constrained	
to	a	minimum	and	maximum	response	to	cisplatin	as	defined	by	controls.	This	effect	on	IC50	
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however	was	not	present	with	24	hr	treatment	(figure	3.26A)	nor	was	it	maintained	with	
prolonged	treatment	(72	hr)	(figure	3.26B).	
When	etoposide	IC50s	were	determined	there	was	only	a	significant	difference	after	72	hr	
treatment.	In	SIAE	clone	2	there	was	a	reduction	in	the	IC50	from	5.1	(±1.3)	to	1.9	(±0.9)	μM	
(p<0.001;	figure	3.27A)	This	difference	in	response	however	was	not	seen	with	induction	
of	expression	in	SIAE	clone	1,	nor	EGFP	expression,	nor	the	catalytic	mutant.	This	effect	on	
IC50	however	was	not	present	with	48	hr	treatment	(figure	3.27A;figure	3.27B).	A	summary	
of	all	IC50	data	can	be	found	in	appendix	7.		
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Figure	3.26	Dose-response	of	inducible	RES256	clones	to	cisplatin	treatment.	(A)	48	hours	after	
treatment	of	cisplatin	IC50s	remain	the	same	between	each	clone	when	gene	expression	 is	off	
(black)	and	when	expression	is	induced	with	doxycycline	treatment	(green)	except	in	the	catalytic	
mutant	S127A	where	expression	of	mutant	protein	reduces	the	 IC50	significantly.	 (B)	72	hours	
after	 treatment	 of	 cisplatin	 no	 significant	 differences	 are	 seen	 when	 protein	 expression	 is	
induced	 with	 doxycycline	 treatment.	 Data	 analysed	 using	 the	 sigmoidal	 dose-response	 EC50	
comparison	 using	 constrained	 and	 normalised	 data	 by	 GraphPad	 Prism	 6	 software	 data	
presented	as	mean	±SEM	(*	p<0.05)	n=3	
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Figure	3.27	Dose-response	of	inducible	RES256	clones	to	etoposide	treatment.	(A)	48	hours	after	
treatment	of	etoposide	IC50s	remain	the	same	between	each	clone	when	gene	expression	is	off	
(black)	and	when	expression	is	induced	with	doxycycline	treatment	(green)	(B)	72	hours	after	
treatment	of	etoposide	no	significant	differences	are	seen	when	protein	expression	is	induced	
with	doxycycline	treatment	in	any	of	the	clones	except	SIAE	clone	2	where	the	IC50	is	significantly	
reduced	with	induction	of	protein	expression	(green).		Data	analysed	using	the	sigmoidal	dose-
response	 EC50	 comparison	 using	 constrained	 and	 normalised	 data	 by	 GraphPad	 Prism	 6	
software	data	presented	at	mean	±SEM	(**	p<0.01)	n=3	
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4 Discussion	
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4.1 Introduction	
The	 ganglioside	 acetylation	 pathway	 appears	 to	 be	 atypically	 expressed	 in	
medulloblastoma	tissues	and	cell	lines.	The	expression	of	the	acetylation	pathway	appears	
to	be	in	favour	of	the	acetylated	form	of	GD3,	GD3A.	In	medulloblastoma	subgrouped	tissue	
samples	the	expression	of	Cas1	and	SIAE	appear	to	be	regulated	in	order	to	support	our	
hypothesis	 that	 this	 balance	 is	 in	 favour	 of	 GD3A.	 The	 expression	 of	 the	 acetylated	
ganglioside	also	appears	to	correlate	with	M	stage	as	the	highest	levels	of	expression	of	the	
hypothesised	acetylation	enzyme	Cas1	are	seen	the	in	the	highest	M	stage	in	this	sample	
set	(M3).	The	expression	of	the	human	endogenous	deacetylation	enzyme	SIAE	was	also	
shown	 to	 be	 lowest	 in	 the	 higher	M	 stage	 subgroups	 which	 further	 indicates	 that	 the	
expression	of	GD3A	is	likely	to	be	highest	in	this	subset	of	patients.		
When	explored	in	medulloblastoma	cell	lines,	the	expression	of	GD3	and	GD3A	was	seen	at	
high	 levels.	The	expression	of	 these	two	gangliosides	 is	 in	 favour	of	GD3A.	 In	SIAE	over-
expression	studies	the	highest	expresser	of	GD3A,	RES256	was	transfected	with	inducible	
constructs.	SIAE	over-expression,	but	not	expression	of	the	catalytic	mutant	nor	the	empty	
vector	 control,	 led	 to	 the	depolarisation	of	 the	mitochondrial	membrane	potential.	 The	
expression	of	SIAE	also	caused	the	RES256	cells	to	be	more	susceptible	to	treatment	with	
etoposide	but	not	cisplatin,	chemotherapeutics	commonly	used	to	treat	medulloblastoma.	
In	 light	 of	 this	 work,	 the	 GD3	 acetylation	 pathway	 may	 have	 an	 important	 role	 in	
maintaining	 viability	 of	RES256	 cells.	As	 a	proof	of	 principle	 study	 SIAE	over-expression	
appears	to	influence	the	mitochondrial	membrane	potential,	and	response	to	the	cell-cycle	
specific	drug	etoposide.		
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4.2 The	GD3	acetylation	pathway	in	neoplastic	disease	
The	GD3	acetylation	pathway	has	previously	been	described	as	a	pathway	necessary	for	
the	development	of	the	brain	(Mendez-Otero	&	Santiago	2003;	Liang	et	al.	2011;	Yu	et	al.	
2004)	 and	 in	malignancies	 such	 as	 high	 grade	 gliomas	 (Birks	 et	 al.	 2011).	 Of	 particular	
interest	to	this	project	is	GD3’s	role	in	the	developing	cerebellum.	GD3	is	expressed	by	the	
neuronal	 granule	 precursor	 cells	 of	 the	 developing	 cerebellum	 where	 it	 guides	 their	
migration	(Goldman	&	Reynolds	1996).	The	granule	neuron	precursors	are	a	known	cell	of	
origin	of	SHH,	group	3	and	group	4	medulloblastomas.	Upon	maturation	of	the	brain,	GD3	
rapidly	accumulates	within	the	supernumary	cells	where	 it	causes	their	mitochondrially-
mediatated	apoptosis	(Birks	et	al.	2011;	Higgins	et	al.	2015).	After	birth,	the	expression	of	
GD3	is	virtually	absent	(Yu	et	al.	2012;	Yu	et	al.	2004).	In	some	cancers	of	neural	crest	origin,	
such	as	high	grade	gliomas	(Birks	et	al.	2011),	melanomas	(Ohkawa	et	al.	2008),	and	as	we	
show	 here,	 in	 medulloblastomas,	 GD3	 becomes	 re-expressed.	 In	 acute	 lymphoblastic	
leukaemia	 (ALL),	 high	 levels	 of	 GD3	 have	 been	 shown	 to	 protect	 from	 a	 pro-apoptotic	
phenotype,	 due	 to	 acetylation	 of	 GD3	 (GD3A).	 GD3A	 can	 protect	 from	 GD3-mediated	
apoptosis	 and	 this	 balance	 of	 GD3	 and	 GD3A	 is	 thought	 to	 influence	 cell	 survival.	 The	
expression	of	GD3	in	medulloblastoma	has	been	previously	described	in	little	detail,	with	
functional	relevance	absent	(Gottfries	et	al.	1990).		
In	other	cancers	this	pathway	has	proved	to	be	important	for	cell	survival	(Mukherjee	et	al.	
2008)	(Parameswaran	et	al.	2013)	and	invasion	(Hamamura	et	al.	2011;	Shibuya	et	al.	2012;	
Ohkawa	et	al.	2015).	In	ALL,	the	expression	of	O-acetylated	sialic	acids	such	as	GD3A	were	
shown	have	enhanced	expression.	This	was	also	reported	in	melanoma	(Ritter	et	al.	1990),	
Basalioma	(Fahr	&	Schauer	2001)	and	breast	cancer	(Marquina	et	al.	1996).	In	a	study	on	
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ALL,	 the	 balance	 of	 activities	 of	 the	 sialic	 acid	O-acetyl	 transferase	 (SOAT;	 a	 family	 of	
enzymes	in	which	Cas1	resides),	and	SIAE	were	investigated	and	it	was	found	that	SOAT	
activity	was	enhanced	whereas	SIAE	activity	was	reduced	(Mandal	et	al.	2012).	This	balance	
of	activity	in	favour	of	SOAT	provides	evidence	for	the	preference	for	acetylation	of	GD3	by	
these	cells.	This	acetylation	is	important	as	it	has	been	shown	to	positively	correlate	with	
chemo-resistant	disease	and	therefore	impacts	on	patient	survival	(Giussani	et	al.	2014).		
In	glioblastoma	multiforme	(GBM),	the	most	common	and	most	aggressive	neoplastic	brain	
tumour	of	adulthood,	a	delicate	balance	exists	between	GD3	and	GD3A	which	influences	
cell	survival.	In	a	study	by	Birks	et.	al	transfection	of	primary	and	established	GBM	cell	lines	
with	 the	 GD3A	 acetyl	 esterase	 enzyme	 haemagluttanin	 esterase	 (HE)	 demonstrated	 a	
reduction	of	viability	when	cleavage	of	GD3A	occurred	(Birks	et	al.	2011).	With	cleavage	of	
GD3A	 this	 study	also	demonstrated	a	 significant	 increase	 in	GD3	expression	 (Birks	et	al.	
2011)	which	leads	to	the	translocation	of	GD3	to	the	mitochondrial	membranes	(Sorice	et	
al.	2012)	and	ultimately	to	apoptosis	(Malisan	&	Testi	2002a).	One	of	the	problems	with	
using	HE	is	its	immunogenicity,	something	which	could	be	overcome	with	the	use	of	SIAE,	
the	human	endogenous	deacetylation	enzyme.	When	high	levels	of	GD3	are	expressed,	cell	
viability	is	maintained	by	GD3A	expression.	This	has	been	shown	to	occur	in	several	cell	lines	
which	can	genetically	switch	on	the	acetyltransferase	machinery,	thought	to	be	Cas1	(Chen	
et	 al.	 2006).	 When	 GD3A	 is	 present	 it	 has	 been	 shown	 that	 GD3A	 cannot	 induce	
mitochondrially-mediated	 apoptosis	 and	 furthermore	 suppresses	 the	 ability	 of	 GD3	 to	
induce	apoptosis	itself	(Malisan	et	al.	2002).	GD3A	expression	has	been	shown	to	protect	
cells	from	chemotherapeutic	insult,	and	also	from	endogenously	added	GD3,	even	at	very	
low	 levels	of	expression	 (Kniep	et	al.	2006).	High	 levels	of	GD3	are	also	associated	with	
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increased	invasive	potential	and	enhanced	malignant	properties	(Ohkawa	et	al.	2015).	This	
effect	may	be	due	to	the	auto-acetylation	of	GD3	to	GD3A	through	the	induction	of	its	own	
acetylation	machinery.	As	the	study	by	Chen	et.	al	exploring	GD3	expression	in	correlation	
with	invasive	potential	did	not	explore	expression	in	a	manner	that	was	able	to	differentiate	
between	the	two	gangliosides,	this	may	be	the	effect	of	GD3	itself	(Chen	et	al.	2006).		
4.3 Synthesis	and	turnover	of	GD3	and	GD3A		
The	ganglioside	synthesis	pathways	have	been	previously	characterised	and	summarised	
(Yu	 et	 al.	 2004)	 and	 the	 major	 players	 in	 the	 turnover	 of	 the	 gangliosides	 have	 been	
discovered	 in	 recent	 years.	 The	 enzyme	 that	 synthesises	GD3	 is	 ST8Sia1,	 the	 gene	 that	
encodes	this	enzyme	is	located	on	chromosome	12	at	12p12.1.	In	Yu	et.	al’s	study,	it	was	
stated	that,	assuming	the	concentration	of	the	substrate	of	ST8Sia1	(GM3)	is	in	constant	
supply,	 the	 outcome	 (GD3	 expression)	 is	 dependent	 on	 the	 enzyme	 that	 catalyses	 its	
synthesis,	and	the	enzyme	that	consumes	the	ganglioside	intermediate	(Yu	et	al.	2004).	In	
other	words,	to	increase	the	expression	of	the	ganglioside	GD3,	the	cell	has	to	express	the	
ganglioside	 (via	 ST8Sia1	 expression	or	 increased	 ST8Sia1	 activity)	 but	 also	decrease	 the	
expression	(or	activity)	of	the	enzyme	that	uses	it	as	a	substrate	(ST8Sia5).			
Another	enzyme	that	regulates	this	pathway	is	the	human	endogenous	acetyl-transferase	
enzyme	 Cas1,	 whose	 encoding	 gene	 is	 located	 on	 chromosome	 7	 at	 7q21.3.	 Cas1	 is	
hypothesised	to	play	a	role	in	the	acetylation	of	GD3	(Arming	et	al.	2011).	There	is	 little	
known	about	this	enzyme	and	its	roles	in	vivo,	however	a	recent	study	by	(Baumann	et	al.	
2015),	 showed	 that	 knock-down	 of	 the	 Cas1	 gene	 CASD1	 using	 clustered	 regularly-
interspaced	 short	 palindromic	 repeat/	 crispr-associated	 protein	 (CRIPSR/Cas)	 genome	
editing,	 abolished	 GD3	 acetylation	 in	 HAP1,	 HEK293T	 and	 CHO	 cells	 when	 cells	 also	
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expressed	 ST8Sia1.	 	 This	 study	 provides	 evidence	 for	 the	 involvement	 of	 Cas1	 in	 GD3	
acetylation.	
The	 final	enzyme	 thought	 to	play	a	 role	 in	 the	 regulation	of	 this	pathway	 is	 the	human	
endogenous	 deacetylation	 enzyme	 SIAE,	 whose	 gene	 is	 located	 on	 chromosome	 11	 at	
11q24.2.	SIAE	is	known	to	regulate	the	expression	of	GD3	and	GD3A	and	has	been	described	
in	 acute	 lymphoblastic	 leukaemia	 (ALL)	 (Mandal	 et	 al.	 2012).	 SIAE	 has	 been	 shown	 to	
promote	survival	and	drug	 resistance	 in	ALL	 (Mukherjee	et	al.	2008)	and	 in	pre-B	acute	
lymphoblastic	leukaemia	(Parameswaran	et	al.	2013).	In	the	Parameswaran	et.	al	study,	the	
cell	surface	and	intracellular	9-O-acetyl	groups	from	sialic	acids	were	de-acetylated	using	
CHE-Fc	esterase,	sodium	salicylate	and	a	9-O-acetyl	esterase	lentiviral	vector	described	by	
(Malisan	et	al.	2002).	They	confirmed	that	GD3	deacetylation	was	occurring	and	showed	
that	 in	 pre-B	 acute	 lymphoblastic	 leukaemia	 cells	 this	 treatment	 proved	 to	 be	 lethal	
(Parameswaran	et	al.	2013).			
4.4 GD3	 synthesis	 enzymes	 are	 atypically	 expressed	 in	medulloblastoma	
across	subgroups	and	metastatic	stages	
From	 this	 study	we	 show	 that	 the	 enzymes	 involved	 in	 regulation	 of	 this	 pathway	 are	
affected	at	the	mRNA	level	 in	medulloblastoma	tissue	using	a	sub-grouped	and	M-stage	
classification	approach.		
When	the	mRNA	expression	of	ST8Sia1	was	investigated	using	a	bioinformatics	approach	
(figure	3.2A),	the	expression	was	found	to	be	significantly	down-regulated	in	comparison	
to	non-neoplastic	foetal	and	adult	brain	controls	(p<0.0001).		Interestingly,	the	expression	
of	ST8Sia1	is	not	significantly	different	between	non-neoplastic	foetal	and	adult	brain.	This	
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is	interesting	because	it	is	widely	reported	that	GD3	expression	is	tightly	developmentally	
controlled	and	that	GD3	expression	is	virtually	absent	in	the	adult	brain	(Yu	et	al.	2012).	
This	can	be	explained		as	GD3	can	be	used	as	an	intermediary	ganglioside	that	is	converted	
into	the	more	complex	gangliosides	that	are	known	to	be	expressed	in	the	adult	brain	(Yu	
et	al.	 2004).	When	 the	 samples	were	analysed	according	 to	molecular	 subgroup	 (figure	
3.4A)	 there	was	a	 significantly	 lower	expression	of	 ST8Sia1	 found	 in	 the	best	prognosis	
subgroup,	WNT,	compared	to	SHH	and	group	4	(p<0.0001).	This	difference	in	expression	
may	 suggest	 that	 the	 WNT	 subgroup	 has	 the	 lowest	 GD3	 expression.	 This	 has	 some	
relevance	to	a	study	carried	out	in	glioblastoma	multiforme	cell	lines	which	targeted	co-
expressed	GD3A	and	neuron-glial	2	(NG2)	with	an	antibody	conjugated	toxin	(Higgins	et	al.	
2015)	as	co-expression	of	GD3A	and	NG2	had	previously	been	reported	(Chekenya	et	al.	
1999).	 In	 another	 study	 a	 relationship	 between	 GD3A	 (which	 correlated	 with	 invasive	
potential)	and	NG2	(which	correlated	with	high	proliferation)	was	shown	to	be	inversely	
correlated	i.e.	cells	that	expressed	high	levels	of	GD3A	expressed	very	low	levels	of	NG2	and	
vice	versa	(Chekenya	&	Pilkington	2002).		As	GD3	is	known	to	be	correlated	with	invasive	
potential	in	gliomas	(Ohkawa	et	al.	2015)	and	the	WNT	subgroup	is	very	rarely	metastatic	
(Taylor	et	al.	2012),	this	could	provide	further	evidence	to	support	the	hypothesis	that	GD3	
expression	is	low	in	this	subgroup.	In	work	done	by	Dr	Taylor’s	group	in	Toronto,	appendix	
8,	the	mRNA	expression	of	NG2	was	found	to	be	highest	in	the	WNT	subgroup	which	also	
supports	this	data,	implying	that	GD3A	expression	is	likely	to	be	lowest	in	this	subgroup.		On	
the	contrary,	the	most	metastatic	subgroup,	group	3,	did	not	have	the	highest	expression	
of	 ST8Sia1.	 Group	 3	 expression	 was	 found	 to	 be	 significantly	 lower	 than	 the	 rarely	
metastatic	 SHH	subgroup	 (p<0.0001),	which	had	 the	highest	expression	of	 ST8Sia1.	The	
expression	of	ST8Sia1	was	similar	in	group	3	and	group	4	samples.		
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When	 the	 expression	 of	 ST8Sia1	 was	 examined	 at	 the	 metastatic	 stage	 (figure	 3.7A),	
expression	was	low	overall	but	highest	expression	was	seen	in	the	M3	stage	of	disease.	This	
correlates	with	GD3’s	 role	 in	 invasion	however	 this	data	was	not	 significant,	 and	as	we	
found	ST8Sia1	expression	to	be	low	at	the	mRNA	level	this	led	us	to	believe	that	ST8Sia1	
may	not	be	the	only	enzyme	involved	in	the	expression	of	GD3.	As	suggested	by	Yu	(2004)	
the	expression	of	the	enzyme	that	uses	GD3	as	a	substrate	was	also	investigated.		
In	support	of	the	hypothesis	that	GD3	expression	is	high,	we	would	expect	the	expression	
of	 ST8Sia5	 to	 be	 low	 as	 this	 would	 not	 further	 convert	 GD3	 into	 the	 more	 complex	
gangliosides	summarised	in	figure	1.5.	The	expression	of	ST8Sia5	was	found	to	be	higher	in	
the	WNT	and	SHH	subgroups	which	are	the	least	invasive	(figure	3.4B),	suggesting	that	the	
expression	of	GD3	in	these	subgroups	may	be	converted	into	the	GD2	or	GT3	gangliosides	
(figure	3.3).	The	lowest	expression	of	ST8Sia5	was	seen	in	the	more	metastatic	subgroups	
3	and	4,	suggesting	that	the	expression	of	GD3	in	these	subgroups	may	be	higher	as	it	is	
less	likely	to	be	converted	to	GD2	or	GT3	(figure	3.4B).		
When	 the	 expression	 of	 this	 enzyme	 was	 explored	 at	 the	 M	 stage	 (figure	 3.7B),	 the	
expression	was	expected	to	be	lowest	in	the	most	metastatic	subgroup	M3	as	this	would	
correlate	 with	 the	 highest	 expected	 GD3	 expression	 level.	 ST8Sia5	 was	 found	 to	 be	
significantly	lower	in	M3	compared	to	M0	(p<0.05)	in	support	of	the	hypothesis.		
4.4.1 Bioinformatics	summary	of	the	GD3	synthesis	enzymes	
 
Taken	together	the	bioinformatics	data	for	ST8Sia1	and	ST8Sia5	suggest	that	the	expression	
of	GD3	is	higher	in	the	most	metastatic	subgroups,	group	3	and	group	4.	The	expression	of	
ST8Sia5	 suggests	 less	 of	 the	 expressed	 ganglioside	 could	 be	 converted	 to	 GD2	 or	 GT3	
despite	the	expression	of	ST8Sia1	being	low	in	these	subgroups.	The	expression	of	GD3	is	
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also	suggested	to	be	highest	in	the	M3	stage	of	disease;	this	is	due	to	the	lowest	expression	
of	ST8Sia5	suggesting	a	low	level	of	GD3	would	be	converted	into	downstream	gangliosides.	
The	activity	of	the	enzymes	must	also	be	considered	however	to	fully	determine	this	to	be	
the	case,	but	due	to	the	fact	that	these	samples	are	of	limited	size	and	that	samples	are	not	
metabolically	active	this	cannot	be	determined.	The	expression	of	the	gangliosides	cannot	
be	determined	directly	using	samples	from	the	bioinformatics	approach	as	this	tissue	was	
used	 for	 microarray	 and	 sample	 processing	 (paraffin	 embedding)	 is	 incompatible	 with	
ganglioside	analysis	(Debarbieux	et	al.	2009;	Schwarz	&	Futerman	1997).	
4.5 GD3	 and	 GD3A	 turnover	 enzymes	 are	 atypically	 expressed	 in	
medulloblastoma	across	subgroups	and	metastatic	stages	
If	 the	expression	of	GD3	 is	considered	to	be	present,	 then	the	 two	major	enzymes	 that	
control	the	processing	of	GD3	to	GD3A	are	Cas1	and	SIAE.	The	expression	of	Cas1	was	found	
to	 be	 significantly	 up-regulated	 in	medulloblastoma	 tissue	 compared	 to	 non-neoplastic	
foetal	 and	 adult	 brain	 controls	 (p<0.0001)	 (figure	 3.2B).	 The	 high	 expression	 of	 Cas1	
suggests	 that	 there	 could	 be	 high	 expression	 of	 GD3A	 in	 these	 tumours.	 When	
medulloblastoma	tissue	samples	were	subgrouped,	the	expression	of	Cas1	was	shown	to	
be	 lowest	 in	WNT	and	SHH	subgroups	which	are	rarely	metastatic,	suggesting	they	may	
express	 less	 GD3A	 (figure	 3.6A).	 Cas1	 expression	 was	 significantly	 lower	 in	 the	 WNT	
subgroup	compared	to	group	3	(p<0.05;	figure	3.6A)	and	group	4	(p<0.001;	figure	3.6A)	this	
also	supports	the	hypothesis	that	the	least	metastatic	subgroup	expresses	less	GD3A	than	
the	more	metastatic	subgroups.	Expression	was	significantly	 lower	 in	 the	SHH	subgroup	
compared	 to	 group	 4	 (p<0.0001;	 figure	 3.6A)	 but	 not	 group	 3.	 The	 highest	 levels	 of	
expression	of	Cas1	were	seen	in	groups	3	and	4	suggesting	that	there	may	be	the	highest	
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levels	of	GD3A	in	these	subgroups,	if	Cas1	is	the	enzyme	responsible	for	acetylation	of	GD3.	
Group	4	samples	expressed	the	most	Cas1	despite	not	being	the	most	metastatic	subgroup,	
but	this	may	be	promising	as	group	4	is	the	most	common	subgroup.	If	there	is	a	high	level	
of	GD3A	expression	in	group	4,	the	most	common	subgroup,	if	deacetylation	of	GD3A	is	a	
good	therapeutic	target,	then	this	treatment	could	be	relevant	to	a	significant	proportion	
of	patients.	While	not	being	the	most	metastatic	subgroup,	a	subset	of	group	4	patients	do	
present	with	metastatic	disease	(Taylor	et	al.	2012).	
When	 expression	 of	 Cas1	was	 characterised	 by	metastatic	 stage,	 increasing	 expression	
correlated	with	increasing	M	stage	(figure	3.8A).	There	was	significantly	higher	expression	
of	 Cas1	 in	M3	 samples	 compared	 to	M0	 (p<0.05)	 suggesting	 that	 if	 Cas1	 is	 the	 enzyme	
responsible	for	GD3	acetylation,	that	GD3A	expression	may	be	higher	in	the	M3	subgroup.	
This	once	again	supports	previous	data	in	other	cancers	that	GD3A	expression	correlates	
with	invasive	potential	(Hamamura	et	al.	2011;	Shibuya	et	al.	2012).		
Further	characterisation	of	 this	pathway	 involved	 the	human	endogenous	deacetylation	
enzyme	SIAE.	This	enzyme	was	an	important	discovery	to	the	regulation	of	this	pathway	
and	also	 its	use	as	a	therapeutic	target.	Previous	studies	 involving	deacetylation	of	GD3	
have	 utilised	 enzymes	 that	 are	 not	 endogenous,	 such	 as	 the	 influenza	 enzyme	
haemagluttinin	esterase	used	by	Birks	et.	al	for	a	study	on	glioblastoma	multiforme	(Birks	
et	 al.	 2011).	 This	 enzyme	proved	 to	be	highly	 immunogenic,	 since	 it	was	not	human	 in	
origin,	and	therefore	would	not	be	able	to	be	used	in	the	clinic.	This	study,	if	successful,	
could	 overcome	 this	 problem,	 as	 the	 human	 endogenous	 enzyme	 would	 not	 be	
immunogenic.		
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The	 expression	 of	 SIAE	 was	 significantly	 down-regulated	 in	 medulloblastoma	 tissue	
compared	to	non-neoplastic	foetal	and	adult	brain	controls	(p<0.0001)	(figure	3.2C).	This	
suggests	 that	 the	expression	of	GD3A	would	be	 lower	 in	medulloblastoma	compared	 to	
non-neoplastic	brain.	Interestingly	there	was	also	a	significantly	higher	expression	level	of	
GD3A	in	adult	non-neoplastic	brain	compared	to	foetal	non-neoplastic	brain	(p<0.05;	figure	
3.2C),	suggesting	a	higher	level	of	GD3A	in	the	adult	brain	compared	to	foetal	brain,	despite	
reports	of	virtually	absent	GD3A	expression	in	the	developed	nervous	system	(Svennerholm	
et	al.	1989).	This	data	may	show	a	limitation	of	this	method,	that	mRNA	does	not	correlate	
with	protein	expression,	or	 that	expression	of	 the	SIAE	enzyme	does	not	correlate	with	
activity.	Highest	expression	of	SIAE	was	seen	in	the	WNT	subgroup,	which	expressed	SIAE	
significantly	more	than	SHH	(p<0.0001;	figure	3.5B),	group	3	(p<0.02;	figure	3.5B)	and	group	
4	 subgroups	 (p<0.0001;	 figure	 3.5B).	 As	 the	WNT	 subgroup	 is	 the	 least	metastatic	 this	
supports	the	hypothesis	that	GD3A	expression	is	lower	in	this	subgroup	along	with	the	SHH	
subgroup.	The	lowest	level	of	expression	was	seen	in	the	SHH	subgroup	which	expressed	
SIAE	significantly	less	than	group	3	(p<0.05;	figure	3.5B)	and	group	4	(p<0.01;	figure	3.5B).	
From	this	data,	the	expression	of	GD3A	could	be	expected	to	be	highest	in	the	SHH	subgroup	
and	lowest	in	the	WNT	subgroup.	
When	 SIAE	 expression	 was	 characterised	 by	 metastatic	 stage	 (figure	 3.8B),	 there	 was	
significantly	higher	expression	in	the	M0	and	M1	subgroups	compared	to	M3	(p<0.05	and	
p<0.02	respectively).	From	this	data,	it	would	suggest	that	there	could	be	more	GD3A	in	the	
more	metastatic	subgroup	M3	compared	to	M0	and	M1	as	there	is	a	lower	expression	of	
SIAE	in	these	subgroups.		
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4.5.1 Bioinformatics	summary	of	the	GD3	and	GD3A	turnover	enzymes	
	
In	2012,	 the	current	consensus	of	medulloblastoma	molecular	subgroups	was	published	
(Taylor	et	al.	2012),	which	linked	together	the	molecular	subgroups	and	genetic	alterations.	
The	genes	encoding	ST8Sia5	and	Cas1	are	located	on	18q21.1	and	7q21.3	respectively.	It	is	
known	that	there	are	gains	in	both	of	these	chromosomes	in	group	3	and	group	4	subgroups	
which	may	suggest	that	expression	of	these	enzymes	are	up-regulated	in	these	subgroups.	
This	 is	 only	 supported	 by	 bioinformatics	 data	 for	 Cas1,	 which	 shows	 an	 increase	 of	
expression	 in	 these	 subgroups.	 The	 bioinformatics	 data	 for	 ST8Sia5	 shows	 it	 is	 actually	
significantly	down-regulated	in	these	subgroups,	suggesting	a	low	level	of	expression.		
Taken	together	this	data	suggests	that	the	GD3	acetylation	pathway	is	in	favour	of	GD3A	in	
the	most	metastatic	subgroups	and	in	the	worst	prognosis	subgroups	group	3	and	group	4	
at	the	mRNA	level.		
4.6 GD3	and	GD3A	are	re-expressed	by	medulloblastoma	cell	lines	
In	the	medulloblastoma	cell	lines	used	in	this	study	(RES256,	UW402	and	CHLA-01-Med),	
there	was	a	high	level	of	both	GD3A	and	GD3	within	the	cells	(figure	3.9).	Flow	cytometry	
data	showed	an	average	expression	of	GD3A	for	each	cell	line	to	be	85.4,	74.4	and	79.4	%	
respectively	 and	 the	 expression	 of	 GD3	 was	 56.7,	 61.3	 and	 45.1	 %	 respectively.	 This	
supports	the	hypothesis	that	GD3A	is	protecting	the	cells	from	GD3-mediated	apoptosis.	
Despite	reports	that	GD3A	can	protect	from	GD3-mediated	apoptosis	at	low	levels	(Kniep	
et	al.	2006)	we	found	similar	levels	of	both	gangliosides.		
On	the	cell	surface,	expression	of	GD3A	by	RES256,	UW402	and	CHLA-01-Med	cell	lines	was	
36.0,	 17.5	 and	 0.6	%	 respectively,	whereas	 GD3	 expression	was	 55.0,	 62.2	 and	 77.1	%	
237	
respectively.	 It	 has	 been	 shown	 that	 GD3A	 can	 protect	 from	 GD3	 mediated	 apoptosis	
(Malisan	et	al.	2002;	Chen	et	al.	2006;	Mukherjee	et	al.	2008).	In	this	instance,	if	GD3	is	not	
capable	of	collapsing	the	mitochondrial	membrane	potential,	it	can	be	utilised	on	the	cell	
surface	and	co-localise	with	other	factors	such	as	Yes	kinase	and	platelet-derived	growth	
factor	 receptor	 alpha	 (PDGFRα)	 where	 it	 can	 increase	 the	 invasive	 potential	 of	 cells	
(Ohkawa	et	al.	2015).	GD3	requires	internalisation	to	become	acetylated	to	GD3A	(Schauer	
2004;	Malisan	&	Testi	2002a),	this	may	explain	why	so	little	GD3A	is	expressed	on	the	cell	
surface.		
Only	one	of	these	cell	lines	has	a	published	known	subgroup,	CHLA-01-Med	is	known	to	be	
a	group	4	medulloblastoma	(Erdreich-Epstein	et	al.	2014).	 It	 can	be	speculated	that	 the	
RES256	cell	line	belongs	to	either	the	SHH	or	WNT	subgroup	as	this	cell	line	harbours	a	TP53	
mutation	(Zhukova	Thesis,	2012).	TP53	mutations	are	enriched	in	WNT	patients	(16%)	and	
SHH	 patients	 (21%),	 and	 these	 mutations	 are	 virtually	 absent	 in	 group	 3	 and	 group	 4	
tumours	(p<0.001)	(Zhukova	et	al.	2013).	The	absence	of	TP53	mutations	in	groups	3	and	4	
is	 because	 of	 the	 location	 of	 the	 TP53	 gene	 on	 the	 short	 arm	 of	 chromosome	 17.	
Chromosome	17p	is	commonly	lost	in	these	subgroups,	and	there	are	gains	in	the	long	arm,	
as	they	harbour	isochromosome	17q	(i[17q])	(Taylor	et	al.	2012).		The	UW402	cell	line	is	
known	to	be	TP53	wild-type,	and	its	subgroup	is	currently	unknown	(Zhukova	Thesis,	2012).	
The	 high	 levels	 of	 expression	 support	 the	 hypothesis	 that	 the	 balance	 of	 these	 two	
gangliosides	is	in	favour	of	GD3A	and	is	shown	by	flow	cytometry.	With	regard	to	subgroup	
affiliation,	there	is	no	significant	difference	between	GD3	and	GD3A	expression	between	
the	cell	lines	despite	the	fact	that	RES256	and	CHLA-01-Med	probably	belong	to	different	
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subgroups.	The	subgrouping	of	these	cell	lines	is	currently	being	determined	by	Dr.	David	
Jones,	Heidelberg.		
The	sub-cellular	localisation	of	the	two	gangliosides	is	well	characterised	(Tempera	et	al.	
2008),	 however	 the	 localisation	 of	 the	 gangliosides	 is	 very	 sensitive	 to	 fixation	method	
(Debarbieux	et	al.	2009;	Schwarz	&	Futerman	1997)	and	therefore	no	conclusions	will	be	
drawn	from	these	data	except	that	 the	antigens	are	 found	on	both	the	cell	 surface	and	
intracellularly	and	concur	with	flow	cytometry	data	(figure	3.10).		
Immunofluorescent	studies	of	wild-type	P5	and	P60	mouse	cerebellums	demonstrated	that	
there	was	a	high	level	of	GD3	and	GD3A	expression	in	the	internal	granule	layer	(IGL)	(figure	
3.11A).	 Interestingly,	group	4	disease	 is	thought	to	arise	from	cells	 in	the	IGL	 in	the	>20	
week	foetal	cerebellum	(World	Health	Organisation	2007).	The	P5	cerebellum	represents	a	
32-36	week	brain	and	therefore	this	may	provide	evidence	for	group	4	tumours	arising	from	
GD3	and	GD3A	positive	cells	(Semple	et	al.	2013).	It	has	also	been	shown	in	other	studies	
that	GPCs	express		GD3A	in	the	external	granule	later	(EGL)	in	the	P1	mouse,	representing	
a	 23-32	 week	 human	 brain,	 this	 provides	 further	 evidence	 for	 expression	 of	 both	
gangliosides	in	the	areas	of	the	cerebellum	that	give	rise	to	group	4	disease	at	this	time	of	
development	(Santiago	et	al.	2004).		The	P60	mouse	cerebellum	confirms	that	expression	
of	these	gangliosides	is	absent	in	the	adult	mouse	brain	(representing	a	20+	year	old	human	
adult)	(figure	3.10B)	(Semple	et	al.	2013).	The	absence	of	GD3	and	GD3A	expression	in	the	
P60	 brain	 is	 in	 agreement	 with	 the	 literature	 stating	 that	 the	 expression	 of	 these	
gangliosides	 is	virtually	absent	 in	the	adult	brain	(Svennerholm	et	al.	1989).	 	 In	order	to	
provide	 further	 evidence	 studies	 with	mice	 at	 each	 stage	 of	 development	 where	 each	
subgroup	is	thought	to	arise	would	be	needed.	Lineage	of	the	positive	cells	should	also	be	
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carried	out	in	further	work.	Another	method	to	confirm	the	link	between	GD3	and	GD3A	
expression	in	cells	of	origin	for	this	disease	should	utilise	medulloblastoma	mouse	model	
tissue	for	staining	with	GD3	and	GD3A	antibodies.		
From	an	anatomical	perspective	 it	 is	quite	difficult	to	determine	likely	subgroups	arising	
from	GD3	and	GD3A	positive	cells.	For	example,	the	WNT	subgroup	arises	from	the	forth	
ventricle	 and	often	 infiltrates	 the	brain	 stem	and	 the	 SHH	 subgroup	often	arises	 in	 the	
cerebellar	 hemispheres	 (World	 Health	 Organisation	 2007).	 From	 this	 study	 it	 was	 not	
possible	 to	 determine	 precise	 locations	 from	 the	 tissue	 available	 but	 would	 be	 an	
interesting	 avenue	 for	 further	 work.	 This	 study	 would	 require	 tissue	 from	 appropriate	
developmental	stages	of	the	brain	in	order	to	determine	precise	locations	of	GD3	and	GD3A	
positive	staining,	if	any.		
4.7 Over-expression	of	SIAE	in	RES256	cells		
The	next	stage	was	to	select	a	cell	line	for	overexpression	of	SIAE,	as	the	involvement	of	
Cas1	is	speculated,	it	was	not	deemed	appropriate	for	knock-down	studies.	As	there	were	
similar	 levels	 of	 GD3A	 in	 the	 three	 cell	 lines	 investigated,	 the	 cell	 line	with	 the	 highest	
percentage	of	intracellular	GD3A	expression,	RES256	was	chosen.	Many	attempts	at	stable	
cell	lines	using	pEGFP-N3,	pEGFP-N3-SIAE	and	pEGFP-N3-SIAE-His	constructs	were	carried	
out,	with	only	 successful	 colony	 selection	 and	expansion	occurring	 in	 the	empty	 vector	
control	cell	line	RES256	pEGFP-N3.	We	therefore	concluded	that	SIAE	expression	may	be	
toxic	to	the	cells	and	continued	with	transient	expression	of	SIAE	using	the	same	constructs	
(appendix	1).	This	also	proved	inconclusive	due	to	poor	transfection	efficiency	(appendix	
2),	there	was	no	change	in	either	the	expression	of	GD3	or	GD3A,	and	when	the	collapse	of	
the	 mitochondrial	 membrane	 potential	 was	 explored,	 there	 was	 also	 no	 change	 in	
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polarisation	(data	not	shown).	It	is	important	to	note	that	two	isoforms	of	SIAE	exist,	the	
lysosomal	variant	(variant	1),	and	the	cytosolic	variant	(variant	2).	It	is	generally	accepted	
that	the	cleavage	of	9-O-acetylated	sialic	acids	are	cleaved	by	the	lysosomal	isoform	of	SIAE	
which	is	transported	into	the	cytoplasm	(Mandal	et	al.	2012)	and	it	has	been	demonstrated	
by	(Orizio	et	al.	2015)	that	the	cytosolic	form	of	this	enzyme	has	not	been	isolated	in	human	
tissue.		Therefore,	the	lysosomal	isoform	of	SIAE	was	used	for	overexpression	studies.	
4.8 An	inducible	system	approach	to	SIAE	over-expression	reveals	changes	
in	GD3	expression		
An	 inducible	 system	 approach	 was	 used	 to	 over-express	 SIAE	 that	 allowed	 cells	 to	 be	
cultured	in	the	absence	of	expression	from	the	construct,	maintaining	viability.	In	order	to	
screen	the	initial	expression	of	the	construct	pCMV-TetOn3G,	a	Tet-responsive	luciferase	
assay	 was	 used	 and	 showed	 that	 this	 protein	 was	 capable	 of	 inducing	 expression	 of	
luciferase	and	therefore	was	suitable	 for	 induction	of	SIAE	expression	(appendix	4).	The	
next	 round	of	 screening	 involved	 the	Tet-responsive	 constructs	 containing	 the	genes	of	
interest,	EGFP	and	either	SIAE	or	SIAE	S127A.	The	SIAE	S127A	expressing	cell	line	contains	
a	gene	with	a	mutation	in	the	catalytic	triad	of	the	SIAE	enzyme.	This	was	discovered	to	
have	very	little	catalytic	activity	by	(Surolia	et	al.	2010;	Orizio	et	al.	2015;	Chellappa	et	al.	
2013)	and	was	used	as	a	control.		
When	cells	were	isolated	and	tested	for	expression,	cells	were	treated	with	doxycycline,	
initiating	expression	of	SIAE	by	the	construct.	Screening	of	these	constructs	was	carried	out	
by	immunocytochemistry.	This	approach	utilised	the	induction	of	EGFP	expression	(figure	
3.16).	This	EGFP	was	not	a	fusion	protein	as	the	construct	contained	an	internal	ribosomal	
entry	site,	this	was	important	to	ensure	no	stearic	hindrance	occurred	when	the	enzyme	
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attempted	to	bind	substrate	(GD3A).	As	the	EGFP	gene	was	cloned	into	multiple	cloning	site	
2	of	this	plasmid	the	expression	was	poor	and	lost	rapidly.	This	phenomenon	is	known	in	
the	 literature	 (Mizuguchi	 et	 al.	 2000;	 Bouabe	 et	 al.	 2008)	 and	 allowed	 screening	 of	
constructs	but	no	downstream	interference	with	the	spectra	of	antibodies	or	dyes	used	in	
subsequent	assays.		
SIAE	expression	was	assessed	by	Western	blot	analysis	and	confirmed	that	gene	expression	
was	not	leaky	(figure	3.17).	The	appearance	of	two	bands	on	each	blot	showed	the	fully	
glycosylated	active	form	of	SIAE	at	62	kDa	(Orizio	et	al.	2015),	and	a	32	kDa	protein	which	
possibly	results	from	cleavage	of	SIAE.	
When	SIAE	gene	expression	was	induced	with	the	addition	of	doxycycline,	GD3A	expression	
did	not	significantly	decrease	as	expected	(figure	3.22A).	This	may	be	due	to	the	time	point	
assayed	(48	hours	as	suggested	by	the	manufacturer	of	the	inducible	system	constructs).	
The	turnover	of	GD3	autoacetylation	is	thought	to	be	6	hours	(Chen	et	al.	2006).	Further	
time	points	were	assayed	and	SIAE	over-expression	confirmed	(data	not	shown).	The	48	
hour	time	point	was	used	for	further	experiments	however	as	the	mitochondrial	membrane	
potential	 collapse	was	 seen	at	 this	 time.	 This	 assay	had	 short-comings	 as	we	 could	not	
assess	enzymatic	activity	of	SIAE	directly.	Although	the	fully	glycosylated	‘active’	form	of	
protein	was	seen	by	Western	blot	analysis,	we	could	not	confirm	that	this	enzyme	was	an	
active	esterase.	Despite	this	there	was	a	concomitant	significant	increase	in	the	expression	
of	 GD3	 (p<0.05;	 figure	 3.22B),	 so	 one	 can	 assume	 that	 the	 esterase	 activity	 of	 SIAE	 is	
present	(figure	3.22B).	The	lack	of	GD3A	cleavage	can	be	explained	by	the	auto-acetylation	
phenomenon	of	GD3	which	has	been	demonstrated	using	exogenously	added	GD3	(Chen	
et	al.	2006).	If	GD3	does	induce	its	own	acetylation	machinery,	the	expression	of	Cas1	could	
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be	explored	in	further	studies	to	determine	its	involvement	in	this	pathway.			
When	the	GD3	and	GD3A	expression	was	investigated	in	empty	vector	control	cells	(EGFP)	
there	was	a	significant	decrease	in	the	expression	of	GD3A	despite	there	being	no	esterase	
cloned	 into	 the	 plasmid	 (p<0.05;	 figure	 3.22A).	 When	 the	 expression	 of	 GD3	 was	
determined	it	was	shown	that	there	was	no	significant	increase	in	expression,	suggesting	
that	 GD3A	 deacetylation	 that	 did	 occur	 should	 not	 affect	 the	mitochondrial	membrane	
potential.		
In	the	catalytic	mutant	SIAE-S127A,	there	were	no	significant	changes	in	the	expression	of	
either	 ganglioside,	 suggesting	 that	 there	 would	 be	 no	 changes	 in	 the	 mitochondrial	
membrane	potential.		
4.9 SIAE	overexpression	collapses	the	mitochondrial	membrane	potential	
in	RES256	cells		
As	 high	 levels	 of	 GD3	 are	 known	 to	 collapse	 the	 mitochondrial	 membrane	 potential	
(Malisan	 &	 Testi	 2002a),	 this	 was	 explored	 (figure	 3.23).	 It	 is	 also	 known	 that	 these	
gangliosides	exist	in	balance	in	order	to	protect	cells	from	apoptosis	(Birks	et	al.	2011)	and	
therefore	the	collapse	of	the	mitochondrial	membrane	potential	would	only	occur	if	this	
threshold	 was	 reached.	 Upon	 induction	 of	 SIAE	 wild-type	 (clone	 1)	 expression,	 the	
mitochondrial	membrane	significantly	depolarised	(p<0.05;	figure	3.23),	demonstrated	by	
the	presence	an	increase	of	green	monomers	of	JC-1	dye	compared	to	red	aggregates.	This	
depolarisation	did	not	occur	with	the	catalytic	mutant	cell	line	SIAE-S127A	nor	did	it	occur	
in	the	empty	vector	control	EGFP.	Interestingly	the	collapse	of	the	membrane	potential	did	
not	occur	in	clone	2.	However,	this	clone	may	reach	significance	with	higher	numbers	of	
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replicates.	It	must	also	be	noted	that	the	collapse	of	the	mitochondrial	membrane	potential	
is	a	transient	event	and	therefore	the	lack	of	significant	depolarisation	seen	with	SIAE	clone	
2	may	be	due	to	an	incorrect	time	point	for	this	clone	to	be	assayed.	Another	explanation	
for	this	difference	in	results	between	clones	includes	trafficking	of	GD3	and	GD3A	to	the	cell	
membrane,	 a	 well-known	 phenomenon	 (Birks	 et	 al.	 2011).	 This	 experiment	 also	
demonstrated	flaws,	the	high	levels	of	depolarisation	of	the	mitochondrial	membranes	at	
the	start	seen	in	each	clone	demonstrate	that	cell-preparation	may	need	to	be	optimised	
to	get	an	accurate	representation	of	membrane	potentials.	It	is	also	clear	that	to	determine	
cell	death,	be	 it	by	 intrinsic	or	extrinsic	apoptosis	or	autophagy,	all	of	which	have	been	
described	with	regard	to	GD3’s	effects	(Matarrese	et	al.	2014;	Malisan	&	Testi	2002a),	other	
means	carried	out	in	conjunction	with	JC-1	assays	such	as	caspase	release,	cytochrome	c	
translocation	assays	etc	are	required.	
SIAE	has	been	shown	to	be	a	secreted	enzyme	in	its	fully	glycosylated	form	(Orizio	et	al.	
2015),	conditioned	media	studies	were	therefore	carried	out.	Interestingly,	the	only	clone	
that	secreted	active	enzyme	was	the	catalytic	mutant	SIAE-S127A	cell	line	(figure	3.18).	This	
is	potentially	because	there	was	very	little	62	kDa	protein	present	when	the	lysates	of	SIAE-
wild-type	 cells	 were	 analysed.	 There	 was	 however	 considerably	 more	 of	 the	 lower	
molecular	weight	32	kDa	band	seen	in	the	wild-type	expressing	cells.	The	32	kDa	cleavage	
product	of	SIAE	may	also	have	other	roles	other	than	acetyl	esterase	activity,	this	however	
would	require	further	investigation	to	elucidate.	To	investigate	possible	identities	of	the	32	
kDa	product	the	human	lysosomal	SIAE	sequence	was	run	through	peptide-cutter	software	
to	analyse	the	sequence	for	cleavage	sites.	When	the	sequence	was	analysed	there	was	
only	one	candidate	for	cleavage	giving	rise	to	these	molecular	weights	that	did	not	disturb	
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the	antibody	binding	sequence,	this	candidate	was	casapse	1.	This	potential	cleavage	site	
is	modelled	in	figure	3.21.	Capsase	1	is	an	enzyme	that	has	known	involvement	in	neuronal	
cell-death	following	a	diverse	range	of	insults	(Denes	et	al.	2012).	As	medulloblastoma	is	a	
cancer	that	arises	from	neural	stem	cells	(particularly	groups	3	and	4),	which	give	rise	to	
neurons	(Marshall	et	al.	2014)	this	may	be	of	particular	 interest	due	to	caspase	1	being	
implicated	in	neuronal	cell	death.	
Another	 role	 of	 caspase	 1	 is	 within	 the	 inflammasome,	 it	 has	 been	 suggested	 in	
medulloblastoma	 that	 ATP	 is	 released	 by	 apoptotic	 cells	 and	 recruits	 the	 NLRP3	
inflammasome	(Knight	et	al.	2013)	via	the	purine	receptor	P2X7	the	mechanism	of	which	
has	 been	 described	 in	 dendritic	 cells	 and	 breast	 cancer	 (Ghiringhelli	 et	 al.	 2009).	 This	
process	involves	caspase	1	activation.	GD3	is	also	known	to	have	a	role	in	modulating	the	
immune	system	when	shed	which	perhaps	helps	to	regulate	the	inflammatory	response.	
While	preliminary	and	in	need	of	further	investigation,	this	may	have	relevance	and	will	be	
subject	to	further	investigation	beyond	this	project.	
4.10 Chemotherapeutic	response	with	SIAE	overexpression		
One	of	the	purposes	of	a	new	therapeutic	approach	to	medulloblastoma	is	to	reduce	the	
toxicity	of	existing	chemotherapeutics.	The	current	chemotherapeutic	regime	is	aggressive	
and	has	significant	effects	on	the	developing	nervous	system	and	therefore	the	patient’s	
quality	of	life	(Kim	et	al.	2011).	There	is	a	need	to	either	replace	existing	drugs	or	reduce	
the	 dose	 of	 existing	 treatments	 in	 order	 to	 reduce	 toxicity.	Our	 approach	 for	 this	 is	 to	
overexpress	SIAE	to	try	and	predispose	medulloblastoma	cells	to	existing	treatments.	The	
current	 treatment	 regime	 for	 medulloblastoma	 includes	 lomustine,	 cyclophosphamide,	
vincristine,	methotrexate,	cisplatin	and	etoposide	(Mueller	&	S.	Chang	2009;	Gajjar	et	al.	
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1999;	Michiels	et	al.	1996).		
Following	 literature	 searches	 and	 searches	 of	 clinical	 trial	 data,	 cisplatin	 and	 etoposide	
were	chosen	as	 the	 two	drugs	we	would	 test	 to	 see	 if	 SIAE	overexpression	 significantly	
reduced	viability	of	RES256	cells	(figures	3.24,	3.25).	These	drugs	were	selected	as	the	use	
of	them	remains	in	each	of	the	treatment	protocols	researched.		
Cisplatin	is	activated	upon	entering	cells	where	the	chloride	atoms	are	replaced	with	water	
molecules	 by	 displacement.	 The	 hydrolysed	 product	 is	 a	 potent	 electrophile	which	 can	
react	with	neutrophiles	such	as	the	sulfhydryl	groups	on	proteins	or	nitrogen	donor	groups	
of	nucleic	acids	(Dasari	&	Tchounwou	2014).The	cytotoxic	effect	of	cisplatin	is	primarily	due	
to	the	interaction	with	the	N7-sites	of	purine	DNA	bases	to	form	DNA-protein	and	DNA-
DNA	interstrand	and	intrastrand	crosslinks	(Eastman	et	al.	1987).	These	cross-links	cause	
DNA	 damage	 in	 cancer	 cells	 which	 block	 cell	 division	 and	 result	 in	 apoptosis.	 	 The	
intrastrand	cross-links	of	purine	bases	are	the	most	notable	changes	in	DNA	with	cisplatin	
treatment.	 They	 include	 d(GpG)	 adducts	 (90	 %)	 and	 d(ApG)	 adducts	 (10	 %)	 (Dasari	 &	
Tchounwou	2014).		
Cisplatin	did	not	significantly	reduce	RES256	cell	viability	with	induction	of	empty	vector	
control	expression,	nor	with	SIAE	wild-type	or	mutant	expression	at	24	hours	(figure	3.24A).	
After	48	hours	of	cisplatin	treatment	there	was	a	significant	reduction	in	viability	with	3	μM	
cisplatin	 in	 wild-type	 SIAE	 clone	 1	 (p<0.001)	 but	 this	 effect	 was	 not	 concentration-
dependent	 and	was	 not	maintained	with	 higher	 doses	 (figure	 3.24B).	 There	was	 also	 a	
significant	reduction	in	cell	viability	of	S127A	expressing	cells	with	cisplatin	treatment	with	
4	and	11	μM	(p<0.05;	figure	3.24B)	and	with	12	μM	cisplatin	(p<0.01;	figure	3.24B).	After	
72	hours	of	 cisplatin	 treatment	 there	was	 a	 significant	difference	 in	 EGFP	 viability	with	
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vehicle	control	(p<0.05;	figure	3.24C)	and	7	μM	cisplatin	treatment	(p<0.05;	figure	3.24C).	
There	was	also	a	significant	 reduction	 in	viability	with	13μM	cisplatin	 treatment	 in	SIAE	
clone	1	(p<0.05;	figure	3.24C).	There	were	also	significant	differences	between	3,	11	and	
13	μM	cisplatin	treatment	(p<0.05;	figure	3.24C)	and	12	μM	cisplatin	treatment	(p<0.001;	
figure	3.24C)	in	the	SIAE-S127A	expressing	clone.			
This	suggests	that	cisplatin	treatment	has	a	greater	effect	on	viability	with	induction	of	gene	
expression	with	time	as	the	most	significant	data,	particularly	when	the	catalytic	mutant	
expresser	 is	 seen	 at	 72	 hours.	 This	 data	 however	 does	 demonstrate	 some	 significance	
outside	of	clinically	achievable	concentrations	(generally	accepted	to	be	up	to	10	μM	in	the	
brain)	(Stewart	et	al.	1995).	When	analysed	as	a	dose-response,	the	catalytic	mutant	SIAE-
S127A	had	a	reduced	IC50	with	induction	of	gene	expression	(p<0.05)	demonstrating	that	
the	drug	is	having	a	greater	effect	when	the	mutant	enzyme	is	expressed.	As	the	catalytic	
mutant	did	not	demonstrate	any	significant	changes	in	GD3	or	GD3A	expression,	nor	any	
significant	depolarisation	of	 the	mitochondrial	membrane	potential,	 it	may	be	 that	 this	
effect	does	not	involve	the	gangliosides.		
As	 well	 as	 this,	 cells	 were	 still	 viable,	 even	 with	 high	 concentrations	 of	 cisplatin,	
mechanisms	 of	 resistance	 were	 investigated.	 (Siddik	 et	 al.	 2003)	 suggests	 many	
mechanisms	of	resistance;	two	of	these	are	relevant	to	the	RES256	cell	line.	TP53	mutation	
can	contribute	to	resistance	by	inhibition	of	p53-dependent	apoptotic	programs.	Another	
mechanism	 is	 overexpression	 of	 ERBB2	 (Her2)	 which	 is	 known	 to	 correlate	 with	 poor	
prognosis	in	medulloblastoma.		There	are	several	pathways	that	ERBB2	overexpression	can	
affect	which	 contribute	 to	 cisplatin	 resistance,	 but	 the	major	mechanism	 in	 this	 case	 is	
inactivation	 of	 the	 pro-apoptotic	 protein	 Bad	 following	 its	 phosphorylation	 by	 protein	
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kinase	b	(Akt)	(Siddik	et	al.	2003).	Furthermore,	the	RES256	cell	line	was	positive	for	ERBB2	
expression	with	67.9%		of	the	population	staining	positive	for	the	antigen	(Zomerman	et	al.	
2015).	
Etoposide	 is	 a	 chemotherapeutic	 whose	 main	 target	 is	 topoisomerase	 II,	 an	 enzyme	
involved	in	inducing	double	strand	transient	breaks	in	DNA	in	order	for	a	cell	to	replicate,	
and	for	 tangles	 in	DNA	to	be	removed.	The	transient	breaks	 in	DNA	are	generated	by	a	
topoisomerase	II	/	DNA	complex	(cleavage	complex)	which	can	be	stabilised	permanently	
by	etoposide.	This	drug	prevents	re-ligation	of	the	double-strand	DNA	break.	These	double-
strand	 DNA	 breaks	 are	 lethal	 to	 the	 cell	 as	 there	 is	 failure	 in	 DNA	 damage	 repair	
mechanisms	(Montecucco	et	al.	2015).	The	tumour	suppressor	p53	plays	an	important	role	
in	etoposide-induced	apoptosis	 and	 is	 regulated	by	 the	drug	 (Dey	et	 al.	 2010).	Another	
mechanism	of	action	of	etoposide	has	been	described	in	isolated	mitochondria	from	Jurkat	
cells	 (Robertson	 et	 al.	 2000).	 In	 this	 study	 the	mitochondrial	 membrane	 potential	 was	
shown	to	collapse	with	50	µM	etoposide	treatment.	Although	this	study	was	carried	out	in	
a	cell-free	system,	as	we	hypothesised	that	 the	mitochondrial	membrane	potential	may	
collapse	with	SIAE	overexpression	(due	to	increased	levels	of	GD3),	the	drug	was	chosen	to	
determine	if	an	additive	or	synergistic	effect	could	be	achieved	with	SIAE	overexpression.		
Etoposide	significantly	reduced	RES256	cell	viability	with	induction	of	empty	vector	control	
expression	at	24	hours	of	treatment	with	7	and	12	μM	(p<0.05;	figure	3.25A)	and	with	13	
μM	treatment	 (p<0.01;	 figure	3.25A).	 In	SIAE	wild-type	expressing	cells	 (clone	2)	12	μM	
etoposide	treatment	also	had	a	significant	difference	with	gene	expression	(p<0.01;	figure	
3.25A).	 SIAE	 2	 and	 SIAE-S127A	 mutant	 expression	 at	 24	 hours	 however	 were	 not	
significantly	different	 (figure	3.25A).	After	48	hours	of	etoposide	treatment	 there	was	a	
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significant	reduction	in	viability	with	11	μM	etoposide	in	EGFP	expressing	clones	(p<0.005;	
figure	3.25B)	and	with	13	μM	treatment	(p<0.01;	figure	3.25B).	There	was	also	a	significant	
reduction	in	cell	viability	with	etoposide	treatment	at	1	and	4	µM	(p<0.05;	figure	3.25B).	
After	72	hours	of	 cisplatin	 treatment	 there	was	a	 significant	difference	1	μM	etoposide	
treated	cells	(p<0.05;	figure	3.25C).	
Clinically	achievable	levels	of	etoposide	in	the	brain	are	not	well	reported	in	the	literature.	
Publications	 on	 extraneural	 tumours	 such	 as	 neuroblastoma	 (Kiya	 et	 al.	 1992)	 and	
leukaemia	suggest	levels	in	the	plasma	can	reach	up	to	50	µM	(Wen	et	al.	2000)	this	is	very	
unlikely	 in	 the	brain	due	 to	 the	blood-brain	 (or	blood-tumour)	barrier.	 It	 has	 also	been	
shown	that	etoposide	concentrations	in	the	tumour	core	are	higher	than	that	of	the	rest	of	
the	brain	(Stewart	et	al.	1984).	Based	on	this	it	 is	difficult	to	suggest	a	clinically	relevant	
range	of	etoposide	concentrations.	This	may	also	mean	that	the	study	by	Robertson	(2000)	
used	clinical	unachievable	levels	of	the	drug	which	may	mean	that	the	mechanism	of	action	
proposed	by	this	study	does	not	take	place	at	concentrations	achievable	in	vivo	(Robertson	
et	 al.	 2000).	 In	 addition,	 the	effects	of	 etoposide	 are	potentiated	with	 time	 (Kiya	 et	 al.	
1992).	 Despite	 early	 indications	 of	 etoposide	 seeming	 more	 effective	 using	 our	 initial	
analysis	 by	 dose	 (figure	 3.25)	 particularly	 in	 the	 EGFP	 clone,	when	 analysed	 as	 a	 dose-
response	(figure	3.27)	only	wild-type	expressing	clone	2	showed	a	significant	reduction	in	
IC50	compared	to	controls.	Interestingly,	SIAE	clone	2	was	the	only	clone	to	demonstrate	a	
significant	increase	in	GD3	expression	with	induction	of	SIAE	expression.		
These	data	suggest	that	SIAE	expression	may	affect	cell	viability	when	cells	are	treated	with	
etoposide,	perhaps	due	to	changes	in	the	cell-cycle	as	etoposide	is	a	cell-cycle	dependent	
drug.	 High	 levels	 of	 GD3	 have	 been	 shown	 (via	 overexpression	 of	 ST8Sia1)	 to	 increase	
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proliferation	(Cazet	et	al.	2009).	As	GD3	has	been	shown	to	increase	in	SIAE	clone	2	with	
induction	of	expression,	this	increase	could	then	cause	the	cells	to	re-enter	the	cell	cycle	
and	proliferate,	allowing	etoposide	to	bind.	This	increase	in	GD3	was	not	seen	in	clone	1,	
but	neither	was	a	reduction	in	IC50	which	may	suggest	that	GD3	may	play	a	role.	There	was	
some	resistance	seen	with	etoposide	as	the	viability	of	cells	remained	at	around	40	%	with	
treatment.	It	has	been	demonstrated	that	RES256	cells	have	mutant	TP53	status	(Zhukova	
Thesis,	2012),	and	that	the	mechanism	of	cell	death	by	etoposide	is	reliant	on	p53.	It	has	
also	been	shown	that	medulloblastoma	cells	with	mutations	in	TP53	are	resistant	(or	less	
sensitive)	to	etoposide	treatment	(Meley	et	al.	2010).		
The	 reported	 IC50	data	obtained	 from	MTS	experiments	 shown	 in	 figures	3.26	and	3.27	
should	not	be	considered	final.	MTS	experiments	report	the	metabolic	state	of	cells	and	it	
is	clear	 that	 there	 is	a	difference	 in	the	starting	viability	 in	SIAE	clone	2	expressing	cells	
treated	for	72	hours	with	etoposide.	This	reduction	in	IC50	therefore	may	not	be	an	accurate	
representation	of	the	effect	of	etoposide,	but	rather	an	altered	metabolic	state	as	a	result	
of	this	experimental	condition.	In	order	to	determine	accurate	and	reliable	IC50	data	the	
experiments	carried	out	using	MTS	assays	must	also	be	carried	out	as	colony	formation	
assays	to	determine	drug	responses.	The	IC50	data	shown	in	figures	3.26	and	3.27	must	also	
be	 repeated	 across	 a	 narrower	 range	 of	 drug	 concentrations.	 In	 order	 to	 determine	
accurate	IC50	data	there	should	be	at	least	5	data	points	reported	before	a	50	%	response	
is	seen.	Limitations	in	the	experimental	methods	are	recognised	and	in	further	work	should	
be	further	optimised	and	repeated.		
4.11 Conclusions	
One	of	the	aims	of	this	work	was	to	demonstrate	that	GD3	and	GD3A	were	re-expressed	by	
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medulloblastoma	cells	and	that	a	balance	between	them	existed.	We	have	shown	that	the	
expression	of	 these	 two	gangliosides	 is	high,	and	 that	 the	balance	of	GD3	 to	GD3A	 is	 in	
favour	of	GD3A	within	these	cells,	as	hypothesised.	We	demonstrate	that	the	expression	of	
GD3A	is	low	on	the	cell-surface,	which	is	supportive	of	work	by	Chen	(H.	Y.	Chen	et	al.	2006)	
stating	that	GD3	requires	internalisation	to	be	acetylated.	We	investigated	the	role	of	these	
two	 gangliosides	 in	 medulloblastoma	 cell	 viability	 by	 over-expressing	 the	 human	
endogenous	deacetylation	enzyme	SIAE.	Over-expression	of	SIAE	significantly	increased	the	
expression	of	GD3	in	these	cells,	but	not	in	catalytic	mutant	cells	or	empty	vector	controls.	
Further	 to	this	we	demonstrated	 in	preliminary	work	that	 the	mitochondrial	membrane	
potential	could	be	depolarised	with	induction	of	SIAE	over-expression	(in	clone	1	only),	but	
experimental	limitations	make	conclusions	difficult	to	draw,	other	methods	such	as	caspase	
3/7	 activation,	 cytochrome	 c	 release	 or	 studies	 of	 bcl-2	 or	 bax	 are	 necessary	 to	 draw	
conclusion	on	this	topic.	We	also	demonstrated	that	with	treatment	of	these	cell	lines	with	
cisplatin	and	etoposide,	the	IC50	with	etoposide	treatment	is	significantly	reduced	in	wild-
type	SIAE	expressing	clone	2	with	72	hour	treatment.	We	did	not	demonstrate	any	changes	
in	 susceptibility	 to	 cisplatin-mediated	 reductions	 in	 cell	 viability	 possibly	 in	 wild-type	
expressing	 clones	 suggesting	 that	 SIAE	over-expression	 causes	 changes	 in	 the	 cell	 cycle	
which	does	not	affect	the	response	to	cisplatin.	We	did	however	demonstrate	a	significant	
reduction	in	cell	viability	in	the	mutant	expressing	cell	line	after	48	hours	of	treatment	with	
cisplatin.		
It	 could	be	 investigated	 in	 further	work	 if	 the	 increase	 in	GD3	expression	of	viable	cells	
could	increase	invasive	potential,	something	that,	if	true,	could	affect	the	potential	success	
of	this	therapeutic	approach.	If	the	invasive	potential	 is	 increased	then	cell	survival	may	
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increase,	 something	 not	 desirable	 in	 a	 therapy.	 If,	 however	 trafficking	 of	 GD3	 to	 the	
mitochondria	 is	 sufficient	 to	 cause	 a	 reduction	 in	 cell	 viability	 this	 increase	 in	 invasive	
potential	would	be	unlikely.	 In	 support	of	 this,	 studies	on	 this	 pathway	 in	 glioblastoma	
multiforme	showed	that	invasive	potential	was	not	increased	upon	cleavage	of	GD3A	(Birks	
et	al.	2011).		
We	 also	 demonstrate	 that	 SIAE	 can	 be	 secreted	 and	 that	 there	 is	 a	 greater	 amount	 of	
secretion	in	the	catalytically	mutated	clone.	This	may	be	due	to	caspase	1	involvement,	but	
will	 be	 subject	 to	 further	work	 to	 support	 or	 reject	 this	 hypothesis	 and	 further	 dissect	
mechanisms	 of	 reduced	 viability	 in	 these	 cells.	 Caspase	 1	 involvement	 will	 also	 be	
investigated	with	down-stream	apoptosis	assays,	such	as	executioner	caspase	3	assays	in	
order	to	determine	if	cell	death	occurs	and	by	which	mechanisms	if	it	does.		
4.12 Further	work	
In	 this	 study	we	have	demonstrated	 as	 a	 proof	 of	 principle	 that	 this	 pathway	 could	be	
utilised	as	a	therapeutic	target.	In	further	work	more	cell	lines	should	be	used	in	order	to	
further	demonstrate	this	principle.	Gene	delivery	should	also	be	a	focus	of	further	study,	in	
work	done	by	(Birks	et	al.	2011)	the	baculovirus	has	shown	promise	for	this	application.	
This	 approach	 could	be	utilised	as	a	method	of	 targeting	 cells	 left	behind	after	 surgical	
resection	to	either	cause	their	mitochondrially-mediated	apoptosis,	or	sensitise	them	to	
lower	doses	of	chemotherapy.	It	would	obviously	be	important	if	this	were	to	reach	the	
clinic	to	ensure	that	lower	doses	of	chemotherapy	did	not	risk	under-treatment	of	disease	
and	that	the	doses	used	are	clinically	achievable.	
The	limitations	of	the	JC-1	assay	and	chemotherapy	experiments	described	above	require	
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further	optimisation	before	conclusions	can	be	drawn,	it	would	therefore	be	important	for	
these	 experiments	 to	 be	 carried	 out	 in	 further	 work.	 Other	 considerations	 should	 be	
combinations	 of	 chemotherapy	 to	 determine	 if	 any	 synergism	 occurs	 with	 SIAE	 over-
expression	 and	 current	 therapeutic	 regimes.	 Of	 particular	 interest	 would	 be	
mitochondrially-targeted	 agents	 such	 as	 clomipramine,	 a	 tricyclic	 antidepressant	 drug	
which	has	shown	promise	in	the	treatment	of	glioma.	Another	agent	of	interest	for	that	
targets	mitochondria	that	has	shown	promise	in	SHH		medulloblastoma	is	dichloroacetate,	
a	drug	that	targets	pyruvate	kinase	(Di	Magno	et	al.	2014)	.	This	could	help	to	determine	
optimum	time	for	delivery	of	this	gene	if	it	were	to	reach	the	clinic.		
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Appendix	1	–	Plasmid	maps	and	sequence	homology	of	pEGFP-N3,	pEGFP-
N3-SIAE	and	pEGFP-N3-SIAEHis	
	
Dr.	Reinhard	Vlasak,	our	collaborator	at	the	University	of	Salzberg,	Austria,	provided	SIAE	
constructs	for	overexpression	studies	(appendix	1.1).	The	pEGFP-N3	construct	encodes	a	
red-shifted	variant	of	wild-type	green	fluorescent	protein	(GFP),	which	has	been	optimised	
for	brighter	expression	and	a	higher	level	of	expression	in	mammalian	cells.	This	enhanced	
green	 fluorescent	 protein	 (EGFP)	 has	 amino	 acid	 substitutions	 of	 F64L	 and	 S65T	 that	
generate	a	brighter	fluorophore	than	wild-type	GFP.	The	coding	sequence	of	EGFP	contains	
190	silent	base	changes	that	optimise	the	sequence	for	human	codon	usage	preferences.		
The	constructs	provided	were	pEGFP-N3	(empty	vector	control);	pEGFP-N3-SIAE	(wild-type	
enzyme)	and	pEGFP-N3-SIAE-His	(wild-type	enzyme	containing	a	His-tag).	
The	multiple	cloning	site	(MCS)	in	pEGFP-N3	is	between	the	immediate	early	promoter	of	
cytomegalovirus	(CMV)	and	the	EGFP	gene.	Genes	that	are	cloned	into	the	multiple	cloning	
site	are	expressed	as	N-terminal	fusion	proteins	with	EGFP.	SV40	polyadenylation	signals	
downstream	of	the	EGFP	gene	direct	proper	processing	of	the	3’	end	of	the	EGFP	mRNA.	
The	 vector	 backbone	 also	 contains	 an	 SV40	 origin	 of	 replication	 in	 mammalian	 cells	
expressing	the	SV40	T-antigen.	A	neomycin	resistance	gene	(Neor)	consisting	of	the	SV40	
early	 promoter,	 the	 neomycin/kanamycin	 resistance	 gene	 of	 Tn5,	 and	 polyadenylation	
signals	from	the	herpes	simplex	virus	thymidine	kinase	(HSK	TK)	gene,	allows	the	selection	
of	stably	transfected	cell	lines	with	G-418.	A	bacterial	promoter	located	upstream	of	this	
gene	expresses	kanamycin	resistance	in	E.coli.	In	E.coli	this	construct	also	provides	a	pUC	
origin	of	replication	and	an	f1	origin	for	single	stranded	DNA	production.		
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The	 constructs	 were	 sequenced	 (appendix	 1.2)	 to	 ensure	 that	 gene	 inserts	 had	 been	
incorporated	correctly,	standard	pCMV	primers	and	a	downstream	sequencing	primer	due	
to	transcript	length	(Eurofins	Genomics).		
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Appendix	1.1Plasmid	maps	of	pEGFP-N3,	pEGFP-N3-SIAE	and	pEGFP-
N3-SIAEHis	provided	by	Dr.	Reinhard	Vlasak.		
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Appendix	1.2	Homology	of	SIAE	sequences	cloned	into	plasmids	shown	in	appendix	1.1.	
The	 sequences	 contained	within	 pEGFP-N3	 and	pEGFP-SIAEHis	were	 homologous	 to	
reference	 SIAE	 isoform	 1	 sequences	 from	 the	 Ensembl	 genome	 browser	
(http://www.ensembl.org).	One	base	pair	change	was	seen	at	1515	however	this	codes	
for	the	same	amino	acid.	The	SIAEHis	sequence	contains	a	C-terminal	His	tag	(6	histidine	
residues).	
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Appendix	 2	 –	 Transfection	 efficiency	 and	 GD3/GD3A	 changes	 in	 cells	
transfected	with	pEGFP-N3,	pEGFP-N3-SIAE	and	pEGFP-N3-SIAEHis		
	
pEGFP-N3,	 pEGFP-N3-SIAE	 and	 pEGFP-N3-SIAE-His	 constructs	 were	 cloned	 into	 RES256	
cells.	After	two	weeks	in	selection	media	that	had	been	replenished	every	4	days,	colonies	
had	not	formed	for	selection	(data	not	shown).		
In	order	to	determine	if	SIAE	overexpression	had	an	effect	on	GD3A	deacetylation	in	RES256	
cells,	 transient	 transfections	 with	 the	 same	 constructs	 were	 carried	 out.	 Cells	 were	
transfected	as	previously	described.	After	the	incubation	period	of	24	hours,	the	cells	were	
instead	harvested	for	analysis	of	GD3	and	GD3A	(Appendix	2.1),	and	transfection	efficiency	
(Appendix	2.2).	
The	transfection	efficiency	of	the	transiently	transfected	cell	lines	was	examined	by	EGFP	
assay	and	was	poor	(7.5	%	for	SIAE	expressing	cells;	appendix	2.2).	Transfection	of	pEGFP-
N3-SIAEHis	was	determined	by	anti-His	Western	blot.	Protein	expression	was	not	detected	
using	this	method	suggesting	poor	transfection	efficiency	(data	not	shown).	Changes	in	the	
GD3	and	GD3A	content	was	not	significant	as	determined	by	flow	cytometry	(appendix	2.1),	
which	may	be	due	to	such	poor	transfection	efficiency.	JC-1	assays	were	also	carried	out	to	
determine	if	the	balance	of	GD3	and	GD3A	had	been	altered,	and	reduced	viability	of	the	
transfected	 cells,	 this	 data	demonstrated	no	 loss	 in	 cell	 viability	 and	no	 changes	 in	 the	
mitochondrial	membrane	polarisation	(data	not	shown).		
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Appendix	2.1	Transient	expression	of	SIAE	does	not	affect	GD3	and	GD3A	
expression	 in	RES256	cells.	Cells	 transfected	with	SIAE	did	not	express	
significantly	different	levels	of	GD3	or	GD3A	compared	to	empty	vector	
controls	 (pEGFP-N3).	 (p>0.05).	 Data	 analysed	 by	 One-Way	 analysis	 of	
Variance	and	Tukey’s	multiple	comparison	post-hoc	test	using	Graph	Pad	
Prism	6	software	n=3	±	SEM	
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Appendix	 2.2	 Transfection	 efficiency	 is	 low	 in	
transiently	 transfected	 cell	 lines.	 Transfection	
efficiency	assay	based	on	EGFP	expression	showed	on	
average	pEGFP-N3	was	transfected	into	33.6	%	of	cells	
and	pEGFP-N3-SIAE	into	7.5	%	of	cells.	N=3	±	SEM	
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Appendix	 3	 –	 Plasmid	 maps	 and	 sequence	 homology	 of	 pCMV-TetOn3G,	
pTRE3G-IRES-EGFP,	 pTRE3G-IRES-EGFP-SIAE	 and	 pTRE3G-IRES-EGFP-SIAE-
S127A	
	
Inducible	system	SIAE	constructs	for	overexpression	studies	were	purchased	from	Clontech	
and	EGFP,	SIAE	and	SIAE-S127A	genes	cloned	into	the	backbone	as	previously	described.	
The	pCMV-TetOn3G	construct	encodes	a	doxycycline	responsive	protein	which	undergoes	
a	conformational	change	with	doxycycline	binding	allowing	the	binding	of	the	protein	to	
PTRE3G,	driving	gene	transcription.	The	Tet-On	3G	transactivator	protein	was	developed	by	
Clontech	and	displays	high	sensitivity	to	doxycycline.	The	pTRE3G-IRES-EGFP,	pTRE3G-IRES-
EGFP-SIAE	and	pTRE3G-IRES-EGFP-SIAE-S127A	constructs	are	shown	in	appendix	3.1.	
The	 inducuble	 promoter	 (PTRE3G)	 allows	 very	 low	 basal	 expression	 and	 high	 maximal	
expression	with	doxycycline	induction.	There	are	7	repeats	of	a	19	bp	tet	operator	sequence	
which	is	located	upstream	of	the	CMV	promoter.	When	doxycycline	is	present	the	Tet-On	
3G	protein	binds	specifically	to	the	PTRE3G	and	activates	the	transcription	of	EGFP	and	SIAE	
(or	 SIAE-S127A).	 The	 PTRE3G	 promoter	 lacks	 binding	 sites	 for	 endogenous	 mammalian	
transcription	factors	so	is	virtually	silent	in	the	absence	of	doxycycline.		
The	 constructs	 were	 sequenced	 (appendix	 3.2)	 to	 ensure	 that	 gene	 inserts	 had	 been	
incorporated	correctly	(Eurofins	Genomics).		
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Appendix	3.3	Plasmid	maps	for	inducible	system	studies.	(A)	All	cells	were	transfected	
first	with	pCMV-TetOn3G.	(B)	Empty	vector	control	pTRE3G-IRES-EGFP.	(C-D)	Cells	were	
transfected	with	either	(C)	or	(D).		
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Appendix	3.2	Homology	of	SIAE	sequences	cloned	into	plasmids	shown	in	appendix	3.1.	
The	 sequences	 contained	within	pTRE3G-IRES-SIAE	and	pTRE3G-IRES-SIAE-S127A	were	
homologous	to	reference	SIAE	isoform	1	sequences	from	the	Ensembl	genome	browser	
(http://www.ensembl.org).	 The	 S127A	mutation	 is	 confirmed	 at	 bases	 379-390	which	
encodes	an	amino	acid	substitution	from	a	serine	to	an	alanine	residue.		
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Appendix	4	–	Induction	testing	of	pCMV-TetOn3G	clones	
	
In	order	to	generate	double-stable	inducible	system	cell	lines,	cells	were	first	transfected	
with	 pCMV-TetOn3G	 constructs	 (appendix	 3.1).	 To	 determine	 the	 clones	 that	 best	
expressed	the	Tet-On	3G	protein,	and	were	therefore	capable	of	inducing	expression	of	tet-
responsive	constructs,	 transient	transfections	using	a	tet-responsive	 luciferase	construct	
was	carried	out.		
pTRE3G-Luc	is	a	construct	whose	expression	is	driven	by	Tet	On	3G	protein.	In	order	for	the	
Tet	On	3G	protein	to	bind	to	the	promoter	of	the	pTRE3G-Luc	construct	doxycycline	must	
be	present.	Doxycycline	induces	a	conformational	change	in	the	Tet	On	3G	protein	which	
allows	 binding	 to	 the	 promoter.	 	 The	 biding	 of	 the	 protein	 to	 the	 promoter	 drives	
expression	of	luciferase	which	is	then	quantified	using	a	dual	luciferase	assay	described	in	
chapter	2	(appendix	4.2).		
Fold-induction	of	the	luciferase	protein	was	defined	as	the	fold-change	between	cells	in	the	
presence	and	absence	of	doxycycline.	This	was	used	as	a	measure	of	 induction	of	each	
clone.	Clones	1,	3	and	6	were	determined	as	the	clones	best	able	to	induce	gene	expression	
and	were	used	to	generate	inducible	system	cell	lines.	Clone	1	was	the	clone	that	produced	
cultures	expressing	each	of	the	proteins	and	was	used	for	down-stream	analysis.	
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Appendix	4.1	pTRE3G-Luc.	Doxycycline-responsive	luciferase	construct	
used	to	determine	the	capability	of	clones	to	induce	protein	expression.		
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Appendix	4.2	RES256	clones	express	functional	tet-responsive	protein.	25	RES256	
clones	 were	 tested	 to	 confirm	 expression	 of	 doxycycline-responsive	 protein.	
Clones	 1,3	 and	 6	were	 the	 best	 inducers	 of	 gene	 expression	 as	 shown	 by	 the	
highest	fold-induction	of	luciferase	expression.		
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Appendix	5	–	RES256	Antibiotic	selection	of	clones	
	
For	stable	transfection,	the	concentration	of	G-418	and	puromycin	required	to	remove	cells	
that	have	not	integrated	plasmid	DNA	was	determined.	pCMV-TetOn3G	constructs	contain	
a	G-418	resistance	cassette	and	pTRE3G-IRES	constructs	were	co-transfected	with	a	linear	
puromycin	resistance	gene	at	a	ratio	that	makes	it	unlikely	for	this	DNA	to	be	integrated	
without	plasmid	DNA.		
G-418	concentrations	that	resulted	 in	reduced	viability	of	cells	without	resistance	genes	
were	determined	by	MTS	assay	as	previously	described.	The	concentration	that	caused	a	
greater	than	50%	reduction	in	cell	viability	after	5	days	of	treatment,	and	no	viable	cells	
after	15	days	of	treatment	was	deemed	1	mg/mL	for	RES256	cells	(appendix	5.1A).		
The	concentration	of	puromycin	 required	 for	no	viable	cells	 to	 remain	after	6	days	was	
determined	as	previously	described.	The	concentration	used	to	remove	viable	RES256	cells	
that	did	not	integrate	a	resistance	gene	into	the	genome	was	1.5	μg/mL	(appendix	5.1B).		
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Appendix	5.1	RES256	kill	curves.	(A)	G-418	dose-response	for	
15	days	shows	a	decrease	in	viability	with	increasing	dose	and	
time.	 A	 doseof	 1000	µg/mL	 caused	 a	 signficant	 reduction	 in	
viability	after	5	days	(green)	and	by	15	days	(pink)	viability	had	
plateued.	 (B)	 Puromycin	 dose-response	 for	 5	 days	 shows	 a	
decrease	in	viability	after	3	and	5	days	(green	and	blue)	with	
0.5	µg	puromycin	making	this	the	concentration	used	to	select	
transfected	clones..	N=3	±	SEM	
A	
B	
[G-418	µg/mL]	
[Puromycin	µg/mL]	
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Appendix	6	–	Cell	line	authentication		
	
The	cell	lines	used	in	this	project	were	authenticated	to	ensure	there	was	no	contamination	
with	other	cell	 lines	and	microbes.	The	cell	 lines	used	 throughout	 this	project	were	 the	
medulloblastoma	 cell	 lines	 RES256,	 CHLA-01-Med	 and	UW402,	 and	 also	 the	metastatic	
melanoma	cell	line	MeWo.	
The	authenticity	of	cell	 lines	used	 in	the	following	experiments	were	confirmed	by	DNA	
fingerprint	 analysis	 carried	 out	 by	 Mrs.	 Katie	 Loveson	 (Appendix	 6.1).	 This	 genotyping	
confirms	the	expression	of	several	short	tandem	repeat	sequences	of	DNA	that	are	unique	
to	the	cell	line.	This	data	was	compared	to	published	genotypes	where	available.	This	PCR	
based	technique	described	previously	was	carried	out	to	ensure	quality	of	data.		
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Appendix	6.0.1	DNA	fingerprint	analysis	of	the	cell	lines	used	in	this	project.	(A)	MeWo,	
(B)	 RES256,	 (C)	 UW402	 and	 (D)	 CHLA-01-Med	 medulloblastoma	 cell	 lines.	 These	
fingerprints	 are	 unique	 to	 each	 cell	 line	 and	 are	 used	 to	 ensure	 no	 contamination	 of	
cultures	occurred	throughout	this	project.	The	data	is	also	represented	in	tabular	form	
with	data	from	each	gene	amplified	shown.	
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Morphology	
	
The	morphology	of	each	cell	line	was	examined	throughout	the	study	using	phase	contrast	
microscopy.	By	inspecting	cultures	regularly,	it	was	ensured	that	contaminations	could	be	
identified	 quickly	 as	 well	 as	 any	 morphological	 changes	 that	 may	 occur	 following	 any	
treatments	could	be	investigated.	
MeWo	is	a	commercially	available	metastatic	melanoma	derived	from	a	lymph	node.	These	
cells	are	elongated,	homogenous	and	are	of	high	passage.	(Appendix	6.2A)		
RES256	and	UW402	are	high	passage	cell	lines	and	therefore	homogenous	(appendix	6.2B-
C).	These	cell	lines	have	small	rounded	cells	that	have	few	processes.		
CHLA-01-Med	 is	 a	 commercially	 available	 medulloblastoma	 cell	 line	 which	 grows	 in	
suspension	culture.	These	cells	grow	as	large	spheres	and	some	as	single	cell	suspension,	
but	are	morphologically	similar.	This	cell	line	is	also	high	passage	(appendix	6.2D).			
Only	one	of	the	medulloblastoma	cell	lines	has	a	published	known	subgroup,	CHLA-01-Med	
is,	 a	 group	 4	 medulloblastoma	 described	 by	 (Erdreich-Epstein	 et	 al.	 2014).	 It	 can	 be	
speculated	that	the	RES256	cell	line	belongs	to	either	the	SHH	or	WNT	subgroup	as	this	cell	
line	harbours	a	TP53	mutation	described	by	(Zhukova	Thesis,	2012).	TP53	mutations	are	
enriched	in	WNT	patients	(16	%)	and	SHH	patients	(21	%),	and	these	mutations	are	virtually	
absent	in	group	3	and	group	4	tumours	shown	by	(Zhukova	et	al.	2013).	The	absence	of	
TP53	mutations	in	groups	3	and	4	is	because	of	the	location	of	the	TP53	gene	on	the	short	
arm	of	chromosome	17.	Chromosome	17p	is	commonly	lost	in	these	subgroups,	and	there	
are	gains	in	the	long	arm,	as	they	harbour	isochromosome	17q	(i[17q].		The	UW402	cell	line	
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is	 known	 to	 be	 TP53	 wild-type,	 shown	 by	 (Zhukova	 Thesis,	 2012)	 and	 its	 subgroup	 is	
currently	unknown.	by	flow	cytometry.		
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Appendix	6.2	Morphology	of	cell	lines	used	in	this	project	was	monitored	for	changes	
to	determine	contamination	and	morphological	changes	with	treatment.	(A)	MeWo,	a	
surface	adherent	melanoma	cell	line	known	to	express	GD3	and	GD3A,	Passage	85;	(B)	
RES256	a	surface	adherent	medulloblastoma	cell	line	Passage	86;	(C)	UW402,	a	surface	
adherent	 medulloblastoma	 cell	 line	 Passage	 106;	 (D)	 CHLA-01-Med	 a	 group	 4	
medulloblastoma	 cell	 line	 that	 grows	 as	 clusters	 and	 as	 single	 cells	 in	 suspension	
Passage	(from	receipt)	10.	Cells	imaged	using	an	Olympus	IX71	inverted-phase	contrast	
microscope	using	a	4	X	objective		
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Appendix	7-	IC50	data	after	treatments	with	cisplatin	and	etoposide	
		
The	 IC50	 is	 the	 concentration	 of	 (inhibitory)	 drug	 (or	 antagonist)	 required	 for	 a	 50	 %	
reduction	in	response.	In	this	case	the	concentration	of	chemotherapeutic	required	for	a	
50	%	reduction	 in	cell	viability.	 IC50	data	 for	each	time	point	and	clone	 is	 shown	below.	
Significant	changes	in	IC50s	are	shown	in	green.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 302	
Appendix	7.1-	IC50s	for	each	clone	after	treatment	with	cisplatin	or	etopside.	Significant	
data	 shown	 in	 green.	 Data	 analysed	 by	 GraphPad	 Prism	 6	 software	 using	 non-linear	
regression	analysis	of	logIC50.	n=3.	
	
	
	
	 	
Clone	 Drug	
IC50	-	Dox	(µM)	±	95	%	
CI	
IC50	+	Dox	(µM)	±	95	%	
CI	 Time	Point	(Hours)	 p	value		
Statistically	
significant?	
EGFP	 Cisplatin	 4.3 ± 1.2 4.2 ± 0.9 24	 0.9303 No	
SIAE	1	 Cisplatin	 3.7 ± 1.4 n.d 24	 0.4091 No	
SIAE	2	 Cisplatin	 3.4 ± 1.3 2.4 ± 1.1 24	 0.4091 No	
S127A	 Cisplatin	 3.1 ± 1.3 2.7 ± 0.8 24	 0.6675 No	
EGFP	 Etoposide	 4.6 ± 3.8 n.d 24	 0.8028 No 
SIAE	1	 Etoposide	 2.4 ± 1.1 3.0 ± 2.2 24	 0.7065 No	
SIAE	2	 Etoposide	 4.1 ± 1.9 1.2 ± 0.9 24	 0.0744 No	
S127A	 Etoposide	 n.d 4.5 ± 2.0 24	 0.1691 No	
EGFP	 Cisplatin	 3.6 ± 2.9 3.8 ± 1.2 48	 0.8485 No	
SIAE	1	 Cisplatin	 2.3 ± 0.4 2.0 ± 0.4 48	 0.2769 No	
SIAE	2	 Cisplatin	 1.8 ± 0.7 2.8 ± 0.5 48	 0.1058 No	
S127A	 Cisplatin	 4.1 ± 0.6 3.1 ± 0.5 48	 0.0165 Yes	
EGFP	 Etoposide	 6.7 ± 2.9 6.6 ± 1.8 48	 0.9785 No	
SIAE	1	 Etoposide	 3.0 ± 0.6 2.3 ± 0.6 48	 0.1547 No	
SIAE	2	 Etoposide	 2.1 ± 0.5 1.6 ± 0.5 48	 0.3322 No	
S127A	 Etoposide	 3.0 ± 0.6 2.8 ± 0.5 48	 0.6991 No	
EGFP	 Cisplatin	 2.7 ± 0.6 2.0 ± 0.6 72	 0.1727 No	
SIAE	1	 Cisplatin	 1.3 ± 0.3 1.0 ± 0.2 72	 0.2153 No	
SIAE	2	 Cisplatin	 1.1 ± 0.3 1.1 ± 0.3 72	 0.9892 No	
S127A	 Cisplatin	 1.8 ± 0.4 1.7 ± 0.4 72	 0.7893 No	
EGFP	 Etoposide	 3.0 ± 1.4 4.2 ± 1.1 72	 0.3198 No	
SIAE	1	 Etoposide	 3.5 ± 0.3 2.8 ± 0.2 72	 0.3899 No	
SIAE	2	 Etoposide	 5.1 ± 1.3 1.9 ± 0.9 72	 0.0034 Yes	
S127A	 Etoposide	 3.5 ± 1.0 1.9 ± 0.9 72	 0.0718 No	
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Appendix	8-	High	NG2	mRNA	expression	is	associated	with	the	WNT	subgroup	
	
	
	
	
	
Appendix	 8.1	 NG2	 mRNA	 expression	 in	 Medulloblastoma	 subgroups.	 NG2	 expression	 is	
highest	 in	 WNT	 group	 of	 Medulloblastomas	 providing	 supportive	 evidence	 that	 GD3A	
expression	is	lowest	in	this	subgroup	as	also	supported	by	data	in	chapter	3	and	published	
work	 which	 demonstrates	 an	 inverse	 correlation	 between	 NG2	 and	 GD3A	 expression	 in	
glioma.	Similar	expression	of	NG2	is	seen	in	SHH	group	3	and	group	4	samples.	(Data	from	
Taylor	group,	Toronto).		
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Appendix	9	–	UPR16	Form	and	ethical	approval	letter	
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